{"6f0af73257e6b995fe875a235de60e7dd92d6c80": [["IntroductionIn December of 2019, the World Health Organization (WHO) was notified by Chinese officials of a pneumonia of unknown etiology that had affected nearly 44 individuals.", [["pneumonia", "DISEASE", 108, 117], ["a pneumonia", "PROBLEM", 106, 117], ["pneumonia", "OBSERVATION", 108, 117]]], ["On January 7, 2020, Chinese researchers isolated a novel coronavirus now known as SARS-CoV-2 that causes the disease COVID- 19 .", [["coronavirus", "DISEASE", 57, 68], ["coronavirus", "ORGANISM", 57, 68], ["SARS-CoV-2", "ORGANISM", 82, 92], ["coronavirus", "SPECIES", 57, 68], ["SARS-CoV", "SPECIES", 82, 90], ["a novel coronavirus", "PROBLEM", 49, 68], ["SARS", "PROBLEM", 82, 86], ["CoV", "TEST", 87, 90], ["the disease COVID", "PROBLEM", 105, 122], ["disease", "OBSERVATION", 109, 116]]], ["Proper mitigation of continued spread of the virus relies on rapid and accurate laboratory testing to confirm positive cases.", [["the virus", "PROBLEM", 41, 50], ["accurate laboratory testing", "TEST", 71, 98], ["positive cases", "PROBLEM", 110, 124], ["spread", "OBSERVATION_MODIFIER", 31, 37], ["virus", "OBSERVATION", 45, 50]]], ["One of the first published reports of an asymptomatic transmission of disease came from a family cluster in China, 1 opening the possibility that positive patients could unknowingly be infecting others and that the number of positive cases was being underreported.IntroductionAnalysis of the viral load in an asymptomatic patient in China found that the levels were similar to those of symptomatic patients.", [["patients", "ORGANISM", 155, 163], ["patient", "ORGANISM", 322, 329], ["patients", "ORGANISM", 398, 406], ["patients", "SPECIES", 155, 163], ["patient", "SPECIES", 322, 329], ["patients", "SPECIES", 398, 406], ["disease", "PROBLEM", 70, 77], ["positive cases", "PROBLEM", 225, 239], ["the viral load", "TEST", 288, 302], ["the levels", "TEST", 350, 360], ["disease", "OBSERVATION", 70, 77], ["viral load", "OBSERVATION", 292, 302]]], ["2 These findings present a challenge to successful contact tracing and exposure control.", [["contact tracing", "TEST", 51, 66], ["exposure control", "TREATMENT", 71, 87]]], ["Taken together, the data underlay the importance of not only physical distancing, but more importantly expansive testing and isolation of positive cases regardless of the presence of symptoms to contain and mitigate the SARS-CoV-2 pandemic.IntroductionIt remains critical that clinicians understand the relationships between test results from virologic and serologic testing and the performance of these diagnostic assays in order to prescribe appropriate drug therapy.", [["SARS-CoV-2 pandemic", "DISEASE", 220, 239], ["SARS-CoV-2", "ORGANISM", 220, 230], ["expansive testing", "TEST", 103, 120], ["positive cases", "PROBLEM", 138, 152], ["symptoms", "PROBLEM", 183, 191], ["the SARS", "TEST", 216, 224], ["pandemic", "PROBLEM", 231, 239], ["virologic and serologic testing", "TEST", 343, 374], ["these diagnostic assays", "TEST", 398, 421], ["appropriate drug therapy", "TREATMENT", 444, 468]]], ["Accurate interpretation and assessment of viral exposure and/or immunological response may impact pharmacotherapy decisions.", [["Accurate interpretation", "TEST", 0, 23], ["assessment", "TEST", 28, 38], ["viral exposure", "PROBLEM", 42, 56], ["pharmacotherapy decisions", "TREATMENT", 98, 123], ["viral exposure", "OBSERVATION", 42, 56]]], ["As no \"cure\" currently exists for SARS-CoV-2 infection, clinical utility of validated serologic testing may have a role in clinical decision making as antibody detection may be used as an indicator of the stage of COVID-19 progression to aid in management of the disease.", [["SARS-CoV-2 infection", "DISEASE", 34, 54], ["SARS-CoV-2", "ORGANISM", 34, 44], ["SARS-CoV", "SPECIES", 34, 42], ["SARS", "PROBLEM", 34, 38], ["CoV-2 infection", "PROBLEM", 39, 54], ["validated serologic testing", "TEST", 76, 103], ["antibody detection", "TEST", 151, 169], ["COVID", "TEST", 214, 219], ["management", "TREATMENT", 245, 255], ["the disease", "PROBLEM", 259, 270], ["infection", "OBSERVATION", 45, 54], ["disease", "OBSERVATION", 263, 270]]], ["Thus, it is essential that patients who are seropositive be identified in order to properly design treatments.IntroductionThere are many different ways to test for SARS-CoV-2.", [["SARS", "DISEASE", 164, 168], ["patients", "ORGANISM", 27, 35], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 164, 174], ["patients", "SPECIES", 27, 35], ["SARS-CoV", "SPECIES", 164, 172], ["SARS", "TEST", 164, 168], ["CoV", "TEST", 169, 172]]], ["In this review, we briefly describe the current and future approaches for clinical testing for COVID-19 including molecular and serological testing as well as their benefits and limitations.", [["clinical testing", "TEST", 74, 90], ["COVID", "TEST", 95, 100], ["molecular and serological testing", "TEST", 114, 147]]], ["We reviewed original papers published in PubMed since the COVID-19 outbreak up to the time of writing using the following terms: COVID-19, SARS-CoV-2, diagnostics, testing, RT-PCR, serology, and antigen.Accepted ArticleThis article is protected by copyright.", [["the COVID", "TEST", 54, 63], ["COVID", "TEST", 129, 134], ["SARS-CoV", "TEST", 139, 147], ["diagnostics", "TEST", 151, 162], ["testing", "TEST", 164, 171], ["RT-PCR", "TEST", 173, 179], ["serology", "TEST", 181, 189]]], ["All rights reservedNucleic Acid Amplification Test: Gold Standard RT-PCRGenetic information for the viral genome SARS-CoV-2 originally appeared in the community online resource (https://virological.org).", [["viral genome SARS-CoV-2", "DNA", 100, 123], ["the viral genome SARS", "PROBLEM", 96, 117]]], ["Nucleic acid amplification technology (NAAT) based on polymerase chain reaction (PCR), which is regarded as the \"gold standard\" for virus detection.", [["Nucleic acid", "CHEMICAL", 0, 12], ["Nucleic acid amplification technology", "TEST", 0, 37], ["polymerase chain reaction", "PROBLEM", 54, 79], ["PCR", "TEST", 81, 84], ["virus detection", "TEST", 132, 147]]], ["The diagnosis of COVID-19 relies on the detection of the SARS-CoV-2 RNA by real-time reverse transcriptase polymerase chain reaction (RT-PCR).", [["COVID-19", "CHEMICAL", 17, 25], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 57, 67], ["COVID-19", "DNA", 17, 25], ["SARS-CoV-2 RNA", "RNA", 57, 71], ["reverse transcriptase", "PROTEIN", 85, 106], ["SARS-CoV", "SPECIES", 57, 65], ["COVID", "TEST", 17, 22], ["the detection", "TEST", 36, 49], ["the SARS", "PROBLEM", 53, 61], ["CoV", "TEST", 62, 65], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 85, 132], ["RT-PCR", "TEST", 134, 140]]], ["3, 4 The viral RNA is detectable in nasopharyngeal and oropharyngeal swab samples as well as respiratory secretions during the acute phase of viral infection.Nucleic Acid Amplification Test: Gold Standard RT-PCRGenetic material is extracted from patient samples and reverse transcriptase is used to make a complementary DNA strand from the viral RNA.", [["nasopharyngeal", "ANATOMY", 36, 50], ["oropharyngeal swab samples", "ANATOMY", 55, 81], ["respiratory secretions", "ANATOMY", 93, 115], ["samples", "ANATOMY", 254, 261], ["viral infection", "DISEASE", 142, 157], ["nasopharyngeal", "CANCER", 36, 50], ["oropharyngeal swab samples", "ORGANISM_SUBSTANCE", 55, 81], ["patient", "ORGANISM", 246, 253], ["DNA", "CELLULAR_COMPONENT", 320, 323], ["viral RNA", "RNA", 9, 18], ["reverse transcriptase", "PROTEIN", 266, 287], ["viral RNA", "RNA", 340, 349], ["patient", "SPECIES", 246, 253], ["The viral RNA", "TEST", 5, 18], ["nasopharyngeal and oropharyngeal swab samples", "TEST", 36, 81], ["respiratory secretions", "PROBLEM", 93, 115], ["viral infection", "PROBLEM", 142, 157], ["Nucleic Acid Amplification Test", "TEST", 158, 189], ["Gold Standard RT-PCRGenetic material", "TREATMENT", 191, 227], ["reverse transcriptase", "TREATMENT", 266, 287], ["a complementary DNA strand", "PROBLEM", 304, 330], ["the viral RNA", "PROBLEM", 336, 349], ["viral RNA", "OBSERVATION", 9, 18], ["nasopharyngeal", "ANATOMY", 36, 50], ["oropharyngeal swab", "ANATOMY", 55, 73], ["respiratory", "ANATOMY", 93, 104], ["secretions", "OBSERVATION", 105, 115], ["viral", "OBSERVATION_MODIFIER", 142, 147], ["infection", "OBSERVATION", 148, 157], ["viral RNA", "OBSERVATION", 340, 349]]], ["Selective amplification of the target nucleic acid from the sample is achieved by designing target-specific forward and reverse primers flanking regions of interest (ROIs) that are unique to the SARS-CoV-2 genome (Figure 1 ): replicase open reading frame (ORF1a/b), spike (S), envelop (E), membrane (M), and nucleocapsid (N).Understanding Target Selection and Assay Sensitivity/SpecificityThe genome of SARS-CoV-2 has been characterized and compared to other coronaviruses to identify homology.", [["sample", "ANATOMY", 60, 66], ["membrane", "ANATOMY", 290, 298], ["nucleic acid", "CHEMICAL", 38, 50], ["SARS", "DISEASE", 195, 199], ["spike (S)", "GENE_OR_GENE_PRODUCT", 266, 275], ["envelop (E)", "GENE_OR_GENE_PRODUCT", 277, 288], ["membrane", "CELLULAR_COMPONENT", 290, 298], ["SARS-CoV-2", "ORGANISM", 403, 413], ["forward and reverse primers flanking regions", "DNA", 108, 152], ["SARS-CoV-2 genome", "DNA", 195, 212], ["Figure 1", "DNA", 214, 222], ["replicase open reading frame", "DNA", 226, 254], ["ORF1a", "DNA", 256, 261], ["S", "DNA", 273, 274], ["envelop", "DNA", 277, 284], ["E", "DNA", 286, 287], ["SARS-CoV", "SPECIES", 195, 203], ["SARS-CoV", "SPECIES", 403, 411], ["the target nucleic acid", "TEST", 27, 50], ["reverse primers flanking regions of interest (ROIs)", "PROBLEM", 120, 171], ["the SARS", "TEST", 191, 199], ["CoV", "TEST", 200, 203], ["spike (S)", "PROBLEM", 266, 275], ["Assay Sensitivity", "TEST", 360, 377], ["Specificity", "TEST", 378, 389], ["SARS", "PROBLEM", 403, 407], ["SARS", "OBSERVATION", 403, 407]]], ["5 The genome of SARS-CoV-2 shares 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV.", [["nucleotide", "CHEMICAL", 38, 48], ["SARS", "DISEASE", 67, 71], ["SARS", "DISEASE", 113, 117], ["nucleotide", "CHEMICAL", 38, 48], ["SARS-CoV-2", "ORGANISM", 16, 26], ["human", "ORGANISM", 107, 112], ["SARS-CoV", "ORGANISM", 113, 121], ["human", "SPECIES", 107, 112], ["SARS-CoV-2", "SPECIES", 16, 26], ["human SARS-CoV", "SPECIES", 107, 121], ["SARS", "TEST", 16, 20], ["CoV", "TEST", 21, 24], ["nucleotide identity", "TEST", 38, 57], ["bat SARS", "TEST", 63, 71], ["human SARS", "TEST", 107, 117]]], ["Preferred targets or ROIs include ORF1a/b, ORF1b-nsp14, nonstructural RNA dependent RNA polymerase (RdRp), S, E, or N gene of SARS-CoV-2.", [["ORF1a", "GENE_OR_GENE_PRODUCT", 34, 39], ["b", "GENE_OR_GENE_PRODUCT", 40, 41], ["ORF1b-nsp14", "GENE_OR_GENE_PRODUCT", 43, 54], ["nonstructural RNA dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 56, 98], ["RdRp", "GENE_OR_GENE_PRODUCT", 100, 104], ["S, E", "GENE_OR_GENE_PRODUCT", 107, 111], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 126, 136], ["ORF1a", "DNA", 34, 39], ["ORF1b", "DNA", 43, 48], ["nsp14", "DNA", 49, 54], ["nonstructural RNA dependent RNA polymerase (RdRp), S, E, or N gene", "DNA", 56, 122], ["SARS-CoV-2", "DNA", 126, 136], ["SARS-CoV", "SPECIES", 126, 134], ["ROIs", "TEST", 21, 25], ["ORF1a", "TEST", 34, 39], ["ORF1b", "TEST", 43, 48], ["nonstructural RNA dependent RNA polymerase", "PROBLEM", 56, 98], ["SARS", "PROBLEM", 126, 130]]], ["A detailed genetic analysis of SARS-CoV-2 with other coronaviruses, those with low and high case fatality rates, found that pathogenicity is predicted most by the regions of the spike and nucleocapsid proteins.", [["SARS", "DISEASE", 31, 35], ["SARS-CoV-2", "ORGANISM", 31, 41], ["coronaviruses", "ORGANISM", 53, 66], ["nucleocapsid proteins", "GENE_OR_GENE_PRODUCT", 188, 209], ["spike and nucleocapsid proteins", "PROTEIN", 178, 209], ["SARS-CoV", "SPECIES", 31, 39], ["A detailed genetic analysis", "TEST", 0, 27], ["SARS", "TEST", 31, 35], ["CoV", "TEST", 36, 39], ["other coronaviruses", "PROBLEM", 47, 66], ["pathogenicity", "PROBLEM", 124, 137], ["the spike", "PROBLEM", 174, 183], ["nucleocapsid proteins", "PROBLEM", 188, 209], ["pathogenicity", "OBSERVATION", 124, 137]]], ["6 A recent study has identified selective mutations in the SARS-COV-2 genome; therefore, it is essential to avoid certain ROIs when designing primers and probes.", [["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 59, 69], ["SARS-COV-2 genome", "DNA", 59, 76], ["A recent study", "TEST", 2, 16], ["selective mutations", "PROBLEM", 32, 51], ["the SARS", "PROBLEM", 55, 63], ["certain ROIs", "PROBLEM", 114, 126], ["selective", "OBSERVATION_MODIFIER", 32, 41], ["mutations", "OBSERVATION", 42, 51]]], ["7 Although the mutation rate of SARS-CoV-2 remains to be determine, it is estimated to be moderate compared to influenza.", [["SARS", "DISEASE", 32, 36], ["influenza", "DISEASE", 111, 120], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 32, 42], ["SARS-CoV", "SPECIES", 32, 40], ["the mutation rate", "TEST", 11, 28], ["SARS", "PROBLEM", 32, 36], ["CoV", "TEST", 37, 40], ["influenza", "PROBLEM", 111, 120], ["moderate", "OBSERVATION_MODIFIER", 90, 98], ["influenza", "OBSERVATION", 111, 120]]], ["Based on the natural viral mutation and recombination rates, targeting more than one ROI can mitigate the risk of loss of sensitivity should potential mutations arise.", [["the natural viral mutation", "PROBLEM", 9, 35], ["recombination rates", "TEST", 40, 59], ["loss of sensitivity", "PROBLEM", 114, 133], ["mutations arise", "PROBLEM", 151, 166]]], ["8 Monitoring of genomic variations in SARS-CoV-2 is ongoing in case assay re-design is needed.Accepted ArticleThis article is protected by copyright.", [["SARS", "DISEASE", 38, 42], ["SARS-CoV", "SPECIES", 38, 46], ["genomic variations in SARS", "PROBLEM", 16, 42], ["CoV", "TEST", 43, 46]]], ["All rights reserved Target selection can affect assay performance in terms of specificity and sensitivity as well as cross reactivity due to conserved regions.", [["assay performance", "TEST", 48, 65], ["specificity", "TEST", 78, 89], ["sensitivity", "TEST", 94, 105]]], ["The validity of a test is measured by its analytical and clinical sensitivity and specificity.", [["a test", "TEST", 16, 22], ["clinical sensitivity", "TEST", 57, 77]]], ["Analytical sensitivity is the assays ability to reliably detect the minimum concentration of a substance in a sample (also referred to as limit of detection) whereas analytical specificity refers to the ability to detect only the desired analyte in a specimen without cross reacting with other substances.", [["specimen", "ANATOMY", 251, 259], ["Analytical sensitivity", "TEST", 0, 22]]], ["Clinical sensitivity measures how accurately a test identifies positive patients who are infected.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["Clinical sensitivity measures", "TEST", 0, 29], ["a test", "TEST", 45, 51], ["infected", "PROBLEM", 89, 97], ["infected", "OBSERVATION", 89, 97]]], ["A test with 95% sensitivity will identify 95% of patients who have the disease and produces false negatives in 5% of patients (5 out of every 100 patients who are positive test negative); a lower sensitivity test means higher false negative results.", [["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 117, 125], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 117, 125], ["patients", "SPECIES", 146, 154], ["A test", "TEST", 0, 6], ["the disease", "PROBLEM", 67, 78], ["false negatives", "PROBLEM", 92, 107], ["a lower sensitivity test", "TEST", 188, 212]]], ["Clinical specificity, the inverse of sensitivity, determines how accurately a test identifies negative patients who do not have COVID-19.Accepted ArticleA test with 95% specificity will identify 95% of patients who do not have the disease and incorrectly identify 5% of patients who test positive but actually are not infected; a lower specificity test means higher false positives.", [["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 202, 210], ["patients", "ORGANISM", 270, 278], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 202, 210], ["patients", "SPECIES", 270, 278], ["COVID", "TEST", 128, 133], ["ArticleA test", "TEST", 146, 159], ["the disease", "PROBLEM", 227, 238], ["a lower specificity test", "TEST", 328, 352], ["higher false positives", "PROBLEM", 359, 381], ["disease", "OBSERVATION", 231, 238], ["false positives", "OBSERVATION", 366, 381]]], ["A test with good analytical sensitivity and specificity does not necessarily correlate with clinical sensitivity and specificity.", [["A test", "TEST", 0, 6], ["clinical sensitivity", "TEST", 92, 112]]], ["(See section on Assay Limitations for a discussion on implications of false positive and negative tests.)Accepted ArticleThe WHO has established protocols for various testing kits developed around the world with a listing of the targeted viral regions ( Table 1 ).", [["targeted viral regions", "DNA", 229, 251], ["false positive", "PROBLEM", 70, 84], ["various testing kits", "TEST", 159, 179], ["viral", "OBSERVATION", 238, 243]]], ["One of the first RT-PCR assays published for SARS-CoV-2 was developed by Germany Charit\u00e9 and targeted the RdRp, E, and N genes of the virus.", [["SARS-CoV-2", "ORGANISM", 45, 55], ["E", "GENE_OR_GENE_PRODUCT", 112, 113], ["RdRp, E, and N genes", "DNA", 106, 126], ["SARS-CoV", "SPECIES", 45, 53], ["the first RT-PCR assays", "TEST", 7, 30], ["SARS", "PROBLEM", 45, 49], ["CoV", "TEST", 50, 53], ["the RdRp", "TEST", 102, 110], ["the virus", "PROBLEM", 130, 139], ["virus", "OBSERVATION", 134, 139]]], ["The assay, designed using synthetic nucleic acid technology and in the absence of available virus isolate or original patient specimens, demonstrated that targeting the E and RdRp gene was highly sensitive while the N gene was slightly less sensitive.", [["specimens", "ANATOMY", 126, 135], ["nucleic acid", "CHEMICAL", 36, 48], ["patient", "ORGANISM", 118, 125], ["E", "GENE_OR_GENE_PRODUCT", 169, 170], ["RdRp", "GENE_OR_GENE_PRODUCT", 175, 179], ["E and RdRp gene", "DNA", 169, 184], ["N gene", "DNA", 216, 222], ["patient", "SPECIES", 118, 125], ["The assay", "TEST", 0, 9], ["synthetic nucleic acid technology", "TREATMENT", 26, 59], ["available virus isolate", "PROBLEM", 82, 105], ["original patient specimens", "TEST", 109, 135], ["the E and RdRp gene", "TEST", 165, 184], ["the N gene", "TEST", 212, 222]]], ["3 Numerous RT-PCR assays targeting various combinations of the ROIs have since been designed to improve and maximize detection sensitivity and specificity.", [["Numerous RT-PCR assays", "TEST", 2, 24], ["the ROIs", "TEST", 59, 67], ["detection sensitivity", "TEST", 117, 138], ["specificity", "TEST", 143, 154]]], ["9 Initially in the United States, production and validation of RT-PCR based testing kits were completed by the Centers for Disease Control and Prevention (CDC) following federal rules and regulations.", [["RT-PCR based testing kits", "TEST", 63, 88], ["Disease Control", "TREATMENT", 123, 138]]], ["The first kits sent out to state health agencies were sidelined by a faulty reagent in the negative control and one primer set (CDC N3) that did not perform well which was later excluded from the kits.", [["The first kits", "TEST", 0, 14], ["a faulty reagent", "TREATMENT", 67, 83]]], ["10 Subsequent studies validated the specificity and sensitivity of the primer-probe setsAccepted ArticleThis article is protected by copyright.", [["Subsequent studies", "TEST", 3, 21], ["the specificity", "TEST", 32, 47], ["the primer", "TREATMENT", 67, 77]]], ["All rights reserved from various assays.", [["various assays", "TEST", 25, 39]]], ["A study conducted by the University of Washington compared the performance of their primer sets against those developed by Germany Charit\u00e9 3 and the US CDC primers (CDC N1 and CDC N2) in the current CDC testing kit.", [["A study", "TEST", 0, 7], ["the US CDC primers", "TEST", 145, 163]]], ["The study found high specificity among all primer sets and variable sensitivity, with the CDC N2 and the Germany E-gene sets being more sensitive than others.", [["Germany E-gene sets", "DNA", 105, 124], ["The study", "TEST", 0, 9], ["the CDC N2", "TEST", 86, 96], ["the Germany E", "TEST", 101, 114]]], ["11 Another study (in preprint) examined the sensitivity and efficiency of four common RT-PCR assays developed by the US CDC, China CDC, Germany Charit\u00e9, and Hong Kong University (HKU).", [["Another study", "TEST", 3, 16], ["the sensitivity", "TEST", 40, 55], ["four common RT-PCR assays", "TEST", 74, 99], ["the US CDC", "TEST", 113, 123]]], ["12 This study also found that while all primer-probe sets can detect SARS-CoV-2, the most sensitive primer-probe sets are the Germany E gene, HKU-ORF1, HKU-N and US CDC N1.", [["SARS-CoV-2", "ORGANISM", 69, 79], ["Germany E", "GENE_OR_GENE_PRODUCT", 126, 135], ["primer-probe sets", "DNA", 40, 57], ["SARS-CoV-2", "DNA", 69, 79], ["primer-probe sets", "DNA", 100, 117], ["Germany E gene", "DNA", 126, 140], ["HKU", "DNA", 142, 145], ["ORF1", "DNA", 146, 150], ["HKU", "DNA", 152, 155], ["SARS-CoV", "SPECIES", 69, 77], ["This study", "TEST", 3, 13], ["SARS", "PROBLEM", 69, 73], ["CoV", "TEST", 74, 77], ["HKU", "TEST", 142, 145], ["HKU", "TEST", 152, 155]]], ["While the US CDC N2 primers had background cross-reactivity, it did not interfere with outcomes of the combined N1 and N2 assay when testing clinical samples from COVID-19 patients.", [["samples", "ANATOMY", 150, 157], ["N2", "CHEMICAL", 119, 121], ["patients", "ORGANISM", 172, 180], ["US CDC N2 primers", "DNA", 10, 27], ["patients", "SPECIES", 172, 180], ["the US CDC N2 primers", "TEST", 6, 27], ["N2 assay", "TEST", 119, 127], ["testing clinical samples", "TEST", 133, 157], ["COVID", "TEST", 163, 168]]], ["12 Other studies have also compared the US CDC N1 and N2 against commercial test kits, reporting similar specificity with variable sensitivity.", [["Other studies", "TEST", 3, 16], ["the US", "TEST", 36, 42], ["commercial test kits", "TEST", 65, 85], ["variable sensitivity", "PROBLEM", 122, 142]]], ["13, 14 To accelerate testing capacity, the US Food and Drug Administration (FDA) released updated guidance on February 29, 2020 opening up the production of diagnostic kits to state labs, laboratories certified under Clinical Laboratory Improvement Amendments (CLIA), and commercial diagnostic developers.", [["accelerate testing capacity", "TEST", 10, 37]]], ["15 Clinical laboratories have the option of either using the CDC primers or other established primers/protocols listed on the WHO website, to produce their own \"laboratory-developed tests\" for in-house use.", [["Clinical laboratories", "TEST", 3, 24], ["the CDC primers", "TREATMENT", 57, 72]]], ["At the time of writing, the US FDA has issued 149 individuals EUAs (commercial and laboratory-developed tests), which includes 125 molecular tests, 23 antibody tests and 1 antigen test.", [["the US FDA", "TEST", 24, 34], ["tests", "TEST", 104, 109], ["molecular tests", "TEST", 131, 146], ["antibody tests", "TEST", 151, 165], ["1 antigen test", "TEST", 170, 184]]], ["The FDA lists all individual EUAs for molecular, antibody, and antigen tests and provides links to these tests the include information on the assay platform, gene targets of the test as well as performance characteristics (sensitivity and specificity).", [["molecular, antibody", "TEST", 38, 57], ["antigen tests", "TEST", 63, 76], ["these tests", "TEST", 99, 110], ["the assay platform", "TEST", 138, 156], ["the test", "TEST", 174, 182]]], ["All rights reserved diagnostic tests.", [["diagnostic tests", "TEST", 20, 36]]], ["FIND's SARS-CoV-2 diagnostic pipeline tracks all tests commercially available or in development worldwide (https://www.finddx.org/covid-19/pipeline/).", [["FIND's SARS", "TEST", 0, 11], ["CoV", "TEST", 12, 15], ["all tests", "TEST", 45, 54]]], ["FIND is conducting independent evaluations of SARS-Cov-2 testing platforms to verify the limit of detection of each test (as reported by the manufacturers) and the clinical performance of the test (https://www.finddx.org/covid-19/sarscov2-eval-molecular/).Assay Performance & LimitationsDiagnostic testing errors can result in false positives and/or false negatives that stem from improper sample collection, testing procedural errors, and variability in assay performance (sensitivity/specificity).", [["sample", "ANATOMY", 390, 396], ["SARS", "TEST", 46, 50], ["Cov-2 testing platforms", "TEST", 51, 74], ["each test", "TEST", 111, 120], ["the test", "TEST", 188, 196], ["Diagnostic testing errors", "TEST", 287, 312], ["false positives", "PROBLEM", 327, 342], ["false negatives that stem", "PROBLEM", 350, 375], ["improper sample collection", "PROBLEM", 381, 407], ["testing procedural errors", "TEST", 409, 434], ["variability in assay performance", "TEST", 440, 472]]], ["Diagnostic tests need to be evaluated to determine their sensitivity and specificity, ideally by comparison with a \"gold standard.\"", [["Diagnostic tests", "TEST", 0, 16]]], ["The lack of a clear-cut gold-standard diagnostic test for SARS-CoV-2 (because the virus is new) makes evaluation of test accuracy challenging; therefore, assay performance needs to be compared to a reference standard.", [["SARS", "DISEASE", 58, 62], ["SARS-CoV-2", "ORGANISM", 58, 68], ["SARS-CoV", "SPECIES", 58, 66], ["standard diagnostic test", "TEST", 29, 53], ["SARS", "PROBLEM", 58, 62], ["CoV", "TEST", 63, 66], ["the virus", "PROBLEM", 78, 87], ["evaluation of test accuracy", "TEST", 102, 129], ["assay performance", "TEST", 154, 171]]], ["The FDA recommends selecting a comparator assay that has established high sensitivity with an internationally recognized standard or FDA SARS-CoV-2 Reference Panel and set the criteria at a minimum of 95% positive and negative agreement as acceptable clinical performance of the assay.Assay Performance & LimitationsWith the strategy to \"test, isolate, contact trace and quarantine\", a false positive result mistakenly identifies a patient as having COVID-19 resulting in unnecessary contact tracing and quarantine.Assay Performance & LimitationsFalse negatives prevent proper contact tracing and quarantine efforts and importantly miss isolating the individual who can now infect others.", [["patient", "ORGANISM", 432, 439], ["patient", "SPECIES", 432, 439], ["a comparator assay", "TEST", 29, 47], ["high sensitivity", "PROBLEM", 69, 85], ["Reference Panel", "TEST", 148, 163], ["the assay", "TEST", 275, 284], ["test", "TEST", 338, 342], ["COVID", "TEST", 450, 455], ["Assay Performance", "TEST", 515, 532]]], ["Timing is critical when testing for SARS-CoV-2 to prevent inaccurate results.", [["SARS-CoV", "SPECIES", 36, 44], ["testing", "TEST", 24, 31], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44]]], ["Depending on the test rendered, testing early or late in the infection cycle could lead to false negative results.", [["infection", "DISEASE", 61, 70], ["the test", "TEST", 13, 21], ["testing", "TEST", 32, 39]]], ["For molecular based assays, the optimal testing window occurs near the end of the first week and into the beginning of the second week after symptom onset ( Figure 2 ).", [["molecular based assays", "TEST", 4, 26], ["the optimal testing window", "TEST", 28, 54]]], ["However, positive tests are possible near the first day of symptom onset.", [["positive tests", "PROBLEM", 9, 23]]], ["16 Persistent positive tests or positive tests in discharged patients after symptom resolution have been documented.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["Persistent positive tests", "PROBLEM", 3, 28], ["positive tests", "TEST", 32, 46], ["symptom resolution", "TEST", 76, 94], ["Persistent", "OBSERVATION_MODIFIER", 3, 13], ["positive", "OBSERVATION", 14, 22]]], ["In a report from South Korea CDC, 285 of a reported 447 re-positive tests were followed; they concluded that there is no evidence that those testing positive long after symptom onset and resolution are re-infected or still infectious.", [["re-positive tests", "TEST", 56, 73], ["those testing positive", "PROBLEM", 135, 157], ["infectious", "PROBLEM", 223, 233], ["no evidence", "UNCERTAINTY", 118, 129], ["infectious", "OBSERVATION", 223, 233]]], ["17 The duration of viral RNA shedding is variable and depend on disease severity;Accepted ArticleThis article is protected by copyright.", [["viral RNA shedding", "PROBLEM", 19, 37], ["disease severity", "PROBLEM", 64, 80], ["viral RNA", "OBSERVATION", 19, 28]]], ["All rights reserved prolonged viral RNA shedding of SARS-CoV-2 is detectable by RT-PCR in patients recovering from COVID-19 for up to 37 days.", [["SARS", "DISEASE", 52, 56], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 52, 62], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["SARS-CoV", "SPECIES", 52, 60], ["SARS", "PROBLEM", 52, 56], ["CoV", "TEST", 57, 60], ["PCR", "TEST", 83, 86], ["COVID", "TEST", 115, 120], ["prolonged", "OBSERVATION_MODIFIER", 20, 29], ["viral RNA", "OBSERVATION", 30, 39]]], ["18, 19 Thus, detection of viral RNA does not necessarily reflect the presence of infectious virus and prolonged viral RNA detection following recovery does not necessarily indicate infectiousness.Accepted ArticleThe implications of false negatives become increasingly significant as governments move forward with reopening and loosening stay at home restrictions.", [["viral RNA", "RNA", 26, 35], ["viral RNA", "PROBLEM", 26, 35], ["infectious virus", "PROBLEM", 81, 97], ["prolonged viral RNA detection", "PROBLEM", 102, 131], ["infectiousness", "PROBLEM", 181, 195], ["false negatives", "TEST", 232, 247], ["reopening", "TREATMENT", 313, 322], ["viral RNA", "OBSERVATION", 26, 35], ["infectious", "OBSERVATION", 81, 91], ["infectiousness", "OBSERVATION", 181, 195], ["loosening stay", "OBSERVATION", 327, 341]]], ["Recent studies have shed light and caution on the interpretation of negative test results (particularly early in the course of infection).", [["infection", "DISEASE", 127, 136], ["Recent studies", "TEST", 0, 14], ["infection", "PROBLEM", 127, 136], ["infection", "OBSERVATION", 127, 136]]], ["One study demonstrated a highly variable false-negative rate for SARS-CoV-2 RT-PCR testing, suggesting one out of five people suspected of COVID-19 may test negative based on pooled analysis of data from 7 studies.", [["SARS", "DISEASE", 65, 69], ["people", "ORGANISM", 119, 125], ["people", "SPECIES", 119, 125], ["SARS-CoV", "SPECIES", 65, 73], ["One study", "TEST", 0, 9], ["SARS", "TEST", 65, 69], ["CoV", "TEST", 70, 73], ["PCR testing", "TEST", 79, 90], ["COVID", "TEST", 139, 144], ["pooled analysis", "TEST", 175, 190], ["7 studies", "TEST", 204, 213], ["highly", "OBSERVATION_MODIFIER", 25, 31], ["variable", "OBSERVATION_MODIFIER", 32, 40], ["false", "OBSERVATION", 41, 46]]], ["20 Therefore, waiting 1 to 3 days after symptom onset can lessen the chances of a false negative result.", [["symptom", "PROBLEM", 40, 47]]], ["If there is high clinical suspicion for infection by SARS-CoV-2, then serial testing is recommended to reduce the false negative rate.", [["infection", "DISEASE", 40, 49], ["SARS", "DISEASE", 53, 57], ["SARS-CoV", "SPECIES", 53, 61], ["infection", "PROBLEM", 40, 49], ["serial testing", "TEST", 70, 84], ["infection", "OBSERVATION", 40, 49], ["negative rate", "OBSERVATION", 120, 133]]], ["Recent studies have begun to investigate clinical performance of SARS-CoV-2 molecular testing to determine optimal time frames for appropriate repeat testing with one study suggesting 15 to 20 days after a positive test and the same or next 2 days after a negative test in patients with a high suspicion for infection.", [["infection", "DISEASE", 308, 317], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 273, 281], ["SARS-CoV", "SPECIES", 65, 73], ["Recent studies", "TEST", 0, 14], ["SARS", "TEST", 65, 69], ["CoV", "TEST", 70, 73], ["molecular testing", "TEST", 76, 93], ["appropriate repeat testing", "TEST", 131, 157], ["one study", "TEST", 163, 172], ["a positive test", "TEST", 204, 219], ["a negative test", "TEST", 254, 269], ["infection", "PROBLEM", 308, 317], ["infection", "OBSERVATION", 308, 317]]], ["21 Understanding the predictive value of NAAT with regards to time from exposure and symptom onset is important as the assay may not have been appropriately validated against a clinically meaningful reference standard for detecting SARS-CoV-2 in the absence of symptoms (during earlier stages of the disease) or in asymptomatic individuals.", [["NAAT", "CANCER", 41, 45], ["SARS-CoV", "SPECIES", 232, 240], ["NAAT", "PROBLEM", 41, 45], ["symptom", "PROBLEM", 85, 92], ["SARS", "PROBLEM", 232, 236], ["CoV", "TEST", 237, 240], ["symptoms", "PROBLEM", 261, 269], ["the disease)", "PROBLEM", 296, 308]]], ["22 The sensitivity of a test must be high for adequate containment measures and assessment of clinical sensitivity in asymptomatic patients is warranted.Accepted ArticleOther limitations of RT-PCR testing that can hinder use, include contamination issues, timeconsuming sample handling 23 and variable detection of SARS-CoV-2 depending on the type of clinical specimen.", [["sample", "ANATOMY", 270, 276], ["specimen", "ANATOMY", 360, 368], ["SARS", "DISEASE", 315, 319], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["SARS-CoV", "SPECIES", 315, 323], ["a test", "TEST", 22, 28], ["assessment", "TEST", 80, 90], ["clinical sensitivity", "TEST", 94, 114], ["RT-PCR testing", "TEST", 190, 204], ["contamination issues", "PROBLEM", 234, 254], ["timeconsuming sample handling", "TEST", 256, 285], ["SARS", "PROBLEM", 315, 319], ["CoV", "TEST", 320, 323], ["clinical specimen", "TEST", 351, 368]]], ["24 Commercial developers have been challenged to improve the real-time PCR method and produce assays with ease of sample collection and/or processing and shorter run times to decrease turnaround times.", [["sample", "ANATOMY", 114, 120], ["PCR method", "TEST", 71, 81], ["sample collection", "TEST", 114, 131]]], ["In addition, the unprecedented need for testing resulted in a severe shortage of reagents and supplies including collection swabs, transport media, extraction kits,Accepted ArticleThis article is protected by copyright.", [["testing", "TEST", 40, 47], ["a severe shortage of reagents", "PROBLEM", 60, 89], ["collection swabs", "TREATMENT", 113, 129], ["transport media", "TREATMENT", 131, 146], ["extraction kits", "TREATMENT", 148, 163]]], ["All rights reserved and RT-PCR enzyme mixtures.", [["RT-PCR enzyme mixtures", "TEST", 24, 46]]], ["To circumvent shortages, suitable alternative solutions were investigated such as comparing the use of various swabs and transport media for SARS-CoV-2 testing.", [["SARS-CoV", "SPECIES", 141, 149], ["suitable alternative solutions", "TREATMENT", 25, 55], ["various swabs", "TREATMENT", 103, 116], ["transport media", "TREATMENT", 121, 136], ["SARS", "PROBLEM", 141, 145], ["CoV-2 testing", "TEST", 146, 159]]], ["25 Saliva as a non-invasive specimen for detection of SARS-CoV-2 represents a suitable reliable alternative to help ease the global shortage of swabs for sampling and personal protective equipment used during collection.", [["specimen", "ANATOMY", 28, 36], ["SARS", "DISEASE", 54, 58], ["Saliva", "ORGANISM_SUBSTANCE", 3, 9], ["SARS-CoV", "SPECIES", 54, 62], ["a non-invasive specimen", "TEST", 13, 36], ["SARS", "PROBLEM", 54, 58], ["sampling", "TREATMENT", 154, 162], ["personal protective equipment", "TREATMENT", 167, 196]]], ["26, 27 The first saliva-based test, developed and validated by Rutgers University, was issued an EAU to allow testing of saliva specimens as an alternative to samples collected through swabbing.High Throughput, Rapid Detection and Point-of-Care DiagnosticsMany of the limitations seen in available testing modalities is the necessity for expensive bulky machines, trained technical staff, and reagents.", [["specimens", "ANATOMY", 128, 137], ["samples", "ANATOMY", 159, 166], ["saliva", "ORGANISM_SUBSTANCE", 17, 23], ["saliva", "ORGANISM", 121, 127], ["specimens", "ORGANISM_SUBSTANCE", 128, 137], ["The first saliva-based test", "TEST", 7, 34], ["saliva specimens", "PROBLEM", 121, 137], ["swabbing", "PROBLEM", 185, 193], ["Rapid Detection", "TEST", 211, 226], ["available testing modalities", "TEST", 288, 316], ["expensive bulky machines", "TREATMENT", 338, 362]]], ["28 These tests are most often performed in large labs at commercial diagnostic facilities or academic centers.", [["These tests", "TEST", 3, 14]]], ["Samples must therefore be sent to these labs, increasing both time and coordination.", [["Samples", "TEST", 0, 7], ["these labs", "TEST", 34, 44]]], ["Improvements to the performance of the assay are available with the use of high throughput platforms, such as the cobas 6800/8800 systems 4 , which involve an automated workflow to enable high throughput testing with minimal hands-on time, and still offering fast, reliable results (e.g., 96 results in about three hours or 384 results for the cobas 6800 System and 960 results for the cobas 8800 System in 8 hours).", [["the assay", "TEST", 35, 44], ["the cobas", "TEST", 110, 119], ["an automated workflow", "TEST", 156, 177], ["the cobas", "TEST", 382, 391]]], ["Other diagnostics that use high throughput platforms for COVID-19 testing that have received an EUA are listed on the FDA website.High Throughput, Rapid Detection and Point-of-Care DiagnosticsThe FDA granted an EUA for the first point-of-care (POC) diagnostic, the Xpert Xpress SARS-CoV-2 test.", [["Other diagnostics", "TEST", 0, 17], ["COVID-19 testing", "TEST", 57, 73], ["the Xpert Xpress SARS", "TEST", 261, 282]]], ["29 The test comes as a self-contained kit where a patient sample is loaded into a cartridge system and gives a readout in 45 minutes without the need of additional reagents or trained personnel.", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["a cartridge system", "TREATMENT", 80, 98], ["additional reagents", "TREATMENT", 153, 172]]], ["This technology allows for medical personnel in the hospital to make rapid assessments and clinical decisions.", [["rapid assessments", "TEST", 69, 86]]], ["Another POC diagnostic that received the FDA's EUA is the Accula SARS-Cov-2 test, a handheld device that also uses PCR technology to detect SARS-CoV-2 in throat and nasal swab specimens.", [["throat", "ANATOMY", 154, 160], ["nasal swab specimens", "ANATOMY", 165, 185], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 140, 150], ["throat", "ORGANISM_SUBDIVISION", 154, 160], ["nasal swab specimens", "ORGANISM_SUBSTANCE", 165, 185], ["SARS-CoV", "SPECIES", 140, 148], ["a handheld device", "TREATMENT", 82, 99], ["PCR technology", "TEST", 115, 129], ["SARS", "TEST", 140, 144], ["CoV", "TEST", 145, 148], ["throat and nasal swab specimens", "TEST", 154, 185], ["throat", "ANATOMY", 154, 160], ["nasal", "ANATOMY", 165, 170]]], ["Specimens are added to a buffer to solubilize the samples and then an aliquot is dispensed in a cassette that contains the proper controls, enzymes, and reagents as well as a detection strip for the assay that is automated from sample extraction to nucleic acid amplification.", [["Specimens", "ANATOMY", 0, 9], ["samples", "ANATOMY", 50, 57], ["nucleic acid", "CHEMICAL", 249, 261], ["enzymes", "PROTEIN", 140, 147], ["a buffer", "TREATMENT", 23, 31], ["an aliquot", "TREATMENT", 67, 77], ["enzymes", "TEST", 140, 147], ["a detection strip", "TEST", 173, 190], ["the assay", "TEST", 195, 204], ["sample extraction", "TREATMENT", 228, 245], ["nucleic acid amplification", "TREATMENT", 249, 275]]], ["Test results are displayed by the visualization of blue test lines on the detection strip after 30 minutes.", [["blue test lines", "CELL_LINE", 51, 66], ["blue test lines", "TEST", 51, 66], ["the detection strip", "TEST", 70, 89]]], ["All rights reserved most rapid POC diagnostic kit with EUA approval from the FDA is the ID NOW COVID-19 test which delivers positive results within 5 minutes and negative results in 13 minutes.", [["COVID", "TEST", 95, 100]]], ["The platform eliminates thermocycling and performs isothermal nucleic acid amplification technology with a sequence-specific fluorescent probe readout.", [["nucleic acid", "CHEMICAL", 62, 74], ["thermocycling", "TREATMENT", 24, 37], ["isothermal nucleic acid amplification technology", "TREATMENT", 51, 99], ["a sequence", "TEST", 105, 115]]], ["All of the above POC tests enable the convenience of on-site testing and rapid detection of SARS-CoV-2.", [["SARS", "DISEASE", 92, 96], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 92, 102], ["SARS-CoV", "SPECIES", 92, 100], ["the above POC tests", "TEST", 7, 26], ["site testing", "TEST", 56, 68], ["rapid detection", "TEST", 73, 88], ["SARS", "TEST", 92, 96], ["CoV", "TEST", 97, 100]]], ["Limitations of these POC testing system are that they are not built for high throughput assessments, can often be more expensive than other options, and have variable sensitivity due to the more rapid nature of the test.", [["these POC testing system", "TEST", 15, 39], ["variable sensitivity", "PROBLEM", 158, 178], ["the test", "TEST", 211, 219]]], ["Studies have been conducted to examine the performance of these POC tests compared to standard RT-PCR or in detection of low levels of viral RNA.", [["viral RNA", "RNA", 135, 144], ["these POC tests", "TEST", 58, 73], ["standard RT-PCR", "TEST", 86, 101], ["low levels of viral RNA", "PROBLEM", 121, 144], ["low levels", "OBSERVATION_MODIFIER", 121, 131], ["viral RNA", "OBSERVATION", 135, 144]]], ["30, 31 One study (comparing Xpert Xpress, ID NOW, and the ePlex systems) found that while all three had 100% specificity (did not exhibit false positive results), Xpert Xpress performed well and had the lowest limit of detection and highest sensitivity, while the ePlex and ID NOW had lower sensitivities.", [["ID NOW", "PROTEIN", 274, 280], ["One study", "TEST", 7, 16], ["Xpert Xpress", "TEST", 163, 175], ["highest sensitivity", "PROBLEM", 233, 252], ["the ePlex", "TEST", 260, 269], ["lower sensitivities", "PROBLEM", 285, 304]]], ["32 Another study determined that the POC test (ID NOW) was less sensitive compared to the traditional RT-PCR assay.", [["Another study", "TEST", 3, 16], ["the POC test", "TEST", 33, 45], ["the traditional RT-PCR assay", "TEST", 86, 114]]], ["33LAMP-and CRISPR-based DiagnosticsThere is urgent need to develop a more rapid, accurate, and point-of-care assay to control and minimize the spread of infection in the community.", [["infection", "DISEASE", 153, 162], ["33LAMP", "SIMPLE_CHEMICAL", 0, 6], ["infection", "PROBLEM", 153, 162], ["infection", "OBSERVATION", 153, 162]]], ["Alternative molecular detection techniques have employed both LAMP-and CRISPR-based methods.", [["CRISPR", "DNA", 71, 77], ["Alternative molecular detection techniques", "TEST", 0, 42], ["both LAMP", "TEST", 57, 66]]], ["Reverse transcription loop-mediated isothermal amplification (RT-LAMP) method is another nucleic acid amplification technique that amplifies small numbers of DNA and RNA templates with high specificity and sensitivity under isothermal conditions.", [["DNA", "CELLULAR_COMPONENT", 158, 161], ["Reverse transcription loop-mediated isothermal amplification", "TREATMENT", 0, 60], ["RT-LAMP) method", "TREATMENT", 62, 77], ["another nucleic acid amplification technique", "TREATMENT", 81, 125], ["small numbers of DNA", "PROBLEM", 141, 161], ["RNA templates", "PROBLEM", 166, 179], ["loop", "OBSERVATION_MODIFIER", 22, 26], ["small", "OBSERVATION_MODIFIER", 141, 146]]], ["34 LAMP is a one-step amplification reaction that requires no thermocycling steps, resulting in shorter \"sample-to-answer\" times than conventional PCR.", [["a one-step amplification reaction", "PROBLEM", 11, 44], ["thermocycling steps", "TREATMENT", 62, 81], ["conventional PCR", "TEST", 134, 150]]], ["Thus, the assay is ideally suited for field-based nucleic acid diagnostics due to rapid results (usually 30 to 60 minutes) and minimal Accepted Article requirements for expensive instrumentation or reagents.", [["nucleic acid", "CHEMICAL", 50, 62], ["the assay", "TEST", 6, 15], ["nucleic acid diagnostics", "TEST", 50, 74], ["expensive instrumentation", "TREATMENT", 169, 194], ["reagents", "TREATMENT", 198, 206]]], ["Previous RT-LAMP assays with improved specificity, visualization techniques or readouts have been developed for detecting MERS-CoV and SARS-CoV.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 122, 130], ["SARS-CoV", "ORGANISM", 135, 143], ["MERS-CoV", "SPECIES", 122, 130], ["SARS-CoV", "SPECIES", 135, 143], ["Previous RT-LAMP assays", "TEST", 0, 23], ["visualization techniques", "TEST", 51, 75], ["SARS", "PROBLEM", 135, 139], ["CoV", "PROBLEM", 140, 143]]], ["Several LAMP-based diagnostics are in the pipeline for detecting SARS-CoV-2 that have been developed by laboratories worldwide including South Korea, 35, 36 China, [37] [38] [39] and the United Kingdom 40 as well as in the United States with LAMP and CRISPR technology developed in combination (discussed in the next section).", [["SARS-CoV", "SPECIES", 65, 73], ["Several LAMP", "TEST", 0, 12], ["SARS", "PROBLEM", 65, 69], ["CoV", "TEST", 70, 73], ["LAMP", "TREATMENT", 242, 246], ["CRISPR technology", "TREATMENT", 251, 268]]], ["A rapid colorimetric assay using RT-LAMP is being developed for the qualitative detection of virus directly from saliva.", [["saliva", "ORGANISM_SUBSTANCE", 113, 119], ["A rapid colorimetric assay", "TEST", 0, 26], ["RT-LAMP", "TREATMENT", 33, 40], ["virus", "PROBLEM", 93, 98]]], ["41 The powerful genome editing technology known as CRISPR (clustered regularly interspaced short palindromic repeats) has also been recently exploited to develop rapid, inexpensive, POC diagnostics for COVID-19 testing.", [["CRISPR", "DNA", 51, 57], ["clustered regularly interspaced short palindromic repeats", "DNA", 59, 116], ["CRISPR (clustered regularly interspaced short palindromic repeats", "PROBLEM", 51, 116], ["POC diagnostics", "TEST", 182, 197], ["COVID", "TEST", 202, 207]]], ["The RNA-targeting CRISPR associated enzyme Cas13 can be programmed to target and destroy single stranded RNA viruses.", [["Cas13", "GENE_OR_GENE_PRODUCT", 43, 48], ["CRISPR associated enzyme", "PROTEIN", 18, 42], ["Cas13", "PROTEIN", 43, 48], ["The RNA", "TEST", 0, 7], ["enzyme Cas13", "TEST", 36, 48], ["single stranded RNA viruses", "PROBLEM", 89, 116], ["stranded RNA viruses", "OBSERVATION", 96, 116]]], ["42 A platform termed SHERLOCK (specific highsensitivity enzymatic reporter unlocking) was developed to combine isothermal preamplification with Cas13 to detect single molecules of RNA or DNA.", [["SHERLOCK", "CHEMICAL", 21, 29], ["Cas13", "SIMPLE_CHEMICAL", 144, 149], ["DNA", "CELLULAR_COMPONENT", 187, 190], ["SHERLOCK", "DNA", 21, 29], ["Cas13", "PROTEIN", 144, 149], ["A platform termed SHERLOCK", "TREATMENT", 3, 29], ["single molecules of RNA", "PROBLEM", 160, 183], ["DNA", "PROBLEM", 187, 190], ["RNA", "OBSERVATION", 180, 183]]], ["43, 44 The CRISPR-Cas13-based SHERLOCK COVID-19 detection protocol searches for unique nucleic acid targets (SARS-CoV-2 Orf1ab and S genes) and uses a dipstick as the visual readout in less than an hour.", [["nucleic acid", "CHEMICAL", 87, 99], ["SARS-CoV-2 Orf1ab", "GENE_OR_GENE_PRODUCT", 109, 126], ["CRISPR", "DNA", 11, 17], ["Cas13", "DNA", 18, 23], ["SHERLOCK COVID-19", "DNA", 30, 47], ["SARS-CoV-2 Orf1ab and S genes", "DNA", 109, 138], ["The CRISPR", "TEST", 7, 17], ["COVID", "TEST", 39, 44], ["detection protocol searches", "TEST", 48, 75], ["unique nucleic acid targets", "TEST", 80, 107], ["SARS", "TEST", 109, 113], ["CoV", "TEST", 114, 117], ["a dipstick", "TEST", 149, 159]]], ["All rights reservedAntigen Detection TestingThe antigen test for SARS-CoV-2 is a diagnostic test designed for rapid detection of viral proteins (antigens).", [["viral proteins", "PROTEIN", 129, 143], ["antigens", "PROTEIN", 145, 153], ["SARS-CoV", "SPECIES", 65, 73], ["Antigen Detection", "TEST", 19, 36], ["The antigen test", "TEST", 44, 60], ["SARS", "TEST", 65, 69], ["CoV", "TEST", 70, 73], ["a diagnostic test", "TEST", 79, 96], ["rapid detection", "TEST", 110, 125], ["viral proteins", "PROBLEM", 129, 143]]], ["While the main advantage of these antigen tests is the speed of the test, they are often plagued with inaccurate results and have lower sensitivity and specificity than nucleic acid assays.Antigen Detection TestingPrevious rapid antigen tests for influenza (H1N1) and respiratory syncytial virus were found to be less sensitive compared with RT-PCR.", [["nucleic acid", "CHEMICAL", 169, 181], ["influenza", "DISEASE", 247, 256], ["respiratory syncytial virus", "DISEASE", 268, 295], ["influenza (H1N1", "ORGANISM", 247, 262], ["respiratory syncytial virus", "ORGANISM", 268, 295], ["respiratory syncytial virus", "SPECIES", 268, 295], ["respiratory syncytial virus", "SPECIES", 268, 295], ["these antigen tests", "TEST", 28, 47], ["the test", "TEST", 64, 72], ["lower sensitivity", "PROBLEM", 130, 147], ["nucleic acid assays", "TEST", 169, 188], ["Antigen Detection", "TEST", 189, 206], ["rapid antigen tests", "TEST", 223, 242], ["influenza", "PROBLEM", 247, 256], ["H1N1", "PROBLEM", 258, 262], ["respiratory syncytial virus", "PROBLEM", 268, 295], ["RT-PCR", "TEST", 342, 348], ["main", "OBSERVATION_MODIFIER", 10, 14]]], ["49, 50 Development of antibodies that are specific to viral antigens is often difficult and time consuming and antigen tests must undergo rigorous quality control measures to ensure specificity and sensitivity.", [["antibodies", "PROTEIN", 22, 32], ["viral antigens", "PROTEIN", 54, 68], ["antibodies", "PROBLEM", 22, 32], ["viral antigens", "TEST", 54, 68], ["antigen tests", "TEST", 111, 124], ["rigorous quality control measures", "TREATMENT", 138, 171], ["specificity", "TEST", 182, 193], ["sensitivity", "TEST", 198, 209]]], ["Although antigen tests are very specific for the virus, they cannot detect all active infections and thus have a higher chance of false negatives than RT-PCR.", [["infections", "DISEASE", 86, 96], ["antigen tests", "TEST", 9, 22], ["the virus", "PROBLEM", 45, 54], ["all active infections", "PROBLEM", 75, 96], ["PCR", "TEST", 154, 157], ["active", "OBSERVATION_MODIFIER", 79, 85], ["infections", "OBSERVATION", 86, 96]]], ["FDA issued an EUA to the first antigen assay, the Sofia 2 SARS Antigen FIA test, which employs immunofluorescence-based lateral flow technology in a sandwich design that is used to detect the viral nucleocapsid protein in nasopharyngeal and nasal swab specimens with test results in 15 minutes.", [["nasopharyngeal", "ANATOMY", 222, 236], ["nasal swab specimens", "ANATOMY", 241, 261], ["nasopharyngeal", "CANCER", 222, 236], ["nasal swab specimens", "CANCER", 241, 261], ["viral nucleocapsid protein", "PROTEIN", 192, 218], ["SARS Antigen FIA test", "TEST", 58, 79], ["immunofluorescence", "TEST", 95, 113], ["the viral nucleocapsid protein", "TEST", 188, 218], ["nasopharyngeal and nasal swab specimens", "TEST", 222, 261], ["nasopharyngeal", "ANATOMY", 222, 236], ["nasal", "ANATOMY", 241, 246]]], ["Future research on the clinical performance of antigen testing compared to NAAT is highly encouraged to determine their diagnostic utility.Serology TestingOutside of nucleic acid amplification-based diagnostics, serological or antibody tests for COVID-19 is another promising testing modality.", [["nucleic acid", "CHEMICAL", 166, 178], ["antigen testing", "TEST", 47, 62], ["NAAT", "TEST", 75, 79], ["Serology", "TEST", 139, 147], ["nucleic acid amplification", "TEST", 166, 192], ["based diagnostics", "TEST", 193, 210], ["serological", "TEST", 212, 223], ["antibody tests", "TEST", 227, 241], ["COVID", "TEST", 246, 251]]], ["Both molecular and serological tests are intended for patients at different stages of the disease process with RT-PCR for detection of current active infection and serology tests for later stages since these assays detect the presence of SARS-CoV-2 antibodies produced by the bodies humoral immune system.", [["infection", "DISEASE", 150, 159], ["patients", "ORGANISM", 54, 62], ["SARS-CoV-2", "ORGANISM", 238, 248], ["immune system", "ANATOMICAL_SYSTEM", 291, 304], ["SARS-CoV-2 antibodies", "PROTEIN", 238, 259], ["patients", "SPECIES", 54, 62], ["SARS-CoV", "SPECIES", 238, 246], ["serological tests", "TEST", 19, 36], ["the disease process", "PROBLEM", 86, 105], ["RT-PCR", "TEST", 111, 117], ["current active infection", "PROBLEM", 135, 159], ["serology tests", "TEST", 164, 178], ["these assays", "TEST", 202, 214], ["SARS", "PROBLEM", 238, 242], ["CoV-2 antibodies", "TEST", 243, 259], ["disease", "OBSERVATION", 90, 97], ["active", "OBSERVATION_MODIFIER", 143, 149], ["infection", "OBSERVATION", 150, 159]]], ["Serologic testing enables the understanding of how patients produce antibodies to SARS-CoV-2, and assays can detect IgA, IgM, IgG, or total antibody.Profiling of early humoral response in one study of patients with COVID-19 determined that IgA andIgM antibodies can be detected as early as 5 days after new infection, with higher levels detected in the second and third week 51, 52 .", [["SARS", "DISEASE", 82, 86], ["infection", "DISEASE", 307, 316], ["patients", "ORGANISM", 51, 59], ["SARS-CoV-2", "ORGANISM", 82, 92], ["IgA", "GENE_OR_GENE_PRODUCT", 116, 119], ["IgM", "GENE_OR_GENE_PRODUCT", 121, 124], ["IgG", "GENE_OR_GENE_PRODUCT", 126, 129], ["patients", "ORGANISM", 201, 209], ["IgA", "GENE_OR_GENE_PRODUCT", 240, 243], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 247, 261], ["antibodies", "PROTEIN", 68, 78], ["IgA", "PROTEIN", 116, 119], ["IgM", "PROTEIN", 121, 124], ["IgG", "PROTEIN", 126, 129], ["total antibody", "PROTEIN", 134, 148], ["IgA", "PROTEIN", 240, 243], ["IgM antibodies", "PROTEIN", 247, 261], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 201, 209], ["SARS-CoV", "SPECIES", 82, 90], ["Serologic testing", "TEST", 0, 17], ["SARS", "TEST", 82, 86], ["CoV", "TEST", 87, 90], ["assays", "TEST", 98, 104], ["IgA", "TEST", 116, 119], ["IgM", "TEST", 121, 124], ["IgG", "TEST", 126, 129], ["total antibody", "TEST", 134, 148], ["one study", "TEST", 188, 197], ["COVID", "TEST", 215, 220], ["IgA andIgM antibodies", "PROBLEM", 240, 261], ["new infection", "PROBLEM", 303, 316], ["early", "OBSERVATION_MODIFIER", 162, 167], ["humoral response", "OBSERVATION", 168, 184], ["infection", "OBSERVATION", 307, 316]]], ["Other studies detected optimal IgM antibodies towards the end of the first week that peaked during the third week after symptom onset, and may correspond to the emergence of negative results by RT-PCR tests as the viral load is cleared (Figure 2) .", [["IgM antibodies", "GENE_OR_GENE_PRODUCT", 31, 45], ["IgM antibodies", "PROTEIN", 31, 45], ["Other studies", "TEST", 0, 13], ["optimal IgM antibodies", "TEST", 23, 45], ["RT", "TEST", 194, 196], ["PCR tests", "TEST", 197, 206], ["the viral load", "TEST", 210, 224]]], ["16, 19, 51, 53 Another report determined earlier IgA seroconversion than IgM 54 or that IgA is detected at higherAccepted ArticleThis article is protected by copyright.", [["IgA", "GENE_OR_GENE_PRODUCT", 49, 52], ["IgA", "GENE_OR_GENE_PRODUCT", 88, 91], ["IgA", "PROTEIN", 49, 52], ["IgM 54", "PROTEIN", 73, 79], ["IgA", "PROTEIN", 88, 91], ["earlier IgA seroconversion", "TEST", 41, 67], ["IgM", "TEST", 73, 76], ["IgA", "TEST", 88, 91]]], ["55 IgG antibodies become detectable later in the infection course around 7-14 days after symptom onset and levels remained relatively high until 6 weeks.", [["infection", "DISEASE", 49, 58], ["IgG", "GENE_OR_GENE_PRODUCT", 3, 6], ["IgG antibodies", "PROTEIN", 3, 17], ["IgG antibodies", "TEST", 3, 17], ["symptom onset", "PROBLEM", 89, 102], ["levels", "TEST", 107, 113], ["infection", "OBSERVATION", 49, 58]]], ["51, 52 While the data remains premature, a small study of 285 patients with COVID-19 reported that 100% of patients tested positive for IgG within 20 days after symptom onset.", [["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 107, 115], ["IgG", "GENE_OR_GENE_PRODUCT", 136, 139], ["IgG", "PROTEIN", 136, 139], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 107, 115], ["premature", "PROBLEM", 30, 39], ["a small study", "TEST", 41, 54], ["COVID", "TEST", 76, 81], ["IgG", "TEST", 136, 139], ["symptom onset", "PROBLEM", 161, 174], ["small", "OBSERVATION_MODIFIER", 43, 48]]], ["Seroconversion for IgG and IgM occurred simultaneously or sequentially between the third and fourth weeks, and both levels plateaued within 6 days after seroconversion.", [["IgG", "GENE_OR_GENE_PRODUCT", 19, 22], ["IgM", "GENE_OR_GENE_PRODUCT", 27, 30], ["IgG", "PROTEIN", 19, 22], ["IgM", "PROTEIN", 27, 30], ["Seroconversion", "TREATMENT", 0, 14], ["IgG", "TEST", 19, 22], ["IgM", "PROBLEM", 27, 30], ["seroconversion", "PROBLEM", 153, 167]]], ["56 Asymptomatic patients may seroconvert later in the course of infection or may not at all.", [["infection", "DISEASE", 64, 73], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["infection", "PROBLEM", 64, 73], ["infection", "OBSERVATION", 64, 73]]], ["57 Another study found that asymptomatic patients have significantly longer duration of viral shedding, lower IgG and neutralizing serum antibody levels compared to the symptomatic group, suggesting that asymptomatic patients may mount a weaker antibody response and immunity may diminish within months of infection.", [["serum", "ANATOMY", 131, 136], ["infection", "DISEASE", 306, 315], ["patients", "ORGANISM", 41, 49], ["IgG", "GENE_OR_GENE_PRODUCT", 110, 113], ["serum", "ORGANISM_SUBSTANCE", 131, 136], ["patients", "ORGANISM", 217, 225], ["IgG", "PROTEIN", 110, 113], ["serum antibody", "PROTEIN", 131, 145], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 217, 225], ["Another study", "TEST", 3, 16], ["viral shedding", "PROBLEM", 88, 102], ["lower IgG", "TEST", 104, 113], ["neutralizing serum antibody levels", "TEST", 118, 152], ["a weaker antibody response", "PROBLEM", 236, 262], ["infection", "PROBLEM", 306, 315], ["infection", "OBSERVATION", 306, 315]]], ["All rights reserved been granted EUAs using various platforms, including ELISAs and CIAs, and all authorized tests are qualitative rather than quantitative.", [["ELISAs", "TEST", 73, 79], ["all authorized tests", "TEST", 94, 114]]], ["A comprehensive listing of all commercially marketed antibody tests granted EUAs are updated on the FDA and FIND websites on a rolling basis.Understanding Target Selection, Assay Sensitivity/Specificity & LimitationsSerology tests are currently being developed for the detection of antibodies (in blood plasma or serum) to two main antigenic targets, the N protein and S protein, including subunits S1 and S2 as well as the receptor-binding domain (RBD) of SARS-CoV-2.", [["blood plasma", "ANATOMY", 297, 309], ["serum", "ANATOMY", 313, 318], ["blood", "ORGANISM_SUBSTANCE", 297, 302], ["plasma", "ORGANISM_SUBSTANCE", 303, 309], ["serum", "ORGANISM_SUBSTANCE", 313, 318], ["S protein", "GENE_OR_GENE_PRODUCT", 369, 378], ["S1", "GENE_OR_GENE_PRODUCT", 399, 401], ["S2", "GENE_OR_GENE_PRODUCT", 406, 408], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 457, 467], ["antibodies", "PROTEIN", 282, 292], ["N protein", "PROTEIN", 355, 364], ["S protein", "PROTEIN", 369, 378], ["S1", "PROTEIN", 399, 401], ["S2", "PROTEIN", 406, 408], ["receptor-binding domain", "PROTEIN", 424, 447], ["RBD", "PROTEIN", 449, 452], ["SARS-CoV", "SPECIES", 457, 465], ["all commercially marketed antibody tests", "TEST", 27, 67], ["Assay Sensitivity", "TEST", 173, 190], ["Specificity", "TEST", 191, 202], ["Serology tests", "TEST", 216, 230], ["the detection", "TEST", 265, 278], ["antibodies", "PROBLEM", 282, 292], ["blood plasma", "TEST", 297, 309], ["serum", "TEST", 313, 318], ["the N protein", "TEST", 351, 364], ["S protein", "TEST", 369, 378], ["subunits S1 and S2", "TREATMENT", 390, 408], ["SARS", "TEST", 457, 461], ["CoV", "TEST", 462, 465], ["S2", "ANATOMY", 406, 408]]], ["The target selection determines crossreactivity and specificity with N being more conserved across coronaviruses than S and within S, the RBD is more conserved than either subunit.Understanding Target Selection, Assay Sensitivity/Specificity & LimitationsProper serology testing requires understanding the performance characteristics and limitations of these tests.", [["RBD", "GENE_OR_GENE_PRODUCT", 138, 141], ["RBD", "PROTEIN", 138, 141], ["Assay Sensitivity", "TEST", 212, 229], ["Specificity", "TEST", 230, 241], ["Proper serology testing", "TEST", 255, 278], ["these tests", "TEST", 353, 364], ["RBD", "OBSERVATION", 138, 141]]], ["Serological tests have varying levels of specificity and sensitivity and can detect past infections in those who are RT-PCR negative.", [["infections", "DISEASE", 89, 99], ["Serological tests", "TEST", 0, 17], ["sensitivity", "TEST", 57, 68], ["past infections", "PROBLEM", 84, 99], ["RT-PCR", "TEST", 117, 123]]], ["False positives can result from cross-reactivity with pre-existing antibodies from previous infections such as other coronaviruses (229E, NL63, OC43, and HKU1 that cause the common cold; SARS-CoV or MERS-CoV; an antibody test with low specificity); whereas negative results may be due to antibodies that have not yet formed during the early stages of infections.", [["infections", "DISEASE", 92, 102], ["infections", "DISEASE", 351, 361], ["coronaviruses", "ORGANISM", 117, 130], ["OC43", "GENE_OR_GENE_PRODUCT", 144, 148], ["HKU1", "GENE_OR_GENE_PRODUCT", 154, 158], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 187, 195], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 199, 207], ["pre-existing antibodies", "PROTEIN", 54, 77], ["antibodies", "PROTEIN", 288, 298], ["SARS-CoV", "SPECIES", 187, 195], ["MERS-CoV", "SPECIES", 199, 207], ["False positives", "PROBLEM", 0, 15], ["pre-existing antibodies", "PROBLEM", 54, 77], ["previous infections", "PROBLEM", 83, 102], ["other coronaviruses", "PROBLEM", 111, 130], ["NL63", "TEST", 138, 142], ["OC43", "TEST", 144, 148], ["the common cold", "PROBLEM", 170, 185], ["SARS", "PROBLEM", 187, 191], ["MERS", "PROBLEM", 199, 203], ["CoV", "PROBLEM", 204, 207], ["an antibody test", "TEST", 209, 225], ["antibodies", "PROBLEM", 288, 298], ["infections", "PROBLEM", 351, 361], ["infections", "OBSERVATION", 92, 102], ["early stages", "OBSERVATION_MODIFIER", 335, 347], ["infections", "OBSERVATION", 351, 361]]], ["Initial studies have shown that N and S1 protein ELISAs could detect SARS-CoV-2 with high specificity; RBD and N protein ELISAs are more sensitive than S1 assays in detecting antibodies in patients with mild infections.", [["infections", "DISEASE", 208, 218], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 69, 79], ["patients", "ORGANISM", 189, 197], ["RBD", "PROTEIN", 103, 106], ["N protein", "PROTEIN", 111, 120], ["S1", "PROTEIN", 152, 154], ["antibodies", "PROTEIN", 175, 185], ["patients", "SPECIES", 189, 197], ["SARS-CoV", "SPECIES", 69, 77], ["Initial studies", "TEST", 0, 15], ["S1 protein ELISAs", "TEST", 38, 55], ["SARS", "TEST", 69, 73], ["CoV", "TEST", 74, 77], ["RBD", "TEST", 103, 106], ["N protein ELISAs", "TEST", 111, 127], ["S1 assays", "TEST", 152, 161], ["mild infections", "PROBLEM", 203, 218], ["mild", "OBSERVATION_MODIFIER", 203, 207], ["infections", "OBSERVATION", 208, 218]]], ["61 Researchers also found that antibodies to N protein are more sensitive than to S protein during early infection using a liquid phase immunoassay called luciferase immunoprecipitation systems.", [["infection", "DISEASE", 105, 114], ["antibodies to N protein", "GENE_OR_GENE_PRODUCT", 31, 54], ["luciferase", "GENE_OR_GENE_PRODUCT", 155, 165], ["antibodies", "PROTEIN", 31, 41], ["N protein", "PROTEIN", 45, 54], ["S protein", "PROTEIN", 82, 91], ["luciferase", "PROTEIN", 155, 165], ["antibodies to N protein", "TEST", 31, 54], ["early infection", "PROBLEM", 99, 114], ["a liquid phase immunoassay", "TEST", 121, 147], ["luciferase immunoprecipitation systems", "TREATMENT", 155, 193], ["infection", "OBSERVATION", 105, 114]]], ["62 A meta-analysis was recently conducted to investigate the performance of all available antibody tests and found that tests using the S antigen are more sensitive than N antigen-based tests.", [["S antigen", "GENE_OR_GENE_PRODUCT", 136, 145], ["N antigen", "GENE_OR_GENE_PRODUCT", 170, 179], ["S antigen", "PROTEIN", 136, 145], ["N antigen", "PROTEIN", 170, 179], ["A meta-analysis", "TEST", 3, 18], ["all available antibody tests", "TEST", 76, 104], ["tests", "TEST", 120, 125], ["the S antigen", "TEST", 132, 145], ["N antigen-based tests", "TEST", 170, 191]]], ["A combined IgG/IgM test displayed better sensitivity than measuring either antibody type alone with ELISA tests being more sensitive than lateral flow immunoassays.", [["IgG", "GENE_OR_GENE_PRODUCT", 11, 14], ["IgG", "PROTEIN", 11, 14], ["IgM", "PROTEIN", 15, 18], ["A combined IgG/IgM test", "TEST", 0, 23], ["ELISA tests", "TEST", 100, 111], ["lateral flow immunoassays", "TEST", 138, 163]]], ["63 A recent study found high sensitivity and specificity of the RBD for antibody detection and its strong association with SARS-CoV-2 neutralizing antibodies.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 123, 133], ["RBD", "PROTEIN", 64, 67], ["SARS-CoV-2 neutralizing antibodies", "PROTEIN", 123, 157], ["SARS-CoV", "SPECIES", 123, 131], ["A recent study", "TEST", 3, 17], ["high sensitivity", "PROBLEM", 24, 40], ["the RBD", "PROBLEM", 60, 67], ["antibody detection", "TEST", 72, 90], ["SARS", "TEST", 123, 127], ["CoV", "TEST", 128, 131], ["2 neutralizing antibodies", "PROBLEM", 132, 157]]], ["59 Studies are ongoing to determine the clinical performance characteristics of various antibody tests across different platforms.", [["various antibody tests", "TEST", 80, 102]]], ["All rights reservedUnderstanding Target Selection, Assay Sensitivity/Specificity & LimitationsThe prevalence of SARS-CoV-2 antibody positive individuals in the US population remains to be determined and is based on the different rates of infection across various locations and populations.Understanding Target Selection, Assay Sensitivity/Specificity & LimitationsThe positive and negative predictive values (PPV and NPV) of antibody tests will affect the overall outcome of testing and are determined by the prevalence of the disease and the sensitivity/specificity of the test.", [["SARS", "DISEASE", 112, 116], ["infection", "DISEASE", 238, 247], ["SARS-CoV-2 antibody", "GENE_OR_GENE_PRODUCT", 112, 131], ["SARS-CoV", "SPECIES", 112, 120], ["Assay Sensitivity", "TEST", 51, 68], ["Specificity", "TEST", 69, 80], ["SARS", "TEST", 112, 116], ["CoV", "TEST", 117, 120], ["2 antibody positive individuals", "PROBLEM", 121, 152], ["infection", "PROBLEM", 238, 247], ["Assay Sensitivity", "TEST", 321, 338], ["Specificity", "TEST", 339, 350], ["PPV", "TEST", 409, 412], ["NPV", "TEST", 417, 420], ["antibody tests", "TEST", 425, 439], ["testing", "TEST", 475, 482], ["the disease", "PROBLEM", 523, 534], ["the sensitivity", "TEST", 539, 554], ["the test", "TEST", 570, 578], ["infection", "OBSERVATION", 238, 247]]], ["PPV is the probability that a patient who tests positive truly has the disease and NPV is the chance that one who tests negative has not been infected.", [["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37], ["PPV", "TREATMENT", 0, 3], ["a patient who tests", "TEST", 28, 47], ["the disease", "PROBLEM", 67, 78], ["NPV", "TEST", 83, 86], ["infected", "OBSERVATION", 142, 150]]], ["In the setting of low prevalence of SARS-CoV-2 infection, even a highly specific test can give a large number of false positives; thus, the PPV will be low.", [["SARS-CoV-2 infection", "DISEASE", 36, 56], ["SARS-CoV-2", "ORGANISM", 36, 46], ["SARS-CoV-2", "SPECIES", 36, 46], ["SARS", "PROBLEM", 36, 40], ["CoV-2 infection", "PROBLEM", 41, 56], ["false positives", "PROBLEM", 113, 128], ["the PPV", "TEST", 136, 143], ["low prevalence", "OBSERVATION_MODIFIER", 18, 32], ["SARS", "OBSERVATION", 36, 40], ["infection", "OBSERVATION", 47, 56], ["large", "OBSERVATION_MODIFIER", 97, 102], ["false positives", "OBSERVATION", 113, 128]]], ["The FDA has summarized the expected performance of the tests it has authorized based on the information FDA reviewed when deciding whether or not to grant these tests an EUA and assuming a prevalence of 5% for PPV and NPV calculations.", [["the tests", "TEST", 51, 60], ["PPV", "TREATMENT", 210, 213], ["NPV calculations", "TEST", 218, 234]]], ["We refer the reader to the FDA's website for the performance characteristics of the individual tests which have received EUA status (https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-authorizedserology-test-performance).Understanding Target Selection, Assay Sensitivity/Specificity & LimitationsAntibody response against SARS-CoV-2 remains poorly understood and the clinical utility of tests is unclear until the assays are properly validated to demonstrate their accuracy.", [["SARS-CoV-2", "ORGANISM", 348, 358], ["SARS-CoV", "SPECIES", 348, 356], ["the individual tests", "TEST", 80, 100], ["Target Selection", "TEST", 261, 277], ["Assay Sensitivity", "TEST", 279, 296], ["Antibody response", "TEST", 322, 339], ["SARS", "TEST", 348, 352], ["CoV", "TEST", 353, 356], ["tests", "TEST", 413, 418], ["the assays", "TEST", 436, 446]]], ["Massive efforts are currently underway to conduct large-scale validation studies on the performance of these assays, which is critical before they can be used in seroprevalence studies for disease surveillance.", [["Massive efforts", "PROBLEM", 0, 15], ["these assays", "TEST", 103, 115], ["seroprevalence studies", "TEST", 162, 184], ["disease surveillance", "TEST", 189, 209]]], ["A collaborative effort by the FDA, NIH, CDC and Biomedical Advanced Research and Development Authority (BARDA) is currently underway to conduct the performance assessments and establish the validity of serological tests against a well-characterized set of clinical samples collected before and during the pandemic and correlate them with neutralization assays.", [["samples", "ANATOMY", 265, 272], ["the performance assessments", "TEST", 144, 171], ["serological tests", "TEST", 202, 219], ["clinical samples", "TEST", 256, 272], ["neutralization assays", "TEST", 338, 359]]], ["The validation dataset is published on the openFDA website (https://open.fda.gov/apis/device/covid19serology/).", [["openFDA website", "DNA", 43, 58]]], ["Properly validated accurate test can then potentially be used in the future as a public health surveillance tool to monitor the epidemiological spread COVID-19, as a risk assessment tool to screen for immunity, or as a screening tool to identify donor patients who have antibodies for convalescent plasma treatment.Accepted ArticleThis article is protected by copyright.", [["plasma", "ANATOMY", 298, 304], ["patients", "ORGANISM", 252, 260], ["plasma", "ORGANISM_SUBSTANCE", 298, 304], ["antibodies", "PROTEIN", 270, 280], ["patients", "SPECIES", 252, 260], ["a risk assessment", "TEST", 164, 181], ["a screening tool", "TEST", 217, 233], ["antibodies", "TREATMENT", 270, 280], ["convalescent plasma treatment", "TREATMENT", 285, 314]]], ["These test kits would include the necessary components and instructions to properly obtain a nasal swab sample while at home.", [["nasal swab sample", "ANATOMY", 93, 110], ["These test kits", "TEST", 0, 15], ["a nasal swab sample", "TEST", 91, 110]]], ["The kits would then be mailed to a central laboratory for testing.", [["testing", "TEST", 58, 65]]], ["On April 21, 2020 the FDA authorized the first molecular diagnostic test with a home collection option for LabCorp's RT-PCR assay to permit testing of samples self-collected by patients at home using the company's home collection kit.Accepted ArticleSubsequently, Rutgers University also received EUA designation for its at-home saliva self-collection assay.", [["samples", "ANATOMY", 151, 158], ["patients", "ORGANISM", 177, 185], ["saliva", "ORGANISM_SUBSTANCE", 329, 335], ["patients", "SPECIES", 177, 185], ["a home collection option", "TREATMENT", 78, 102], ["LabCorp's RT", "TREATMENT", 107, 119], ["PCR assay", "TEST", 120, 129], ["collection assay", "TEST", 341, 357]]], ["Everlywell's COVID-19 Test Home Collection Kit is the first standalone sample collection kit (for self-collecting a nasal sample at home) to be granted an EUA and can be paired with any authorized NAAT at any lab.Accepted ArticleAt-home collection provides an additional solution that limits exposure and keeps patients isolated.Accepted ArticleHowever, there are still some concerns that may need to be addressed.", [["nasal sample", "ANATOMY", 116, 128], ["patients", "ORGANISM", 311, 319], ["patients", "SPECIES", 311, 319], ["Everlywell's COVID", "TEST", 0, 18], ["a nasal sample at home", "TREATMENT", 114, 136], ["ArticleAt-home collection", "TREATMENT", 222, 247], ["an additional solution", "TREATMENT", 257, 279]]], ["The availability of nasopharyngeal swab supply may pose an issue if test needs continue to expand and swabs used for in-person testing are in short supply in some regions.", [["nasopharyngeal swab", "ANATOMY", 20, 39], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 20, 39], ["nasopharyngeal swab supply", "TREATMENT", 20, 46], ["swabs", "TEST", 102, 107], ["person testing", "TEST", 120, 134], ["nasopharyngeal", "ANATOMY", 20, 34]]], ["Companies would need to develop alternative methods of sample collection, such as the use of oral swabs or fingerstick whole blood serology tests to provide some relief for the swab-based tests.", [["sample", "ANATOMY", 55, 61], ["oral swabs", "ANATOMY", 93, 103], ["blood", "ANATOMY", 125, 130], ["oral", "ORGANISM_SUBDIVISION", 93, 97], ["swabs", "ORGANISM_SUBSTANCE", 98, 103], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["sample collection", "PROBLEM", 55, 72], ["oral swabs", "TREATMENT", 93, 103], ["fingerstick whole blood serology tests", "TEST", 107, 145], ["the swab-based tests", "TEST", 173, 193]]], ["Improper self-collection may affect specimen quality and subsequent test results.", [["specimen", "ANATOMY", 36, 44], ["Improper self-collection", "PROBLEM", 0, 24], ["specimen quality", "TEST", 36, 52], ["subsequent test results", "TEST", 57, 80]]], ["At-home sample collection may encounter issues with poor sampling and ongoing studies will need to examine whether samples (saliva, dried blood spot, swabs) self-collected by patients at home and monitored by a provider through telehealth are sufficient specimens for molecular and serology SARS-CoV-2 testing.", [["samples", "ANATOMY", 115, 122], ["blood", "ANATOMY", 138, 143], ["swabs", "ANATOMY", 150, 155], ["specimens", "ANATOMY", 254, 263], ["saliva", "ORGANISM_SUBSTANCE", 124, 130], ["blood", "ORGANISM_SUBSTANCE", 138, 143], ["swabs", "ORGANISM_SUBDIVISION", 150, 155], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["poor sampling", "PROBLEM", 52, 65], ["ongoing studies", "TEST", 70, 85], ["samples", "TEST", 115, 122], ["saliva", "TEST", 124, 130], ["dried blood spot", "TEST", 132, 148], ["swabs", "TEST", 150, 155], ["molecular and serology SARS", "TEST", 268, 295], ["CoV-2 testing", "TEST", 296, 309]]], ["66 Additional limitations to these tests are the time incurred in shipping the test kits as well as the time for the laboratory assessment.ConclusionsIn the face of a pandemic, testing, contact tracing, and isolation are all important parameters to contain the spread of COVID-19.", [["these tests", "TEST", 29, 40], ["the test kits", "TEST", 75, 88], ["the laboratory assessment", "TEST", 113, 138], ["a pandemic", "PROBLEM", 165, 175], ["testing", "TEST", 177, 184], ["contact tracing", "TEST", 186, 201], ["COVID", "TEST", 271, 276], ["pandemic", "OBSERVATION", 167, 175]]], ["While much is unknown about the new coronavirus, it is with certainty that SARS-CoV-2 infection with be a recurring disease.", [["coronavirus", "DISEASE", 36, 47], ["SARS-CoV-2 infection", "DISEASE", 75, 95], ["coronavirus", "ORGANISM", 36, 47], ["SARS-CoV-2", "ORGANISM", 75, 85], ["SARS-CoV-2", "SPECIES", 75, 85], ["the new coronavirus", "PROBLEM", 28, 47], ["SARS", "PROBLEM", 75, 79], ["CoV-2 infection", "PROBLEM", 80, 95], ["a recurring disease", "PROBLEM", 104, 123], ["coronavirus", "OBSERVATION", 36, 47], ["recurring", "OBSERVATION_MODIFIER", 106, 115], ["disease", "OBSERVATION", 116, 123]]], ["Mounting evidence from recent studies demonstrates the existence of viral transmission from presymptomatic and asymptomatic patients.", [["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["recent studies", "TEST", 23, 37], ["viral transmission", "PROBLEM", 68, 86], ["presymptomatic and asymptomatic patients", "PROBLEM", 92, 132], ["viral", "OBSERVATION", 68, 73]]], ["67 In the latter scenario, expansive testing remains a priority on the global level.", [["expansive testing", "TEST", 27, 44], ["expansive", "OBSERVATION_MODIFIER", 27, 36]]], ["Widespread testing must increase in order to effectively enact isolation procedures and contact tracing measures toAccepted ArticleThis article is protected by copyright.", [["Widespread testing", "TEST", 0, 18], ["enact isolation procedures", "TREATMENT", 57, 83]]], ["All rights reserved detect asymptomatic infections in order to break transmission chains and attempt to flatten the curve.", [["infections", "DISEASE", 40, 50], ["asymptomatic infections", "PROBLEM", 27, 50], ["break transmission chains", "TREATMENT", 63, 88], ["asymptomatic", "OBSERVATION_MODIFIER", 27, 39], ["infections", "OBSERVATION", 40, 50]]]], "2b814057839f1420d8b891b0f921f7a2c9c217f1": [["IntroductionIn almost all countries, women live longer than men yet experience poorer mental health, greater disability and greater comorbidities.", [["disability", "DISEASE", 109, 119], ["women", "ORGANISM", 37, 42], ["men", "ORGANISM", 60, 63], ["women", "SPECIES", 37, 42], ["men", "SPECIES", 60, 63], ["IntroductionIn", "TREATMENT", 0, 14], ["greater comorbidities", "PROBLEM", 124, 145]]], ["The excess mortality rates of men, especially those under age 45 , have historically been explained by accidents and injuries.", [["accidents", "DISEASE", 103, 112], ["injuries", "DISEASE", 117, 125], ["men", "ORGANISM", 30, 33], ["men", "SPECIES", 30, 33], ["injuries", "PROBLEM", 117, 125]]], ["However, changing risk factor profiles observed globally, particularly from smoking cessation, have conferred greater survival gains in men.", [["men", "ORGANISM", 136, 139], ["men", "SPECIES", 136, 139], ["changing risk factor profiles", "PROBLEM", 9, 38]]], ["At the same time that these mortality risk factors have changed, the global economic climate has changed dramatically, particularly in recent times in the context of the COVID-19 pandemic.", [["these mortality risk factors", "PROBLEM", 22, 50], ["the global economic climate", "PROBLEM", 65, 92], ["the COVID", "TEST", 166, 175], ["pandemic", "PROBLEM", 179, 187], ["global", "OBSERVATION_MODIFIER", 69, 75], ["economic", "OBSERVATION_MODIFIER", 76, 84], ["climate", "OBSERVATION", 85, 92], ["changed", "OBSERVATION_MODIFIER", 97, 104], ["dramatically", "OBSERVATION_MODIFIER", 105, 117]]], ["Austerity measures in response to economic downturns have and will continue to exacerbate socioeconomic inequalities for all.", [["Austerity measures", "TREATMENT", 0, 18]]], ["These widening socioeconomic inequalities may help explain the weakening female survival advantage [2] .IntroductionA social determinants of health (SDoH) framework seeks to understand how materialist and structuralist health inequities persist throughout life.", [["These widening socioeconomic inequalities", "PROBLEM", 0, 41]]], ["A SDoH approach purports that health outcomes depend on the organisation and distribution of socioeconomic resources across any given society [3] .", [["A SDoH approach", "TREATMENT", 0, 15]]], ["This is despite the fact that, in almost all societies, women and girls, when compared with their male counterparts, have reduced access to the socioeconomic resources -namely education and/or employment -that ensure good health and wellbeing.", [["women", "ORGANISM", 56, 61], ["women", "SPECIES", 56, 61], ["girls", "SPECIES", 66, 71]]], ["This can stem from cultural biases and practices that can commence early in the life course (e.g., discriminatory feeding patterns, gender-based violence, uneven labour divisions) and persist across middle and later life (e.g., the gender pay gap, political impotence [6] ).", [["impotence", "DISEASE", 258, 267], ["middle", "ANATOMY_MODIFIER", 199, 205]]], ["Moreover, SEP may exert its influence on the outcomes of women and girls differently to boys and men at specific stages of the life course.", [["women", "ORGANISM", 57, 62], ["men", "ORGANISM", 97, 100], ["women", "SPECIES", 57, 62], ["girls", "SPECIES", 67, 72], ["boys", "SPECIES", 88, 92], ["men", "SPECIES", 97, 100]]], ["These concepts will, thus, be explored in this paper.AimsThe objective of this paper is to review how, what and when SEP -a construct at the heart of the SDoH theory -shapes the health and longevity of women and girls.", [["heart", "ANATOMY", 141, 146], ["heart", "ORGAN", 141, 146], ["women", "ORGANISM", 202, 207], ["women", "SPECIES", 202, 207], ["girls", "SPECIES", 212, 217], ["heart", "ANATOMY", 141, 146]]], ["We first describe SDoH theory and then use examples from each life course stage to demonstrate how SEP can differentially shape girls'/women's health outcomes compared to boys'/men's.", [["women", "ORGANISM", 135, 140], ["men", "ORGANISM", 177, 180], ["girls", "SPECIES", 128, 133], ["women", "SPECIES", 135, 140], ["boys", "SPECIES", 171, 175], ["men", "SPECIES", 177, 180]]], ["These stages aligning with important SEP transitions rather than those associated with biological development.", [["important SEP transitions", "PROBLEM", 27, 52]]], ["We also consider differences in outcomes between sub-groups of girls/women when other axes of inequalities like ethnicity and residential setting are considered.", [["women", "ORGANISM", 69, 74], ["girls", "SPECIES", 63, 68], ["women", "SPECIES", 69, 74]]], ["We discuss how the timing and trajectory of SEP across the life course may be important in these determinations and conclude by making key recommendations in the context of clinical, research and policy development.Methodological approachGiven the broad scope of our aims, it was not feasible to conduct a systematic review.", [["SEP across the life course", "TREATMENT", 44, 70], ["a systematic review", "TEST", 304, 323]]], ["Using keywords including \"gender\", \"sex\", \"women\", \"girls\", \"social gradient\", \"socioeconomic status\", \"education\", and \"health\", we searched PubMed, Cochrane, CINAHL and EMBASE databases to identify articles published after the year 1990.", [["women", "ORGANISM", 43, 48], ["women", "SPECIES", 43, 48], ["girls", "SPECIES", 52, 57]]], ["Articles published within the last decade, systematic reviews, and primary studies with population-wide or crosscountry samples were preferentially included.", [["samples", "CANCER", 120, 127], ["systematic reviews", "TEST", 43, 61], ["primary studies", "TEST", 67, 82], ["population", "TEST", 88, 98]]], ["We have focused on health conditions that are most pertinent to the lifespan stage in question, e.g., cognitive development in early life, overweight/obesity in adolescence, premature cardiovascular disease (CVD) in adulthood, and frailty in older age.", [["cardiovascular", "ANATOMY", 184, 198], ["overweight", "DISEASE", 139, 149], ["obesity", "DISEASE", 150, 157], ["premature cardiovascular disease", "DISEASE", 174, 206], ["CVD", "DISEASE", 208, 211], ["frailty", "DISEASE", 231, 238], ["cardiovascular", "ANATOMICAL_SYSTEM", 184, 198], ["obesity", "PROBLEM", 150, 157], ["premature cardiovascular disease (CVD)", "PROBLEM", 174, 212], ["obesity", "OBSERVATION", 150, 157], ["cardiovascular disease", "OBSERVATION", 184, 206]]], ["Where possible, we have included studies from non-Western countries.", [["studies", "TEST", 33, 40]]], ["A systematic review of 36 studies [8] found that people of lower SEP have greater risk of mortality, CVD, cancer, amongst other health conditions, than those of higher SEP.", [["cancer", "ANATOMY", 106, 112], ["CVD", "DISEASE", 101, 104], ["cancer", "DISEASE", 106, 112], ["people", "ORGANISM", 49, 55], ["cancer", "CANCER", 106, 112], ["people", "SPECIES", 49, 55], ["A systematic review", "TEST", 0, 19], ["36 studies", "TEST", 23, 33], ["lower SEP", "PROBLEM", 59, 68], ["CVD", "PROBLEM", 101, 104], ["cancer", "PROBLEM", 106, 112], ["lower SEP", "OBSERVATION_MODIFIER", 59, 68], ["mortality", "OBSERVATION", 90, 99], ["cancer", "OBSERVATION", 106, 112]]], ["When data were disaggregated by gender, women of lower SEP were especially vulnerable to coronary heart disease.", [["coronary", "ANATOMY", 89, 97], ["heart", "ANATOMY", 98, 103], ["coronary heart disease", "DISEASE", 89, 111], ["women", "ORGANISM", 40, 45], ["coronary", "MULTI-TISSUE_STRUCTURE", 89, 97], ["heart", "ORGAN", 98, 103], ["women", "SPECIES", 40, 45], ["lower SEP", "PROBLEM", 49, 58], ["coronary heart disease", "PROBLEM", 89, 111], ["coronary heart", "ANATOMY", 89, 103], ["disease", "OBSERVATION", 104, 111]]], ["However, it has been argued that, in the main, SDoH theory is often discussed without considering the inherent gender differences in SEP and its measurement.", [["main", "OBSERVATION_MODIFIER", 41, 45]]], ["This is in spite of the fact that women and girls are most disadvantaged by institutional policies and provisions that govern the labour market and family experiences that drive socioeconomic inequalities [5] .", [["women", "ORGANISM", 34, 39], ["women", "SPECIES", 34, 39], ["girls", "SPECIES", 44, 49]]], ["With this in mind, we now consider how SEP shapes morbidity and mortality of women and girls at critical life stages that align with important SEP transitions.", [["women", "ORGANISM", 77, 82], ["women", "SPECIES", 77, 82], ["girls", "SPECIES", 87, 92], ["SEP shapes morbidity", "PROBLEM", 39, 59]]], ["Given the focus of women's health across the life course has often been centred around sexual and reproductive health, we have selected stages based on SEP transition (e.g., educational attainment in adolescence and young adulthood), acknowledging that they may not occur in the same sequential manner for all women and girls and may vary across countries and settings.Early lifeA SDoH framework is often guided by life course epidemiology; a field largely concerned with the timing of exposures, mechanisms, intermediary factors and resources that drive health inequalities across the life course [5] .", [["women", "ORGANISM", 19, 24], ["women", "ORGANISM", 310, 315], ["women", "SPECIES", 19, 24], ["women", "SPECIES", 310, 315], ["girls", "SPECIES", 320, 325]]], ["However, the evidence shows gender differences are not always apparent in early childhood.", [["not always apparent", "UNCERTAINTY", 51, 70]]], ["For example, birth outcomes are shaped by parental socioeconomic factors and impact upon health across the life course.", [["shaped", "OBSERVATION_MODIFIER", 32, 38]]], ["Studies from industrialised countries have demonstrated that socioeconomic disadvantage at individual (e.g., parental SES), neighbourhood (e.g., poverty, unemployment) and national (e.g., GDP) levels increases the likelihood of adverse birth outcomes, including small-forgestational age, preterm birth, and low birth weight [11, 12] .", [["GDP", "CHEMICAL", 188, 191], ["preterm birth", "DISEASE", 288, 301], ["GDP", "SIMPLE_CHEMICAL", 188, 191], ["Studies", "TEST", 0, 7], ["socioeconomic disadvantage", "PROBLEM", 61, 87], ["national (e.g., GDP) levels", "TEST", 172, 199], ["adverse birth outcomes", "PROBLEM", 228, 250], ["preterm birth", "PROBLEM", 288, 301], ["low birth weight", "PROBLEM", 307, 323], ["small", "OBSERVATION_MODIFIER", 262, 267]]], ["The way in which gender modifies the SEP-health gradient appears dependent on the outcome of interest and the comparator group.", [["dependent", "OBSERVATION_MODIFIER", 65, 74]]], ["For example, lower childhood SEP is known to predict poorer physical and cognitive outcomes and acute medical conditions [13] .", [["lower childhood SEP", "PROBLEM", 13, 32], ["acute medical conditions", "PROBLEM", 96, 120], ["acute", "OBSERVATION_MODIFIER", 96, 101]]], ["For girls, the impact of poverty (as determined by parental income and mother's education) on cognitive developmental delays appears to be pronounced, especially when compared to boys [14] .", [["poverty", "DISEASE", 25, 32], ["cognitive developmental delays", "DISEASE", 94, 124], ["girls", "SPECIES", 4, 9], ["boys", "SPECIES", 179, 183], ["cognitive developmental delays", "PROBLEM", 94, 124], ["pronounced", "OBSERVATION_MODIFIER", 139, 149]]], ["In Australia, the most stark SEP differences in 5-year old's development are within gender groups, with language and cognitive developmental delay more common for both male and female Indigenous children than non-Indigenous children [15] .", [["children", "ORGANISM", 195, 203], ["children", "ORGANISM", 224, 232], ["children", "SPECIES", 195, 203], ["children", "SPECIES", 224, 232]]], ["Data from India suggest that although girls appear to be inoculated against the SEP gradient in early childhood development, this is reversed after age 5, with boys (particularly those in the upper classes) performing better [16] .", [["girls", "SPECIES", 38, 43], ["boys", "SPECIES", 160, 164], ["the SEP gradient", "PROBLEM", 76, 92], ["early", "OBSERVATION_MODIFIER", 96, 101], ["childhood", "OBSERVATION", 102, 111]]], ["Data from 195 countries [17] shows that the more gender unequal a society is, the lower the survival rate of girls compared to boys.", [["girls", "SPECIES", 109, 114], ["boys", "SPECIES", 127, 131]]], ["Again, using the example of India, girls under 12years with cardiac defects are less likely to have their guardians agree to cardiac surgery when compared to boys (70% vs. 44%).", [["cardiac", "ANATOMY", 60, 67], ["cardiac", "ANATOMY", 125, 132], ["cardiac defects", "DISEASE", 60, 75], ["cardiac", "ORGAN", 60, 67], ["cardiac", "ORGAN", 125, 132], ["girls", "SPECIES", 35, 40], ["boys", "SPECIES", 158, 162], ["cardiac defects", "PROBLEM", 60, 75], ["cardiac surgery", "TREATMENT", 125, 140], ["boys", "TEST", 158, 162], ["cardiac", "ANATOMY", 60, 67], ["defects", "OBSERVATION", 68, 75]]], ["Social class greatly influences access to treatment, with 90% of girls in the \"upper class\" receiving the surgery versus 21.3% in the \"upper-lower class\".", [["girls", "SPECIES", 65, 70], ["treatment", "TREATMENT", 42, 51], ["the surgery", "TREATMENT", 102, 113]]], ["Deep-seated social factors perpetuating gender biases, such as the customs of arranged marriages and \"dowry\", appeared to drive these poorer outcomes for girls [18] .AdolescenceSEP remains a powerful predictor of health in adolescence [19, 20] , during which time parental employment, family affluence and composition are commonly constituents of an adolescent's SEP.", [["girls", "SPECIES", 154, 159]]], ["In the US, an inverse association exists between SEP and overweight in adolescent girls (particularly White) but not boys [21] .", [["overweight", "DISEASE", 57, 67], ["girls", "SPECIES", 82, 87], ["boys", "SPECIES", 117, 121]]], ["In other studies, SEP and ethnicity interact to confer risk for physical health conditions like CVD and protective effects on mental health.", [["CVD", "DISEASE", 96, 99], ["other studies", "TEST", 3, 16], ["physical health conditions", "PROBLEM", 64, 90], ["CVD", "PROBLEM", 96, 99]]], ["Data from the UK showed SEP patterning for psychological well-being in girls [22] , with low SEP asserting a stronger influence on Black compared to White girls.", [["girls", "SPECIES", 71, 76], ["girls", "SPECIES", 155, 160], ["SEP patterning", "PROBLEM", 24, 38], ["low SEP", "PROBLEM", 89, 96]]], ["Systolic blood pressure increased with level of disadvantage amongst Black Caribbean girls; a trend that was exacerbated in subsequent years [23] .", [["blood", "ANATOMY", 9, 14], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["girls", "SPECIES", 85, 90], ["Systolic blood pressure", "TEST", 0, 23], ["pressure", "OBSERVATION_MODIFIER", 15, 23], ["increased", "OBSERVATION_MODIFIER", 24, 33]]], ["But cross-country comparisons reveal the complexity of the SEP patterning of health of boys and girls, indicating it is largely context-specific.", [["boys", "SPECIES", 87, 91], ["girls", "SPECIES", 96, 101], ["SEP", "OBSERVATION_MODIFIER", 59, 62], ["patterning", "OBSERVATION_MODIFIER", 63, 73]]], ["For example, in a national comparison of Russian, US and Chinese children/adolescents aged 6-18, higher overweight/obesity was observed for: urban boys in China; urban girls from low-and highincome groups in Russia; and African-American and Mexican-American girls in the US (especially those aged \u226510 years) [24] .", [["overweight", "DISEASE", 104, 114], ["obesity", "DISEASE", 115, 122], ["children", "ORGANISM", 65, 73], ["children", "SPECIES", 65, 73], ["adolescents", "SPECIES", 74, 85], ["boys", "SPECIES", 147, 151], ["girls", "SPECIES", 168, 173], ["girls", "SPECIES", 258, 263], ["obesity", "PROBLEM", 115, 122]]], ["In Zambia, one of the countries with the highest HIV burden in the world, young women have higher rates of HIV infection than young men.", [["HIV infection", "DISEASE", 107, 120], ["women", "ORGANISM", 80, 85], ["HIV", "ORGANISM", 107, 110], ["men", "ORGANISM", 132, 135], ["women", "SPECIES", 80, 85], ["HIV", "SPECIES", 107, 110], ["men", "SPECIES", 132, 135], ["HIV", "SPECIES", 49, 52], ["HIV", "SPECIES", 107, 110], ["HIV infection", "PROBLEM", 107, 120], ["infection", "OBSERVATION", 111, 120]]], ["Yet the gender gap is narrowing in both urban and rural areas [25] attributed primarily to higher educational attainment of both sexes.", [["narrowing", "PROBLEM", 22, 31], ["gap", "OBSERVATION_MODIFIER", 15, 18], ["narrowing", "OBSERVATION", 22, 31], ["both", "OBSERVATION_MODIFIER", 35, 39], ["urban", "OBSERVATION_MODIFIER", 40, 45], ["rural", "OBSERVATION_MODIFIER", 50, 55]]], ["An increasing proportion of young women enrol and stay in school, thus, delaying their sexual debut [26] .", [["women", "ORGANISM", 34, 39], ["women", "SPECIES", 34, 39], ["increasing", "OBSERVATION_MODIFIER", 3, 13], ["proportion", "OBSERVATION_MODIFIER", 14, 24]]], ["In addition to preventing sexually transmitted infections, education can help prevent precocious pregnancy.", [["sexually transmitted infections", "DISEASE", 26, 57], ["sexually transmitted infections", "PROBLEM", 26, 57], ["precocious pregnancy", "PROBLEM", 86, 106], ["infections", "OBSERVATION", 47, 57]]], ["A cross-national comparative study showed evidence of a strong, negative educational gradient in early childbearing in all 20 high-income countries included.", [["A cross-national comparative study", "TEST", 0, 34], ["strong", "OBSERVATION_MODIFIER", 56, 62]]], ["There was also an increase in the prevalence of early childbearing amongst lower educated females born between 1955 and 1981 in 10 of the included countries, with only one country (Poland) showing a decrease in the educational gap [27] .", [["a decrease in the educational gap", "PROBLEM", 197, 230], ["increase", "OBSERVATION_MODIFIER", 18, 26], ["early", "OBSERVATION_MODIFIER", 48, 53], ["childbearing", "OBSERVATION", 54, 66], ["decrease", "OBSERVATION_MODIFIER", 199, 207]]], ["Higher levels of education attainment provide a basis for enhanced self-control and problem-solving skills in adulthood, that can facilitate both the adoption of lifestyle behaviours and entry into environmental contexts that promote health and wellbeing.", [["enhanced self-control", "TREATMENT", 58, 79]]], ["Data from the US show that women's self-rated health, which is typically poorer than men's, improved from 1972-2002, and that this improvement could be largely accounted for by increased educational attainment across this same time period [29] .", [["women", "ORGANISM", 27, 32], ["men", "ORGANISM", 85, 88], ["women", "SPECIES", 27, 32], ["men", "SPECIES", 85, 88], ["the US", "TEST", 10, 16]]], ["In contrast, men did not experience a linear increase in self-rated health in this study, which suggests that women may reap greater health benefits from increased educational attainment.", [["men", "ORGANISM", 13, 16], ["women", "ORGANISM", 110, 115], ["men", "SPECIES", 13, 16], ["women", "SPECIES", 110, 115], ["a linear increase in self-rated health", "PROBLEM", 36, 74], ["this study", "TEST", 78, 88], ["linear", "OBSERVATION_MODIFIER", 38, 44], ["increase", "OBSERVATION_MODIFIER", 45, 53]]], ["This is supported by evidence showing the deleterious health effects of having low educational attainment are more potent for women than men for CVD [30] .", [["CVD", "DISEASE", 145, 148], ["women", "ORGANISM", 126, 131], ["men", "ORGANISM", 137, 140], ["women", "SPECIES", 126, 131], ["men", "SPECIES", 137, 140], ["CVD", "PROBLEM", 145, 148]]], ["This is even true in countries in which a greater number of women are graduating with university degrees than men [31] .Young adulthoodFor many, this period of the lifespan sees individuals in gainful employment for the first time.", [["women", "ORGANISM", 60, 65], ["men", "ORGANISM", 110, 113], ["women", "SPECIES", 60, 65], ["men", "SPECIES", 110, 113], ["true", "OBSERVATION_MODIFIER", 13, 17], ["greater", "OBSERVATION_MODIFIER", 42, 49]]], ["Studies utilising employment related markers like income as a measure of SEP provide some insight into the health inequalities faced by women.", [["women", "ORGANISM", 136, 141], ["women", "SPECIES", 136, 141]]], ["In a cross-sectional survey of working-age Catalonian residents, individual income showed a graded association with self-rated health for both men and women, whereby individuals with lower monthly incomes reported worse health.", [["men", "ORGANISM", 143, 146], ["women", "ORGANISM", 151, 156], ["men", "SPECIES", 143, 146], ["women", "SPECIES", 151, 156]]], ["Individual income accounted for women's poorer self-rated health compared to men's, with analyses adjusting for individual income abolishing this gender difference in health [32] .", [["women", "ORGANISM", 32, 37], ["men", "ORGANISM", 77, 80], ["women", "SPECIES", 32, 37], ["men", "SPECIES", 77, 80]]], ["In a cross-sectional study of 10,000 Barcelona residents, self-rated health was poorer for men in lower occupational classes, compared to that of managers and skilled supervisors.", [["men", "ORGANISM", 91, 94], ["men", "SPECIES", 91, 94], ["a cross-sectional study", "TEST", 3, 26]]], ["In contrast, only women in unskilled jobs had worse self-rated health than the reference category.", [["women", "ORGANISM", 18, 23], ["women", "SPECIES", 18, 23]]], ["Rather, the number of hours per week of domestic labour was an important determinant of self-rated health in women, whereas it was not for men [33] .", [["women", "ORGANISM", 109, 114], ["men", "ORGANISM", 139, 142], ["women", "SPECIES", 109, 114], ["men", "SPECIES", 139, 142]]], ["The impact of children and family composition will be discussed in more detail in the following section.AdulthoodIncome and education continue to shape women's health into mid-life.", [["children", "ORGANISM", 14, 22], ["women", "ORGANISM", 152, 157], ["children", "SPECIES", 14, 22], ["women", "SPECIES", 152, 157]]], ["With respect to the former, the Whitehall Study II shows that men and women with the lowest individual income were significantly more likely to have metabolic syndrome, compared to those with the highest.", [["metabolic syndrome", "DISEASE", 149, 167], ["men", "ORGANISM", 62, 65], ["women", "ORGANISM", 70, 75], ["men", "SPECIES", 62, 65], ["women", "SPECIES", 70, 75], ["the Whitehall Study II", "TEST", 28, 50], ["metabolic syndrome", "PROBLEM", 149, 167], ["metabolic syndrome", "OBSERVATION", 149, 167]]], ["Although the magnitude of this effect was similar for both genders, the use of household income as a measure of SEP revealed a relatively steeper social gradient of health for women than men [34] .", [["women", "ORGANISM", 176, 181], ["men", "ORGANISM", 187, 190], ["women", "SPECIES", 176, 181], ["men", "SPECIES", 187, 190]]], ["With respect to the latter, the gap in self-rated health between the lowest and highest educational levels appears to be widening in many Western countries.", [["the gap", "TEST", 28, 35], ["appears to be", "UNCERTAINTY", 107, 120], ["widening", "OBSERVATION", 121, 129]]], ["This is somewhat dependent upon age, gender and race.", [["somewhat", "OBSERVATION_MODIFIER", 8, 16], ["dependent", "OBSERVATION_MODIFIER", 17, 26]]], ["In US citizens aged 35-49, the education health gap remained relatively stable for men from 1982-2003, whereas educational disparities in selfrated health diverged for white women and converged for black women [35] .", [["men", "ORGANISM", 83, 86], ["women", "ORGANISM", 174, 179], ["women", "ORGANISM", 204, 209], ["men", "SPECIES", 83, 86], ["women", "SPECIES", 174, 179], ["women", "SPECIES", 204, 209]]], ["In a study using US mortality data, middle aged (45-54 years old), white women experienced the greatest increase in the educational gradient of mortality, due to substantially increased mortality rates amongst those with high school diplomas or less [36] .", [["women", "ORGANISM", 73, 78], ["women", "SPECIES", 73, 78], ["a study", "TEST", 3, 10], ["US mortality data", "TEST", 17, 34], ["substantially increased mortality rates", "PROBLEM", 162, 201], ["greatest", "OBSERVATION_MODIFIER", 95, 103], ["increase", "OBSERVATION_MODIFIER", 104, 112]]], ["As discussed previously, educational attainment is a key indicator of age of first pregnancy which, along with family composition and relationship status, is of particular relevance both to women's ability to earn money and their individual health outcomes during this stage of the lifespan.AdulthoodDuring this period of adulthood whereby partnerships are formed and families are started, the role of household and partners' SEP can begin to influence a woman's health.", [["women", "ORGANISM", 190, 195], ["woman", "ORGANISM", 455, 460], ["women", "SPECIES", 190, 195], ["woman", "SPECIES", 455, 460]]], ["While married women have a survival advantage over unmarried women, the premium afforded to married men may be more pronounced [38] .", [["women", "ORGANISM", 14, 19], ["women", "ORGANISM", 61, 66], ["men", "ORGANISM", 100, 103], ["women", "SPECIES", 14, 19], ["women", "SPECIES", 61, 66], ["men", "SPECIES", 100, 103]]], ["Over recent decades, however, the marriage advantage appears to have increased.", [["increased", "OBSERVATION_MODIFIER", 69, 78]]], ["The assumption was that people with lower education were marrying less frequently while those of comparable levels of education tended to marry later.", [["people", "ORGANISM", 24, 30], ["people", "SPECIES", 24, 30]]], ["Yet, US [39] and Norwegian [40] data show that temporal changes in educational status of married people contributed little to the steepening health gradient.", [["people", "ORGANISM", 97, 103], ["people", "SPECIES", 97, 103], ["US", "TEST", 5, 7], ["temporal changes", "PROBLEM", 47, 63]]], ["Interestingly, data from Hungary show that in middle-age, a married woman's SEP has greater influence on her husband's mortality than his SEP on her mortality [41] .", [["woman", "ORGANISM", 68, 73], ["woman", "SPECIES", 68, 73]]], ["A population-wide Norwegian study demonstrated that older men's mortality across all causes of death was strongly associated with their wife's educational status.", [["death", "DISEASE", 95, 100], ["men", "ORGANISM", 58, 61], ["men", "SPECIES", 58, 61], ["Norwegian study", "TEST", 18, 33], ["death", "PROBLEM", 95, 100]]], ["Meanwhile, a husband's income and occupation were related to few causespecific mortality outcomes in women [42] .", [["women", "ORGANISM", 101, 106], ["women", "SPECIES", 101, 106]]], ["Women with higher education levels tend to be more likely to engage in health-promoting behaviours [43] .", [["Women", "ORGANISM", 0, 5], ["Women", "SPECIES", 0, 5]]], ["It is thus plausible they influence the diet, exercise, and smoking/drinking habits of their partners [44] .", [["smoking", "CHEMICAL", 60, 67]]], ["While a recent metaanalysis of over 7 million individuals found that being unmarried led to a greater risk of stroke and mortality for men compared to women [37] , other meta-analyses have found no significant gender differences in the marriage advantage for CVD risk [45] and mortality [46] .AdulthoodChanges in family composition owing to reproduction, child rearing and relationship breakdowns, are defining features of women's adult years.", [["stroke", "DISEASE", 110, 116], ["CVD", "DISEASE", 259, 262], ["men", "ORGANISM", 135, 138], ["women", "ORGANISM", 151, 156], ["women", "ORGANISM", 423, 428], ["men", "SPECIES", 135, 138], ["women", "SPECIES", 151, 156], ["women", "SPECIES", 423, 428], ["stroke", "PROBLEM", 110, 116], ["other meta-analyses", "TEST", 164, 183], ["significant gender differences", "PROBLEM", 198, 228], ["CVD risk", "PROBLEM", 259, 267], ["stroke", "OBSERVATION", 110, 116]]], ["These factors have an important effect on professional attainment, employment conditions and career advancement and financial independence, and therefore how SEP shapes women's health.", [["women", "ORGANISM", 169, 174], ["women", "SPECIES", 169, 174]]], ["While parity (i.e. motherhood) has been positively associated with better CVD risk [47] ) across SEP categories [48] , other studies show that mothers have poorer self-reported health (in spite of similar rates of chronic conditions) particularly those living at or near the poverty line [49] .", [["CVD", "DISEASE", 74, 77], ["mothers", "ORGANISM", 143, 150], ["SEP categories", "TEST", 97, 111], ["other studies", "TEST", 119, 132], ["chronic conditions", "PROBLEM", 214, 232]]], ["Single mothers appear to be particularly disadvantaged in terms of SEP and its impact on health outcomes [51] .", [["mothers", "ORGANISM", 7, 14]]], ["For example, despite greater opportunities for educational and employment attainment over recent generations, there are widening SEP disparities for US women, especially for mothers without partners.", [["women", "ORGANISM", 152, 157], ["women", "SPECIES", 152, 157], ["widening SEP disparities", "PROBLEM", 120, 144], ["widening", "OBSERVATION_MODIFIER", 120, 128]]], ["Since the 1960s, the number of single-parent US households headed by women has tripled.", [["women", "ORGANISM", 69, 74], ["women", "SPECIES", 69, 74]]], ["Ten percent of US women aged 25-54 years live in poverty, a plausible driver of increasing premature mortality rates.", [["women", "ORGANISM", 18, 23], ["women", "SPECIES", 18, 23], ["increasing premature mortality rates", "PROBLEM", 80, 116]]], ["Women aged 35-54 [52] are the only sub-population in the US to have experienced large increases in coronary heart disease mortality since the early 2000s.", [["coronary", "ANATOMY", 99, 107], ["heart", "ANATOMY", 108, 113], ["coronary heart disease", "DISEASE", 99, 121], ["Women", "ORGANISM", 0, 5], ["heart", "ORGAN", 108, 113], ["Women", "SPECIES", 0, 5], ["large increases in coronary heart disease mortality", "PROBLEM", 80, 131], ["large", "OBSERVATION_MODIFIER", 80, 85], ["increases", "OBSERVATION_MODIFIER", 86, 95], ["coronary heart", "ANATOMY", 99, 113], ["disease", "OBSERVATION", 114, 121]]], ["Compared to same-age women in England, US women show earlier risk markers of chronic disease [53] .", [["chronic disease", "DISEASE", 77, 92], ["women", "ORGANISM", 21, 26], ["women", "ORGANISM", 42, 47], ["women", "SPECIES", 21, 26], ["women", "SPECIES", 42, 47], ["chronic disease", "PROBLEM", 77, 92], ["chronic", "OBSERVATION_MODIFIER", 77, 84], ["disease", "OBSERVATION", 85, 92]]], ["Differences for younger US women (45-54 years) are as pronounced as their older female counterparts for CVD risk factors such as obesity, cholesterol, heart attack, angina and stroke.", [["heart", "ANATOMY", 151, 156], ["CVD", "DISEASE", 104, 107], ["obesity", "DISEASE", 129, 136], ["cholesterol", "CHEMICAL", 138, 149], ["heart attack", "DISEASE", 151, 163], ["angina", "DISEASE", 165, 171], ["stroke", "DISEASE", 176, 182], ["cholesterol", "CHEMICAL", 138, 149], ["women", "ORGANISM", 27, 32], ["cholesterol", "SIMPLE_CHEMICAL", 138, 149], ["heart", "ORGAN", 151, 156], ["women", "SPECIES", 27, 32], ["CVD risk factors", "PROBLEM", 104, 120], ["obesity", "PROBLEM", 129, 136], ["cholesterol", "PROBLEM", 138, 149], ["heart attack", "PROBLEM", 151, 163], ["angina", "PROBLEM", 165, 171], ["stroke", "PROBLEM", 176, 182], ["obesity", "OBSERVATION", 129, 136], ["heart", "ANATOMY", 151, 156], ["attack", "OBSERVATION", 157, 163], ["angina", "OBSERVATION", 165, 171], ["stroke", "OBSERVATION", 176, 182]]], ["US health inequalities clinically evident at early ages are best ascribed to socio-political influences rather than conventional risk factors [53] .Late adulthood and older ageAs women reach older age with greater disability and comorbidities, having accumulated less wealth due to relatively fewer employment-related opportunities, it stands to reason that older women are susceptible to the social gradient of health.", [["disability", "DISEASE", 214, 224], ["women", "ORGANISM", 179, 184], ["women", "ORGANISM", 364, 369], ["women", "SPECIES", 179, 184], ["women", "SPECIES", 364, 369], ["greater disability and comorbidities", "PROBLEM", 206, 242]]], ["There is evidence to suggest that indeed women's SEP is more precarious over the life course for reasons discussed in previous sections (e.g., extended periods out of the workforce, reduced access to independent wealth) compared with men's which exhibits greater stability [54] .", [["women", "ORGANISM", 41, 46], ["men", "ORGANISM", 234, 237], ["women", "SPECIES", 41, 46], ["men", "SPECIES", 234, 237], ["indeed women's SEP", "PROBLEM", 34, 52], ["evidence to suggest", "UNCERTAINTY", 9, 28]]], ["For example, current SEP explained less of the variance in self-rated health than childhood SEP for men, whereas current SEP was more important than childhood SEP in explaining variance in self-rated health for women.", [["men", "ORGANISM", 100, 103], ["women", "ORGANISM", 211, 216], ["men", "SPECIES", 100, 103], ["women", "SPECIES", 211, 216]]], ["In addition, all current SEP indicators had a significant influence on self-rated health in older J o u r n a l P r e -p r o o f women, whereas being employed and household net wealth were not significantly associated with self-rated health in older men.", [["women", "ORGANISM", 129, 134], ["men", "ORGANISM", 250, 253], ["women", "SPECIES", 129, 134], ["men", "SPECIES", 250, 253], ["women", "PROBLEM", 129, 134]]], ["Thus, the authors concluded that SEP in childhood was more predictive of older men's self-rated health, while current SEP in older age was more important for women's self-rated health [54] .", [["men", "ORGANISM", 79, 82], ["women", "ORGANISM", 158, 163], ["men", "SPECIES", 79, 82], ["women", "SPECIES", 158, 163]]], ["In New Zealand, the odds for entering their 70s with material hardship were greater for women and M\u0101ori, yet this association was attenuated by mid and late life adverse events such as onset of serious illness [55] .", [["illness", "DISEASE", 202, 209], ["women", "ORGANISM", 88, 93], ["women", "SPECIES", 88, 93], ["mid and late life adverse events", "PROBLEM", 144, 176], ["serious illness", "PROBLEM", 194, 209], ["New", "OBSERVATION_MODIFIER", 3, 6], ["Zealand", "OBSERVATION_MODIFIER", 7, 14]]], ["Interestingly, having children may provide protective health related effects.", [["children", "ORGANISM", 22, 30], ["children", "SPECIES", 22, 30]]], ["The SEP of one's grown children has been shown predictive of risk of parental death, potentially independent of parent's own SEP [56] .", [["death", "DISEASE", 78, 83], ["children", "ORGANISM", 23, 31], ["children", "SPECIES", 23, 31], ["parental death", "PROBLEM", 69, 83]]], ["Of course, the gendered nature of SEP-health trends in this age group are likely to be both outcome and country-specific.", [["likely to be", "UNCERTAINTY", 74, 86]]], ["In South Korea, a longitudinal study of 4165 aged 65+ years found wealth was inversely associated with depressive symptoms (measured using the Center for Epidemiologic Studies of Depression scale) in men, whereas low education and income predicted depression in women [57] .", [["depressive symptoms", "DISEASE", 103, 122], ["depression", "DISEASE", 248, 258], ["men", "ORGANISM", 200, 203], ["women", "ORGANISM", 262, 267], ["men", "SPECIES", 200, 203], ["women", "SPECIES", 262, 267], ["a longitudinal study", "TEST", 16, 36], ["depressive symptoms", "PROBLEM", 103, 122], ["Epidemiologic Studies", "TEST", 154, 175], ["Depression scale", "PROBLEM", 179, 195]]], ["On the other hand, in England, data from the first two waves of the English Longitudinal Study of Ageing (ELSA) found no gender differences for wealth as a predictor of functional impairment (measured using six Activities of Daily Living) in those above 50 years of age [58] .How can we mitigate deleterious effects of SEP on women's health?Interventions and policies that mitigate deleterious effects of SEP on girls' and women's health should target micro-, meso-, and macro-levels.", [["functional impairment", "DISEASE", 169, 190], ["women", "ORGANISM", 326, 331], ["women", "ORGANISM", 423, 428], ["women", "SPECIES", 326, 331], ["girls", "SPECIES", 412, 417], ["women", "SPECIES", 423, 428], ["functional impairment", "PROBLEM", 169, 190], ["Interventions", "TREATMENT", 341, 354], ["meso", "TEST", 460, 464]]], ["Whilst policies that provide universal health coverage is one obvious initiative, coordinated interventions targeting these levels are required to address gendered health inequities in underprivileged populations.", [["universal health coverage", "TREATMENT", 29, 54]]], ["In India, women of low SEP have a lower share of hospital care than men, even when provided free access.", [["women", "ORGANISM", 10, 15], ["men", "ORGANISM", 68, 71], ["women", "SPECIES", 10, 15], ["men", "SPECIES", 68, 71], ["low SEP", "PROBLEM", 19, 26]]], ["This suggests that free hospital care alone is not sufficient to guarantee gender equity in healthcare access [59] .", [["free hospital care", "TREATMENT", 19, 37]]], ["National social security provisions can insulate women's disease and mortality risk.", [["women", "ORGANISM", 49, 54], ["women", "SPECIES", 49, 54], ["mortality risk", "PROBLEM", 69, 83]]], ["This includes the extent to which a nation's welfare provisions allow for an acceptable standard of living independent from family relationships (defamilisation) and insulated from market dependence (decommodification).", [["a nation's welfare provisions", "TREATMENT", 34, 63]]], ["In countries with welfare systems that promote greater financial autonomy for women, a weaker social gradient of health for women would be expected.", [["women", "ORGANISM", 78, 83], ["women", "ORGANISM", 124, 129], ["women", "SPECIES", 78, 83], ["women", "SPECIES", 124, 129], ["welfare systems", "TREATMENT", 18, 33]]], ["A longitudinal analysis of data comparing different welfare regimes within Europe indeed support this hypothesis.", [["A longitudinal analysis", "TEST", 0, 23], ["different welfare regimes", "TREATMENT", 42, 67]]], ["The social gradient of health, as measured by the impact of education, income and wealth on 11-year change in frailty, was steepest for older women residing in Southern European countries that are characterised by less defamilising and decommodifying welfare systems.", [["women", "ORGANISM", 142, 147], ["women", "SPECIES", 142, 147]]], ["However, there is good evidence that the strength of association between women's SEP and their life expectancy varies with level of economic development [62] .Are conventional SEP markers best for understanding women's health over the life course?Conventional SEP markers were developed by and for men and are generally not well-suited to assessing women's socioeconomic circumstances [8] and associated health outcomes.", [["women", "ORGANISM", 73, 78], ["women", "ORGANISM", 211, 216], ["men", "ORGANISM", 298, 301], ["women", "ORGANISM", 349, 354], ["SEP markers", "PROTEIN", 260, 271], ["women", "SPECIES", 73, 78], ["women", "SPECIES", 211, 216], ["men", "SPECIES", 298, 301], ["women", "SPECIES", 349, 354], ["Conventional SEP markers", "TEST", 247, 271], ["good", "OBSERVATION_MODIFIER", 18, 22]]], ["Here, we have provided examples showing specific measures may produce differential health gradients between women and men.", [["women", "ORGANISM", 108, 113], ["men", "ORGANISM", 118, 121], ["women", "SPECIES", 108, 113], ["men", "SPECIES", 118, 121]]], ["If employment markers alone are used to assess women's engagement with the workforce and thus SEP, disengagement with the workforce may be a marker of extreme wealth, child rearing, studying, disability or extreme poverty at different points of the life course.", [["disability", "DISEASE", 192, 202], ["poverty", "DISEASE", 214, 221], ["women", "ORGANISM", 47, 52], ["women", "SPECIES", 47, 52]]], ["Alternatively, using household income assumes women have equal access to pooled resources, which in many cultures is not the case [8] .", [["women", "ORGANISM", 46, 51], ["women", "SPECIES", 46, 51], ["many cultures", "TEST", 100, 113]]], ["This might help explain why some studies using conventional measures show that SEP-related health differences are more pronounced for men [8] .", [["men", "ORGANISM", 134, 137], ["men", "SPECIES", 134, 137], ["conventional measures", "TEST", 47, 68]]], ["Studies where the mortality gradient was stronger for men than women have used employment [63] and occupational exposures [64] .", [["men", "ORGANISM", 54, 57], ["women", "ORGANISM", 63, 68], ["men", "SPECIES", 54, 57], ["women", "SPECIES", 63, 68], ["Studies", "TEST", 0, 7], ["the mortality gradient", "PROBLEM", 14, 36]]], ["Yet classifying women's SEP based on occupation is problematic given that women cannot always be classified appropriately using census data [65] .", [["women", "ORGANISM", 16, 21], ["women", "ORGANISM", 74, 79], ["women", "SPECIES", 16, 21], ["women", "SPECIES", 74, 79]]], ["Thus, appropriate weighting and consideration of interactions between conventional markers of SEP for women (e.g. education, marriage and number of children) may be required to acknowledge women's unique health circumstances.", [["women", "ORGANISM", 102, 107], ["children", "ORGANISM", 148, 156], ["women", "ORGANISM", 189, 194], ["women", "SPECIES", 102, 107], ["children", "SPECIES", 148, 156], ["women", "SPECIES", 189, 194]]], ["For example, the influence of childhood adversity [68] and psychological strain/job satisfaction [66, 67] is stronger for women than men.", [["women", "ORGANISM", 122, 127], ["men", "ORGANISM", 133, 136], ["women", "SPECIES", 122, 127], ["men", "SPECIES", 133, 136]]], ["A study that investigated gender, mortality and SEP by using both social disadvantage (defined by social distance from high SEP [69] ) and occupational class demonstrated that the social gradient of mortality was greater for women when using the former, and greater for men when using the latter [70] .", [["women", "ORGANISM", 225, 230], ["men", "ORGANISM", 270, 273], ["women", "SPECIES", 225, 230], ["men", "SPECIES", 270, 273], ["A study", "TEST", 0, 7]]], ["This suggests that the use of conventional, occupational based SEP indicators may be underestimating the social gradient of health for women.Are conventional SEP markers best for understanding women's health over the life course?Ultimately the best SEP marker by which to assess health inequalities between women/girls and men/boys and amongst women and girls requires consideration of life course epidemiology.", [["women", "ORGANISM", 135, 140], ["women", "ORGANISM", 193, 198], ["women", "ORGANISM", 307, 312], ["men", "ORGANISM", 323, 326], ["women", "ORGANISM", 344, 349], ["women", "SPECIES", 135, 140], ["women", "SPECIES", 193, 198], ["women", "SPECIES", 307, 312], ["girls", "SPECIES", 313, 318], ["men", "SPECIES", 323, 326], ["boys", "SPECIES", 327, 331], ["women", "SPECIES", 344, 349], ["girls", "SPECIES", 354, 359]]], ["For example, an SEP marker like educational attainment may not yield mortality benefits for women when compared to white men but may when compared to non-White women or when considering other inequality axes like age, race, disability or rurality.", [["disability", "DISEASE", 224, 234], ["women", "ORGANISM", 92, 97], ["men", "ORGANISM", 121, 124], ["women", "ORGANISM", 160, 165], ["women", "SPECIES", 92, 97], ["men", "SPECIES", 121, 124], ["women", "SPECIES", 160, 165], ["an SEP marker", "TEST", 13, 26]]], ["An added incentive for developing an approach that uses multiple and contextual SEP indicators is that it may help to further disentangle the gender paradox of women's health.Clinical and policy implicationsIn clinical practice, medical practitioners require robust tools and clinical aids by which to assess and tailor patient care according to SEP.", [["women", "ORGANISM", 160, 165], ["patient", "ORGANISM", 320, 327], ["women", "SPECIES", 160, 165], ["patient", "SPECIES", 320, 327]]], ["There remains an absence of such tools much less those which consider the nuanced issues pertaining to gender or other axes of inequality discussed herewith [72] .", [["such tools", "PROBLEM", 28, 38]]], ["In the United Kingdom and Scotland, the QRISK [73] and ASSIGN [74] algorithms used in clinical practice to determine 10-year absolute CVD risk of J o u r n a l P r e -p r o o f patients include a measure of area-level material deprivation; one of the few such tools to do so.", [["CVD", "DISEASE", 134, 137], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["area-level material deprivation", "TREATMENT", 207, 238]]], ["Whether this measure of SEP is most appropriate for utility in women of different ages, ethnic and other backgrounds remains unclear in the context of the issues discussed in this paper.", [["women", "ORGANISM", 63, 68], ["women", "SPECIES", 63, 68], ["ethnic and other backgrounds", "PROBLEM", 88, 116]]], ["Nevertheless, the advantage of using and further developing and refining risk assessment tools that contain SEP measures is not only critical for greater discrimination between cases and non-cases but for the purpose of equity.", [["refining risk assessment", "TEST", 64, 88], ["SEP measures", "TEST", 108, 120]]], ["In the clinical context, the provision of lifestyle advice, counselling and interventions for preventing and managing chronic physical and mental conditions requires clinicians to appreciate that individuals living under conditions of scarcity cannot freely make decisions about their own health and investments that may, in fact, afford them the opportunity to escape those very circumstances [75] .", [["lifestyle advice", "TREATMENT", 42, 58], ["interventions", "TREATMENT", 76, 89], ["managing chronic physical and mental conditions", "PROBLEM", 109, 156]]], ["Where low SEP is identified, an understanding of how limited economic resources restrict decision making can help guide the implementation of health promoting incentives -especially for those on welfare who have high material deprivation.Clinical and policy implicationsFrom a public health perspective, investment in early life education of all, and especially girls in settings of marked gender inequality, is critical to lifelong health.", [["girls", "SPECIES", 362, 367], ["high material deprivation", "PROBLEM", 212, 237], ["low SEP", "OBSERVATION_MODIFIER", 6, 13]]], ["In conjunction with other interventions, education (both formal attainment and health literacy) appears to be the key to improving SEP and is a strong determinant of future employment and income [76] . .", [["other interventions", "TREATMENT", 20, 39]]], ["However, the greatest reduction to the social gradient of health can arguably be achieved by developing interventions that minimise the extent to which socioeconomic resources confer a health benefit [78] .", [["greatest", "OBSERVATION_MODIFIER", 13, 21], ["reduction", "OBSERVATION_MODIFIER", 22, 31]]], ["One pertinent example is the fortification of flour with folic acid in over 80 countries worldwide.", [["folic acid", "CHEMICAL", 57, 67], ["folic acid", "CHEMICAL", 57, 67], ["flour", "ORGANISM_SUBSTANCE", 46, 51], ["folic acid", "SIMPLE_CHEMICAL", 57, 67], ["folic acid", "TREATMENT", 57, 67]]], ["This is opposed to recommending that women take folic acid supplements during pregnancy, which disadvantages women of lower SEP due to issues of cost and access.", [["folic acid", "CHEMICAL", 48, 58], ["folic acid", "CHEMICAL", 48, 58], ["women", "ORGANISM", 37, 42], ["folic acid", "SIMPLE_CHEMICAL", 48, 58], ["women", "ORGANISM", 109, 114], ["women", "SPECIES", 37, 42], ["women", "SPECIES", 109, 114], ["folic acid supplements", "TREATMENT", 48, 70], ["lower SEP", "PROBLEM", 118, 127], ["cost and access", "TREATMENT", 145, 160]]], ["Preliminary evidence suggests that folic acid fortification of flour at a population-level reduces the risk of neural tube defects in foetuses and improves the folate status of women of reproductive age [79] .Recommendations for additional researchAcknowledging the heterogeneity both between women and men and amongst women in the context of analytic frameworks is critical.", [["neural tube", "ANATOMY", 111, 122], ["foetuses", "ANATOMY", 134, 142], ["folic acid", "CHEMICAL", 35, 45], ["neural tube defects", "DISEASE", 111, 130], ["folate", "CHEMICAL", 160, 166], ["folic acid", "CHEMICAL", 35, 45], ["folate", "CHEMICAL", 160, 166], ["folic acid", "SIMPLE_CHEMICAL", 35, 45], ["flour", "ORGANISM_SUBDIVISION", 63, 68], ["neural tube", "TISSUE", 111, 122], ["foetuses", "ORGAN", 134, 142], ["folate", "SIMPLE_CHEMICAL", 160, 166], ["women", "ORGANISM", 177, 182], ["women", "ORGANISM", 293, 298], ["men", "ORGANISM", 303, 306], ["women", "ORGANISM", 319, 324], ["women", "SPECIES", 177, 182], ["women", "SPECIES", 293, 298], ["men", "SPECIES", 303, 306], ["women", "SPECIES", 319, 324], ["folic acid fortification of flour", "PROBLEM", 35, 68], ["neural tube defects in foetuses", "PROBLEM", 111, 142], ["folic acid", "OBSERVATION", 35, 45], ["neural", "OBSERVATION", 111, 117], ["tube defects", "OBSERVATION", 118, 130]]], ["Pragmatically, research in this area should consider interactions between gender and both conventional and non-conventional SEP markers to ensure that health inequalities for sub-populations are not concealed.", [["non-conventional SEP markers", "TEST", 107, 135], ["sub-populations", "PROBLEM", 175, 190]]], ["Of note, there has been work developing tools by which to assess adolescents' material circumstances and family affluence as a measure of self-reported family socioeconomic status [80] .", [["adolescents", "SPECIES", 65, 76]]], ["Further research is necessary to develop indicators specific to developing countries, given that the majority of this research has been generated in developed countries.ConclusionThe role of SEP on the health and longevity of women and girls is complex and fluctuates throughout the life course.", [["women", "ORGANISM", 226, 231], ["women", "SPECIES", 226, 231], ["girls", "SPECIES", 236, 241]]], ["This trajectory appears dependent upon (i) the outcome of interest and setting in which the research is conducted; (ii) how SEP is defined and the level (macro or micro) at which it is measured; and (iii) the extent to which other axes of inequality are considered (ethnicity, residential setting, Indigenous status).", [["dependent", "OBSERVATION_MODIFIER", 24, 33]]], ["How SEP is measured and applied is an important consideration given that many women are likely to have variable engagement with the workforce and possible financial reliance on others at various stages of the life course.", [["women", "ORGANISM", 78, 83], ["women", "SPECIES", 78, 83]]], ["It is likely that the conventional concept of SEP itself may inherently misrepresent genderbased inequalities in health.", [["is likely", "UNCERTAINTY", 3, 12]]], ["Taking a broader view of SEP, that includes psychosocial inputs and considers SEP as a web of interconnected variables, may provide a more accurate understanding of women's health -relative to men and each other across the life course.", [["women", "ORGANISM", 165, 170], ["men", "ORGANISM", 193, 196], ["women", "SPECIES", 165, 170], ["men", "SPECIES", 193, 196]]], ["This is vital from both clinical and public health perspectives in order to design and deliver interventions which are appropriate for women and girls of lower SEP and thus may assist in ameliorating the social gradient of health.", [["women", "ORGANISM", 135, 140], ["women", "SPECIES", 135, 140], ["girls", "SPECIES", 145, 150], ["interventions", "TREATMENT", 95, 108]]]], "70f3c90a651224f9292378da905af4ec635d5f43": [["Multilingual abstractsPlease see Additional file 1 for translations of the abstract into the six official working languages of the United Nations.Multilingual abstractsThe growing public health concern and the burden of Ebola outbreaksMultilingual abstractsIn the absence of an effective drug and vaccine for the dreadful and deadly outbreak caused by the Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever, there is growing concern for its public health burden in Sub-Saharan Africa.", [["Ebola", "DISEASE", 220, 225], ["Ebola virus disease", "DISEASE", 356, 375], ["EVD", "DISEASE", 377, 380], ["Ebola haemorrhagic fever", "DISEASE", 401, 425], ["Ebola", "ORGANISM", 220, 225], ["Ebola virus", "ORGANISM", 356, 367], ["Ebola haemorrhagic fever", "ORGANISM", 401, 425], ["Ebola virus", "SPECIES", 356, 367], ["Ebola haemorrhagic fever", "SPECIES", 401, 425], ["Ebola virus", "SPECIES", 356, 367], ["an effective drug and vaccine", "TREATMENT", 275, 304], ["the Ebola virus disease", "PROBLEM", 352, 375], ["Ebola haemorrhagic fever", "PROBLEM", 401, 425], ["abstracts", "OBSERVATION", 13, 22], ["abstracts", "OBSERVATION", 159, 168], ["growing", "OBSERVATION_MODIFIER", 172, 179], ["Ebola", "OBSERVATION_MODIFIER", 220, 225], ["Ebola virus", "OBSERVATION", 356, 367], ["Ebola", "OBSERVATION_MODIFIER", 401, 406], ["Sub", "OBSERVATION_MODIFIER", 484, 487]]], ["Since 1976, there have been 885,343 suspected and laboratory confirmed cases of EVD, including 1711 cased on the ongoing disease outbreak has claimed 932 lives in West Africa [1] .", [["EVD", "DISEASE", 80, 83], ["EVD", "PROBLEM", 80, 83]]], ["This part of the world is persistently confronted with this fatal disease which has an incubation period of two to 21 days (averagely 3-13days).", [["this fatal disease", "PROBLEM", 55, 73]]], ["Symptoms range from, firstly, fever and fatigue before descending into headaches, vomiting, violent diarrhoea, then multiple organ failure and massive internal bleeding [1, 2] .", [["organ", "ANATOMY", 125, 130], ["fever", "DISEASE", 30, 35], ["fatigue", "DISEASE", 40, 47], ["headaches", "DISEASE", 71, 80], ["vomiting", "DISEASE", 82, 90], ["diarrhoea", "DISEASE", 100, 109], ["organ failure", "DISEASE", 125, 138], ["bleeding", "DISEASE", 160, 168], ["organ", "ORGAN", 125, 130], ["Symptoms", "PROBLEM", 0, 8], ["fever", "PROBLEM", 30, 35], ["fatigue", "PROBLEM", 40, 47], ["descending into headaches", "PROBLEM", 55, 80], ["vomiting", "PROBLEM", 82, 90], ["violent diarrhoea", "PROBLEM", 92, 109], ["multiple organ failure", "PROBLEM", 116, 138], ["massive internal bleeding", "PROBLEM", 143, 168], ["organ", "ANATOMY", 125, 130], ["failure", "OBSERVATION", 131, 138], ["massive", "OBSERVATION_MODIFIER", 143, 150], ["internal", "OBSERVATION_MODIFIER", 151, 159], ["bleeding", "OBSERVATION", 160, 168]]], ["Ebola typically begins in remote places and can be distributed via hospitals/ healthcare centers or within the community as it takes several infections before the disease is ascertained.", [["Ebola", "DISEASE", 0, 5], ["infections", "DISEASE", 141, 151], ["Ebola", "ORGANISM", 0, 5], ["Ebola", "PROBLEM", 0, 5], ["several infections", "PROBLEM", 133, 151], ["the disease", "PROBLEM", 159, 170], ["infections", "OBSERVATION", 141, 151], ["disease", "OBSERVATION", 163, 170]]], ["The prevalence, morbidity and case fatality of chronological EVD outbreaks showed the persistent resurgence in different regions in Sub-Saharan Africa (see Figure 1) .Multilingual abstractsEbola outbreaks have a case fatality rate of 60-90%, yet no specific drug or vaccine is available for people and/or animals hosts.", [["Ebola", "DISEASE", 189, 194], ["Ebola", "ORGANISM", 189, 194], ["people", "ORGANISM", 291, 297], ["people", "SPECIES", 291, 297], ["morbidity", "PROBLEM", 16, 25], ["chronological EVD outbreaks", "PROBLEM", 47, 74], ["fatality rate", "TEST", 217, 230], ["persistent", "OBSERVATION_MODIFIER", 86, 96], ["resurgence", "OBSERVATION_MODIFIER", 97, 107], ["Sub", "OBSERVATION_MODIFIER", 132, 135], ["abstracts", "OBSERVATION", 180, 189]]], ["As of 4 August 2014, the cumulative number of cases attributed to EVD in the four countries stands at 1711 including 932 deaths.", [["EVD", "DISEASE", 66, 69], ["deaths", "DISEASE", 121, 127], ["EVD", "TREATMENT", 66, 69], ["EVD", "OBSERVATION", 66, 69]]], ["The distribution and classification of the cases are as follows: Guinea, 495 cases (351 confirmed, 133 probable, and 11 suspected), including 363 deaths; Liberia, 516 cases (143 confirmed, 252 probable, and 121 suspected), including 282 deaths; Sierra Leone, 691 cases (576 confirmed, 49 probable, and 66 suspected), including 286 deaths and Nigeria, 9 cases (0 confirmed, 2 probable, and 7 suspected) including 1 death.", [["deaths", "DISEASE", 146, 152], ["deaths", "DISEASE", 237, 243], ["deaths", "DISEASE", 331, 337], ["death", "DISEASE", 414, 419], ["Liberia", "TEST", 154, 161], ["Nigeria", "TEST", 342, 349], ["1 death", "PROBLEM", 412, 419], ["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["Between the 24 and 27 July 2014, a total of 122 new cases (laboratoryconfirmed, probable, and suspect cases) of EVD, and 57 deaths, were reported from the four countries as follows: Guinea, 33 new cases and 20 deaths; Liberia, 80 new cases and 27 deaths; Sierra Leone, 8 new cases and 9 deaths; and Nigeria, 1 new case who died [1].", [["EVD", "DISEASE", 112, 115], ["deaths", "DISEASE", 124, 130], ["deaths", "DISEASE", 210, 216], ["deaths", "DISEASE", 247, 253], ["deaths", "DISEASE", 287, 293], ["EVD", "PROBLEM", 112, 115]]], ["The outbreak is expected to last longer if proper diagnostic tools and rigorous integrated active surveillance response systems are not rapidly established and instituted [3] .", [["rigorous integrated active surveillance response systems", "PROBLEM", 71, 127]]], ["Therefore, the following requirements for rapid, scalable and sustainable responses to EVD and other outbreaks across African countries, and globally, have been identified.Rapid, scalable and sustainable responses to EVD and other outbreaks of diseaseFirst, the need to urgently recognise and coordinate outbreak action-responses in affected African countries and in cross-border neighbours, as well as collaboration with those that experienced outbreaks in the past, is vital.", [["EVD", "DISEASE", 87, 90], ["EVD", "DISEASE", 217, 220], ["diseaseFirst", "DISEASE", 244, 256], ["EVD", "TREATMENT", 87, 90], ["EVD", "TREATMENT", 217, 220]]], ["Overall, Ebola virus socio-ecology systems have shown to be linked by direct and indirect transmission through contact with objects from patients.", [["Ebola virus", "ORGANISM", 9, 20], ["patients", "ORGANISM", 137, 145], ["Ebola virus", "SPECIES", 9, 20], ["patients", "SPECIES", 137, 145], ["Ebola virus", "SPECIES", 9, 20]]], ["For example, the blood or secretions of an infected person or objects that have been contaminated with infected secretions can reach humans from a variety of hosts/sources: na\u00efve infected populations, infected wildlife, fruit and vegetable bats and the handling of infected fruit bats, monkeys, chimpanzees, gorillas, forest antelopes and porcupines are all possible natural hosts (whether ill or dead or found in the jungle or rainforest) [1,2].", [["blood", "ANATOMY", 17, 22], ["secretions", "ANATOMY", 26, 36], ["secretions", "ANATOMY", 112, 122], ["fruit", "ANATOMY", 220, 225], ["infected fruit bats", "DISEASE", 265, 284], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["secretions", "ORGANISM_SUBSTANCE", 26, 36], ["secretions", "ORGANISM", 112, 122], ["humans", "ORGANISM", 133, 139], ["fruit", "ORGANISM_SUBDIVISION", 220, 225], ["vegetable", "ORGANISM_SUBDIVISION", 230, 239], ["monkeys", "ORGANISM", 286, 293], ["gorillas", "ORGANISM", 308, 316], ["person", "SPECIES", 52, 58], ["humans", "SPECIES", 133, 139], ["monkeys", "SPECIES", 286, 293], ["humans", "SPECIES", 133, 139], ["the blood or secretions", "PROBLEM", 13, 36], ["an infected person or objects", "PROBLEM", 40, 69], ["infected secretions", "PROBLEM", 103, 122], ["na\u00efve infected populations", "PROBLEM", 173, 199], ["porcupines", "TREATMENT", 339, 349], ["dead", "PROBLEM", 397, 401], ["infected", "OBSERVATION", 43, 51], ["infected", "OBSERVATION_MODIFIER", 103, 111], ["secretions", "OBSERVATION", 112, 122], ["vegetable bats", "OBSERVATION", 230, 244], ["infected", "OBSERVATION_MODIFIER", 265, 273], ["fruit bats", "OBSERVATION", 274, 284]]], ["Thus, tracking, mapping, reporting and documenting veterinary public health zoonosis surveillance responses, the behaviour and medical history of butchers and poachers, as well as agro-livestock business trading are imperative to be able to establish integrated community-based and national comprehensive early warning and outbreak surveillance response systems.Rapid, scalable and sustainable responses to EVD and other outbreaks of diseaseSecond, understanding the unending transmission dynamics and resurgence is essential to actively identify and map transmission foci and local micro-epidemiological situations, which can lead to implementing prompt, effective response interventions tailored to specific local settings.", [["zoonosis", "DISEASE", 76, 84], ["EVD", "DISEASE", 407, 410], ["EVD", "TREATMENT", 407, 410], ["map transmission foci", "PROBLEM", 551, 572], ["local micro-epidemiological situations", "PROBLEM", 577, 615], ["effective response interventions", "TREATMENT", 656, 688]]], ["Hence, active early warnings approach under the framework of a surveillance response system both for veterinary and human public health should be established and implemented.", [["human", "ORGANISM", 116, 121], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121], ["a surveillance response system", "TEST", 61, 91], ["active", "OBSERVATION_MODIFIER", 7, 13], ["early", "OBSERVATION_MODIFIER", 14, 19]]], ["This system could include, for example, a ban on bush meat consumption, a ban on public places and markets, a reinforcement of safety and inspection regulations on food and fruit eating bats and examining bat migration as well as other animal-household drivers and risk factors [3, 4] .Rapid, scalable and sustainable responses to EVD and other outbreaks of diseaseThird, instituting electronic-based reporting systems based on advances in information and communication technologies (ICTs) is crucial as already about 40% of the West African affected populations use mobile phones (mhealth or ehealth).", [["meat", "ANATOMY", 54, 58], ["EVD", "DISEASE", 331, 334], ["meat", "ORGANISM_SUBDIVISION", 54, 58], ["EVD", "TREATMENT", 331, 334], ["disease", "PROBLEM", 358, 365], ["disease", "OBSERVATION", 358, 365]]], ["Building a local network (e.g. WhatsApp) or crowdsourcing data for targeted active responses, as well as the implementation of a geographical information system (GIS), are necessary spatial-temporal mapping and decision-making support systems to contain Ebola outbreaks.", [["Ebola", "DISEASE", 254, 259], ["Ebola", "ORGANISM", 254, 259], ["support systems", "TREATMENT", 227, 242], ["Ebola outbreaks", "PROBLEM", 254, 269], ["Ebola", "OBSERVATION", 254, 259]]], ["Lessons learnt from other outbreaks including cholera, H7N9 and H1N1 avian influenza, severe acute respiratory syndrome (SARS), Lassa fever, the Middle East respiratory syndrome (MERS), dengue pandemic and the human-animal with environmentalclimate interface in Africa and elsewhere can assist in setting benchmarks for monitoring epicentre/focal early warning alert, incidence and prevalence as well as effective surveillance response interventions measures [1, 5] .", [["cholera", "DISEASE", 46, 53], ["H7N9", "DISEASE", 55, 59], ["avian influenza", "DISEASE", 69, 84], ["acute respiratory syndrome", "DISEASE", 93, 119], ["SARS", "DISEASE", 121, 125], ["Lassa fever", "DISEASE", 128, 139], ["Middle East respiratory syndrome", "DISEASE", 145, 177], ["MERS", "DISEASE", 179, 183], ["dengue pandemic", "DISEASE", 186, 201], ["H1N1 avian influenza", "ORGANISM", 64, 84], ["human", "ORGANISM", 210, 215], ["H1N1 avian influenza", "SPECIES", 64, 84], ["Lassa fever", "SPECIES", 128, 139], ["human", "SPECIES", 210, 215], ["H7N9", "SPECIES", 55, 59], ["Middle East respiratory syndrome (MERS)", "SPECIES", 145, 184], ["human", "SPECIES", 210, 215], ["cholera", "PROBLEM", 46, 53], ["H7N9", "PROBLEM", 55, 59], ["H1N1", "PROBLEM", 64, 68], ["influenza", "PROBLEM", 75, 84], ["severe acute respiratory syndrome", "PROBLEM", 86, 119], ["SARS", "PROBLEM", 121, 125], ["Lassa fever", "PROBLEM", 128, 139], ["the Middle East respiratory syndrome", "PROBLEM", 141, 177], ["effective surveillance response interventions measures", "TREATMENT", 404, 458], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["respiratory syndrome", "OBSERVATION", 99, 119], ["Lassa", "OBSERVATION_MODIFIER", 128, 133], ["Middle", "ANATOMY_MODIFIER", 145, 151], ["respiratory syndrome", "OBSERVATION", 157, 177]]], ["Meanwhile, modelling factors and trends in different changing transmission scenarios could also yield better tactics, as well as strategic evidence not only for policy support, but also for direction, planning and implementation of national and regional early alert and surveillance response systems to control and prevent sentinel sites [4] .", [["modelling factors", "PROBLEM", 11, 28], ["surveillance response systems", "TEST", 270, 299]]], ["Following from the aforementioned three challenges and requirements to respond to EVD outbreaks in Africa, the following actions are recommended to combat EVD as well as other emerging infectious diseases.Mapping the unprecedented geographical migration of EVD across AfricaEbola was first reported in 1976 in Sudan and Congo and named after the river where it was identified.", [["EVD", "DISEASE", 155, 158], ["infectious diseases", "DISEASE", 185, 204], ["EVD", "DISEASE", 257, 260], ["EVD", "TREATMENT", 155, 158], ["EVD across AfricaEbola", "TREATMENT", 257, 279], ["infectious", "OBSERVATION", 185, 195], ["geographical", "OBSERVATION_MODIFIER", 231, 243], ["migration", "OBSERVATION_MODIFIER", 244, 253], ["EVD", "OBSERVATION", 257, 260]]], ["It was later reported in Gabon, Central Africa.", [["Central Africa", "OBSERVATION", 32, 46]]], ["The genus Ebolavirus is one of three members of the Filoviridae family (filovirus), along with the genus Marburgvirus and the genus Cuevavirus, and comprises five distinct species, of which Zaire ebolavirus, Sudan ebolavirus and Bundibugyo ebolavirus are mostly associated with the major EVD outbreaks in Africa.", [["EVD outbreaks", "DISEASE", 288, 301], ["Filoviridae", "GENE_OR_GENE_PRODUCT", 52, 63], ["filovirus", "ORGANISM", 72, 81], ["Zaire ebolavirus", "ORGANISM", 190, 206], ["Sudan ebolavirus", "ORGANISM", 208, 224], ["Bundibugyo ebolavirus", "ORGANISM", 229, 250], ["Bundibugyo ebolavirus", "SPECIES", 229, 250], ["Zaire ebolavirus", "SPECIES", 190, 206], ["Sudan ebolavirus", "SPECIES", 208, 224], ["Bundibugyo ebolavirus", "SPECIES", 229, 250], ["The genus Ebolavirus", "PROBLEM", 0, 20], ["the genus Marburgvirus", "PROBLEM", 95, 117], ["the genus Cuevavirus", "PROBLEM", 122, 142], ["Zaire ebolavirus", "PROBLEM", 190, 206], ["Sudan ebolavirus", "PROBLEM", 208, 224], ["Bundibugyo ebolavirus", "PROBLEM", 229, 250], ["genus Ebolavirus", "OBSERVATION", 4, 20], ["genus Marburgvirus", "ANATOMY", 99, 117], ["genus Cuevavirus", "ANATOMY", 126, 142], ["ebolavirus", "OBSERVATION", 240, 250], ["major", "OBSERVATION_MODIFIER", 282, 287], ["EVD", "OBSERVATION", 288, 291]]], ["Reston ebolavirus and Ta\u00ef Forest ebolavirus are mostly reported in the Asia-Pacific region, especially Philippines and the People's Republic of China, but no symptoms or deaths in humans from these have been reported to date [2] .", [["deaths", "DISEASE", 170, 176], ["Reston ebolavirus", "ORGANISM", 0, 17], ["Ta\u00ef Forest ebolavirus", "ORGANISM", 22, 43], ["humans", "ORGANISM", 180, 186], ["People", "SPECIES", 123, 129], ["humans", "SPECIES", 180, 186], ["Reston ebolavirus", "SPECIES", 0, 17], ["Ta\u00ef Forest ebolavirus", "SPECIES", 22, 43], ["humans", "SPECIES", 180, 186], ["Reston ebolavirus", "PROBLEM", 0, 17], ["Ta\u00ef Forest ebolavirus", "PROBLEM", 22, 43], ["symptoms", "PROBLEM", 158, 166], ["deaths in humans", "PROBLEM", 170, 186], ["ebolavirus", "OBSERVATION", 7, 17], ["Forest ebolavirus", "OBSERVATION", 26, 43], ["no", "UNCERTAINTY", 155, 157]]], ["The disease outbreak has persisted over the years across Central, East and Southern Africa.", [["The disease outbreak", "PROBLEM", 0, 20], ["disease", "OBSERVATION", 4, 11]]], ["On March 21, 2014, the first case of an outbreak was identified in Guinea, West Africa, witnessing a total of 460 cases with 339 fatalities, as it spread beyond the remote rural areas to the capital city of Conakry.", [["fatalities", "DISEASE", 129, 139], ["capital", "ANATOMY_MODIFIER", 191, 198]]], ["Soon after the outbreak was identified, it appeared across the border in the small nation of Liberia on March 30, 2014.", [["border", "OBSERVATION_MODIFIER", 63, 69], ["small", "OBSERVATION_MODIFIER", 77, 82]]], ["This country was the least hit with 339 cases and 156 fatalities thus far.", [["fatalities", "DISEASE", 54, 64]]], ["Later, it was also identified in Sierra Leone in late May 2014, just as it appeared the outbreaks in Guinea and Liberia were winding down.", [["Guinea", "PROBLEM", 101, 107]]], ["It has since spread to at least two Sierra Leone districts with 533 cases claiming at least 233 lives, including 68 deaths of 85 new cases within just four days.", [["deaths", "DISEASE", 116, 122]]], ["Similarly, between 21 and 23 July 2014, 96 new cases and 7 deaths were reported from Liberia and Sierra Leone.", [["deaths", "DISEASE", 59, 65]]], ["In Guinea, 12 new cases and 5 deaths were reported during the same period and one death in Nigeria [1] (see Table 1 ).Mapping the unprecedented geographical migration of EVD across AfricaUnderstanding African cultural and customs practices and how they affect psychosocialbehavioural attitudes towards Ebola outbreaks African economic community according to the World Bank, 2013.", [["deaths", "DISEASE", 30, 36], ["death", "DISEASE", 82, 87], ["Ebola", "DISEASE", 302, 307], ["Ebola", "ORGANISM", 302, 307], ["EVD", "TREATMENT", 170, 173], ["unprecedented", "OBSERVATION_MODIFIER", 130, 143], ["geographical", "OBSERVATION_MODIFIER", 144, 156], ["migration", "OBSERVATION_MODIFIER", 157, 166]]], ["Each country consists broadly of two distinct zones: a sahelian zone (North), largely landlocked, and a more humid, forested coastal zone (South), with the literacy rate varying from 41-62% (see Figure 1 ).", [["the literacy rate", "TEST", 152, 169], ["two", "OBSERVATION_MODIFIER", 33, 36], ["distinct", "OBSERVATION_MODIFIER", 37, 45], ["zones", "OBSERVATION_MODIFIER", 46, 51], ["more", "OBSERVATION_MODIFIER", 104, 108], ["humid", "OBSERVATION_MODIFIER", 109, 114], ["forested", "OBSERVATION_MODIFIER", 116, 124], ["coastal", "OBSERVATION_MODIFIER", 125, 132], ["zone", "OBSERVATION_MODIFIER", 133, 137]]], ["Similar to the conception and spread of the HIV/AIDS pandemic in Africa, one of the main obstacles in reducing the distribution of Ebola has been the widespread ignorance, lack of knowledge and potential panic over EVD, considered to be a 'Satanic or bewitched' disease, leading to trepidation, isolation, dignity impounding, stigmatisation and ostracism from associated socio-ecological and public health consequences.", [["HIV/AIDS pandemic", "DISEASE", 44, 61], ["Ebola", "DISEASE", 131, 136], ["panic", "DISEASE", 204, 209], ["EVD", "DISEASE", 215, 218], ["bewitched' disease", "DISEASE", 251, 269], ["trepidation", "DISEASE", 282, 293], ["stigmatisation", "DISEASE", 326, 340], ["ostracism", "DISEASE", 345, 354], ["Ebola", "ORGANISM", 131, 136], ["HIV", "SPECIES", 44, 47], ["the HIV/AIDS pandemic", "PROBLEM", 40, 61], ["Ebola", "PROBLEM", 131, 136], ["potential panic over EVD", "PROBLEM", 194, 218], ["a 'Satanic or bewitched' disease", "PROBLEM", 237, 269], ["trepidation", "PROBLEM", 282, 293], ["isolation", "TREATMENT", 295, 304], ["dignity impounding", "PROBLEM", 306, 324], ["stigmatisation", "PROBLEM", 326, 340], ["ostracism", "PROBLEM", 345, 354], ["spread", "OBSERVATION_MODIFIER", 30, 36], ["main", "OBSERVATION_MODIFIER", 84, 88], ["obstacles", "OBSERVATION", 89, 98], ["distribution", "OBSERVATION_MODIFIER", 115, 127], ["Ebola", "OBSERVATION", 131, 136], ["widespread", "OBSERVATION_MODIFIER", 150, 160], ["ignorance", "OBSERVATION", 161, 170]]], ["Recently, local residents of the Sadialu village in Sierra Leone were sheltering those infected with Ebola, refusing to go to or escaping from hospitalisation referred as \"death sentence\", and hiding from the local health centre due to circulating beliefs, myths and rumours that the interventions being administered to patients were actually causing the disease (see Figure 2 ).Mapping the unprecedented geographical migration of EVD across AfricaSuch consequences and misconceptions are proscribed in the International Health Regulations (IHR), human rights laws, as well as the Helsinki and the WHO declarations.", [["Ebola", "DISEASE", 101, 106], ["death", "DISEASE", 172, 177], ["EVD", "DISEASE", 431, 434], ["Ebola", "ORGANISM", 101, 106], ["patients", "ORGANISM", 320, 328], ["human", "ORGANISM", 547, 552], ["patients", "SPECIES", 320, 328], ["human", "SPECIES", 547, 552], ["human", "SPECIES", 547, 552], ["the interventions", "TREATMENT", 280, 297], ["the disease", "PROBLEM", 351, 362], ["EVD", "TREATMENT", 431, 434], ["unprecedented", "OBSERVATION_MODIFIER", 391, 404], ["geographical", "OBSERVATION_MODIFIER", 405, 417], ["migration", "OBSERVATION_MODIFIER", 418, 427], ["EVD", "OBSERVATION", 431, 434]]], ["These detail the challenges and opportunities that Ebola and other infectious diseases are currently facing, including neglected tropical disease (NTD) prevention, control and management, as well as health system coverage and service delivery bottlenecks.", [["Ebola", "DISEASE", 51, 56], ["infectious diseases", "DISEASE", 67, 86], ["NTD", "DISEASE", 147, 150], ["Ebola", "ORGANISM", 51, 56], ["Ebola", "PROBLEM", 51, 56], ["other infectious diseases", "PROBLEM", 61, 86], ["neglected tropical disease", "PROBLEM", 119, 145], ["NTD) prevention", "TREATMENT", 147, 162], ["management", "TREATMENT", 176, 186], ["health system coverage", "TREATMENT", 199, 221], ["service delivery bottlenecks", "TREATMENT", 226, 254]]], ["Harnessing all stakeholders' collaboration, communication and networking, including communities, is essential for improving and nurturing community participation, informal and formal health education, ownership and empowerment of the programmes, and patient independence and dignity, as well as ensuring human rights for all ages at all levels in order develop a productive and sustainable African continent and achieve the Millennium Development Goals (MDGs) and global health.Mapping the unprecedented geographical migration of EVD across AfricaHence, accelerating the response through provision of minimum essential information on risk communication for behavioural impact, developmental communication and health promotion/education personnel and community, working in multidisciplinary to respond to the disease outbreak, will be very useful for adequate and appropriate national staff and other national resources to the field operational epidemiologists, clinicians, and public health officers in fostering positive behavioural changes while respecting cultural practices, and impact on local contexts and outbreak dynamics, prevention and control interventions and scaling up outbreak containment measures, especially effective contact tracing.Developing surveillance response systems against Ebola and other infectious disease outbreaksUnfortunately, several countries in Africa, as well as governmental and research institutions, are inadequately equipped in diagnostics, tracking, active reporting, prompt healthcare delivery, and accessible and affordable treatment to combat the Ebola infection and other emerging infectious diseases.", [["Ebola", "DISEASE", 1300, 1305], ["infectious disease", "DISEASE", 1316, 1334], ["Ebola infection", "DISEASE", 1591, 1606], ["infectious diseases", "DISEASE", 1626, 1645], ["patient", "ORGANISM", 250, 257], ["human", "ORGANISM", 304, 309], ["Ebola", "ORGANISM", 1300, 1305], ["Ebola", "ORGANISM", 1591, 1596], ["patient", "SPECIES", 250, 257], ["human", "SPECIES", 304, 309], ["human", "SPECIES", 304, 309], ["EVD across AfricaHence", "TREATMENT", 530, 552], ["the disease outbreak", "PROBLEM", 804, 824], ["control interventions", "TREATMENT", 1146, 1167], ["scaling up outbreak containment measures", "TREATMENT", 1172, 1212], ["Ebola", "PROBLEM", 1300, 1305], ["other infectious disease outbreaks", "PROBLEM", 1310, 1344], ["prompt healthcare delivery", "TREATMENT", 1509, 1535], ["affordable treatment", "TREATMENT", 1556, 1576], ["the Ebola infection", "PROBLEM", 1587, 1606], ["other emerging infectious diseases", "PROBLEM", 1611, 1645], ["productive", "OBSERVATION_MODIFIER", 363, 373], ["unprecedented", "OBSERVATION_MODIFIER", 490, 503], ["geographical", "OBSERVATION_MODIFIER", 504, 516], ["migration", "OBSERVATION_MODIFIER", 517, 526], ["infectious", "OBSERVATION_MODIFIER", 1316, 1326], ["infectious", "OBSERVATION", 1626, 1636]]], ["The development of new tools, strategies and approaches, such as improved diagnostics and novel therapies including vaccines, is needed to prevent, control and contain Ebola as well as SARS, bird flu, Lassa fever, dengue and MERS outbreaks.", [["Ebola", "DISEASE", 168, 173], ["SARS", "DISEASE", 185, 189], ["bird flu", "DISEASE", 191, 199], ["Lassa fever", "DISEASE", 201, 212], ["dengue", "DISEASE", 214, 220], ["MERS", "DISEASE", 225, 229], ["Ebola", "ORGANISM", 168, 173], ["Lassa", "ORGANISM", 201, 206], ["Lassa fever", "SPECIES", 201, 212], ["dengue", "SPECIES", 214, 220], ["novel therapies", "TREATMENT", 90, 105], ["vaccines", "TREATMENT", 116, 124], ["Ebola", "PROBLEM", 168, 173], ["SARS", "PROBLEM", 185, 189], ["bird flu", "PROBLEM", 191, 199], ["Lassa fever", "PROBLEM", 201, 212], ["dengue", "PROBLEM", 214, 220], ["MERS outbreaks", "PROBLEM", 225, 239], ["new", "OBSERVATION_MODIFIER", 19, 22], ["Ebola", "OBSERVATION", 168, 173]]], ["Hence, the urgent need to develop and implement early warning alert and active surveillance response systems for emerging infectious diseases and the control and elimination of NTDs, as well as early warning and emergency systems, cannot be overemphasised.", [["infectious diseases", "DISEASE", 122, 141], ["NTDs", "DISEASE", 177, 181], ["emerging infectious diseases", "PROBLEM", 113, 141], ["NTDs", "PROBLEM", 177, 181]]], ["Timely and effective reporting, documentation and communication of incidence and prevalence by all stakeholders including the health ministries, international and local NGOs, UN agencies, religious leaders, WHO regional and Partners (CDC, MSF, UNICEF, IFRC) continue to work together through the Sub-regional Ebola Outbreak Coordination Center (SEOCC), global health institutions and other stakeholders are paramount in early containment response [4] .", [["Ebola", "DISEASE", 309, 314]]], ["WHO does not recommend any travel or trade restrictions is applied to Guinea, Liberia, Sierra Leone or Nigeria, based on the current information available.", [["trade restrictions", "TREATMENT", 37, 55]]], ["Moreover, people who don't have the knowledge should be educated on how to protect themselves.", [["people", "ORGANISM", 10, 16], ["people", "SPECIES", 10, 16]]], ["Also important is the prompt quarantining of the sick and the dead in line with the African customs and burial traditional, cultural myths and practices, as it is believed in such cultures that corpses are still contagious and customary transmits the disease.Implementing new surveillance tools and strategies to combat Ebola outbreaks and other infectious diseasesThere is an urgent necessity to strengthen the primary healthcare system, and develop more sensitive serological and molecular diagnostic tools, as well as innovative methods and approaches to assess vulnerability in agreement with current practices (see Figure 3 ).", [["Ebola outbreaks", "DISEASE", 320, 335], ["infectious diseases", "DISEASE", 346, 365], ["Ebola", "ORGANISM", 320, 325], ["such cultures", "TEST", 175, 188], ["the disease", "PROBLEM", 247, 258], ["new surveillance tools", "TEST", 272, 294], ["Ebola outbreaks", "PROBLEM", 320, 335], ["other infectious diseases", "PROBLEM", 340, 365], ["infectious", "OBSERVATION_MODIFIER", 346, 356]]], ["This requires further research and development (R&D), capacity building based on international best practices for containing public outbreaks, the drafting of standard processes and operating procedures, biorisk management as samples from patients and animals are an extreme biohazard risk, thorough adherence to the WHO global alert and response operations, and outbreak communication guide-lines.", [["patients", "ORGANISM", 239, 247], ["patients", "SPECIES", 239, 247], ["operating procedures", "TREATMENT", 182, 202], ["biorisk management", "TREATMENT", 204, 222], ["an extreme biohazard risk", "PROBLEM", 264, 289], ["response operations", "TREATMENT", 338, 357]]], ["Moreover, maximizing the advances in genomic, biotechnological and communication technologies provides efficient and improved surveillance tools for early warning system prognostic, monitoring and evaluation control and prevention of outbreaks; these should be based on preventing the source as ascribed in the 'One World-One Health' standpoint [2, 6] .", [["communication technologies", "TREATMENT", 67, 93], ["evaluation control", "TEST", 197, 215], ["outbreaks", "PROBLEM", 234, 243]]], ["In addition, intensive efficacy and pharmacovigilance assessment of these interventions including diagnostics, drugs and vaccines against Ebola and other emerging infectious diseases including NTDs must be carefully re-evaluated, and the cut-offs determined and monitored over time, in addition to enhance cross-border collaboration and strengthen effective coordination across African government and populations [2] [3] [4] .Implementing new surveillance tools and strategies to combat Ebola outbreaks and other infectious diseasesReal-time active surveillance response systems, research priorities and innovative mechanisms for outbreaks include the development of tools targeting early active diagnosis especially at the onset and during the low level of transmission; tracking and mapping; monitoring human and host population migration; forecasting outbreaks based on risk factors; assessment of indicators and minimal essential datasets to guide evidence decision making; strategic planning and effective control; and prevention programmes and response packages tailored to local settings [4, 5] .", [["Ebola", "DISEASE", 138, 143], ["infectious diseases", "DISEASE", 163, 182], ["NTDs", "DISEASE", 193, 197], ["Ebola outbreaks", "DISEASE", 487, 502], ["infectious diseases", "DISEASE", 513, 532], ["Ebola", "ORGANISM", 138, 143], ["Ebola", "ORGANISM", 487, 492], ["human", "ORGANISM", 805, 810], ["human", "SPECIES", 805, 810], ["human", "SPECIES", 805, 810], ["pharmacovigilance assessment", "TEST", 36, 64], ["these interventions", "TREATMENT", 68, 87], ["diagnostics", "TEST", 98, 109], ["drugs", "TREATMENT", 111, 116], ["vaccines", "TREATMENT", 121, 129], ["Ebola", "PROBLEM", 138, 143], ["NTDs", "PROBLEM", 193, 197], ["the cut-offs", "TEST", 234, 246], ["new surveillance tools", "TEST", 439, 461], ["Ebola outbreaks", "PROBLEM", 487, 502], ["other infectious diseases", "PROBLEM", 507, 532], ["outbreaks", "PROBLEM", 630, 639], ["forecasting outbreaks", "PROBLEM", 842, 863], ["assessment of indicators", "TEST", 887, 911], ["strategic planning", "TREATMENT", 978, 996], ["effective control", "TREATMENT", 1001, 1018], ["prevention programmes", "TREATMENT", 1024, 1045], ["response packages", "TREATMENT", 1050, 1067], ["infectious", "OBSERVATION_MODIFIER", 513, 523]]], ["Irrefutably, national and regional inter-sectorial and trans-disciplinary approaches must be adopted and related to ministries and organisations in order to build innovative early warning system surveillance response systems through fostering capacity building and training on outbreaks and emerging infectious disease prevention, control and elimination.", [["infectious disease", "DISEASE", 300, 318], ["fostering capacity building", "TREATMENT", 233, 260], ["emerging infectious disease prevention", "TREATMENT", 291, 329], ["infectious", "OBSERVATION_MODIFIER", 300, 310]]], ["It is also imperative to understand global health involvement and governance, establish monitoring and evaluation (M&E) of research for action programmes, as well as increase funding to support efforts of existing and new consortiums and research projects in Africa.", [["evaluation", "TEST", 103, 113], ["action programmes", "TREATMENT", 136, 153], ["existing and new consortiums", "PROBLEM", 205, 233]]], ["Furthermore, there is need to analyse the socio-economic and cultural factors, the status of prevailing health systems, and the risk factors and determinants of the emergence and spread of outbreaks in Africa.", [["the socio-economic and cultural factors", "PROBLEM", 38, 77], ["the risk factors", "PROBLEM", 124, 140]]], ["Reliable and well-organised monitoring, the establishment of GISs and appraisals of cost-effectiveness in an integrated national health system (with a care management approach) will eventually improve evidence information for policy-makers [4] .", [["a care management approach", "TREATMENT", 149, 175]]], ["In turn, they can make decisions and guide implementers of health programmes to achieve beneficial and innovative sustainable global public health interventions, quality healthcare outcomes and economic prosperity.ConclusionConsolidating and harmonizing the technical support at local, country, regional, and international level is required in mobilizing the international community in support of national efforts in epidemic and pandemic prevention and control.", [["health programmes", "TREATMENT", 59, 76], ["pandemic prevention", "TREATMENT", 430, 449]]], ["Hence, developing, scaling up and strengthening all aspects of the outbreak surveillance response system including contact tracking, public information and community mobilization, case management and infection prevention and control, and effective coordination.", [["infection", "DISEASE", 200, 209], ["community mobilization", "TREATMENT", 156, 178], ["case management", "TREATMENT", 180, 195], ["infection prevention", "TREATMENT", 200, 220], ["infection", "OBSERVATION", 200, 209]]]], "PMC7129132": [["Operating grant support from the National Natural Science Foundation of China (grants no: 81870942, 81471174 and 81520108011), National Key Research and Development Program of China (grant no: 2018YFC1312200), and Innovation Scientists and Technicians Troop Constructions Projects of Henan Province of China (for M. Xue).Competing interestsNone declared.Ethical approvalNot required.", [["Ethical approval", "TREATMENT", 354, 370]]]], "41ee771b9bd14efb72c392edf03b3cff55c9d570": [["IntroductionNeonatal calf diarrhea (NCD) is the most common cause of calf morbidity and mortality, which can exceed 20% in certain instances (Uetake, 2013) .", [["calf diarrhea", "DISEASE", 21, 34], ["NCD", "DISEASE", 36, 39], ["calf", "ORGANISM_SUBDIVISION", 21, 25], ["calf", "ORGANISM_SUBDIVISION", 69, 73], ["calf", "SPECIES", 21, 25], ["calf", "SPECIES", 69, 73], ["Neonatal calf diarrhea", "PROBLEM", 12, 34], ["calf morbidity", "PROBLEM", 69, 83], ["calf", "ANATOMY", 21, 25], ["diarrhea", "OBSERVATION", 26, 34], ["calf", "ANATOMY", 69, 73], ["morbidity", "OBSERVATION", 74, 83]]], ["The factors that influence the etiology of this syndrome include nutritional and sanitary management, immunological aspects, and infectious agents, such as bacteria, viruses, and protozoa (Coura et al., 2015) .", [["this syndrome", "PROBLEM", 43, 56], ["nutritional and sanitary management", "TREATMENT", 65, 100], ["infectious agents", "TREATMENT", 129, 146], ["bacteria", "PROBLEM", 156, 164], ["viruses", "PROBLEM", 166, 173], ["protozoa", "PROBLEM", 179, 187]]], ["Bovine rotavirus A (RVA) is one of the most prevalent viral agents associated with NCD in dairy and beef cattle herds worldwide (Al Mawly et al., 2015; Coura et al., 2015) .IntroductionThe non-enveloped virion of RVA is composed of a triple-layered capsid that surrounds 11 dsRNA segments that encode 6 structural (VP1-VP4, VP6, and VP7) and 6 nonstructural (NSP1-NSP5/6) proteins (Greenberg and Estes, 2009 ).", [["rotavirus A", "CHEMICAL", 7, 18], ["NCD", "DISEASE", 83, 86], ["Bovine rotavirus A", "ORGANISM", 0, 18], ["VP1-VP4", "GENE_OR_GENE_PRODUCT", 315, 322], ["VP6", "GENE_OR_GENE_PRODUCT", 324, 327], ["VP7", "GENE_OR_GENE_PRODUCT", 333, 336], ["NSP1-NSP5/6", "GENE_OR_GENE_PRODUCT", 359, 370], ["RVA", "PROTEIN", 213, 216], ["triple-layered capsid", "PROTEIN", 234, 255], ["VP1", "PROTEIN", 315, 318], ["VP4", "PROTEIN", 319, 322], ["VP6", "PROTEIN", 324, 327], ["VP7", "PROTEIN", 333, 336], ["nonstructural (NSP1-NSP5/6) proteins", "PROTEIN", 344, 380], ["Bovine", "SPECIES", 0, 6], ["beef", "SPECIES", 100, 104], ["cattle", "SPECIES", 105, 111], ["Bovine rotavirus A", "SPECIES", 0, 18], ["RVA", "SPECIES", 20, 23], ["beef", "SPECIES", 100, 104], ["cattle", "SPECIES", 105, 111], ["Bovine rotavirus A (RVA)", "TREATMENT", 0, 24], ["The non-enveloped virion of RVA", "TREATMENT", 185, 216], ["a triple-layered capsid", "TREATMENT", 232, 255], ["VP1", "TEST", 315, 318], ["VP4", "TEST", 319, 322], ["VP6", "TEST", 324, 327], ["VP7", "TEST", 333, 336], ["nonstructural", "TEST", 344, 357], ["NSP1", "TEST", 359, 363], ["NSP5", "TEST", 364, 368], ["proteins", "TEST", 372, 380], ["dsRNA segments", "OBSERVATION", 274, 288]]], ["Based on their antigenic characteristics and sequence analyses of the VP6 gene, viruses within the Rotavirus genus are primarily classified into 9 distinct groups/species (ICTV, 2017; Matthijnssens et al., 2012; Mihalov-Kovacs et al., 2015) ; a newly-proposed species J has been described in the bat .", [["VP6", "GENE_OR_GENE_PRODUCT", 70, 73], ["Rotavirus genus", "ORGANISM", 99, 114], ["bat", "ORGANISM", 296, 299], ["VP6 gene", "DNA", 70, 78], ["sequence analyses", "TEST", 45, 62], ["viruses", "PROBLEM", 80, 87], ["the Rotavirus genus", "PROBLEM", 95, 114], ["species J", "OBSERVATION", 260, 269]]], ["The VP7 and VP4 genes encode 2 structural proteins responsible for the induction of the immune protective response and are used for the binary classification of RVA strains in terms of their G and P genotypes, respectively.", [["VP7", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP4", "GENE_OR_GENE_PRODUCT", 12, 15], ["VP7 and VP4 genes", "DNA", 4, 21], ["structural proteins", "PROTEIN", 31, 50], ["The VP7", "TEST", 0, 7], ["RVA strains", "PROBLEM", 161, 172]]], ["Currently, 36 G and 51 P genotypes are recognized by the Rotavirus Classification Working Group (RCWG, 2017) .IntroductionCalves aged 1 to 3 weeks have antibody levels from passive immunity decreasing to a level that is still sufficiently high to block responses to vaccines but is not sufficiently high to combat infection.", [["Rotavirus", "DISEASE", 57, 66], ["infection", "DISEASE", 314, 323], ["Calves", "ORGANISM", 122, 128], ["P genotypes", "DNA", 23, 34], ["Calves", "SPECIES", 122, 128], ["antibody levels", "TEST", 152, 167], ["passive immunity", "PROBLEM", 173, 189], ["vaccines", "TREATMENT", 266, 274], ["infection", "PROBLEM", 314, 323], ["infection", "OBSERVATION", 314, 323]]], ["Thus, this period is considered a window of opportunity for the infection of microorganisms and, consequently, the occurrence of disease (Chase et al., 2008) .", [["infection", "DISEASE", 64, 73], ["the infection of microorganisms", "PROBLEM", 60, 91], ["disease", "PROBLEM", 129, 136], ["infection", "OBSERVATION", 64, 73], ["disease", "OBSERVATION", 129, 136]]], ["Therefore, the implementation of a cow vaccination program is an important strategy to protect the calves from RVA infection and consequent neonatal diarrhea.IntroductionThe commercial vaccines that are available in Brazil contain inactivated RVA and other infectious agents that are implicated in NCD.", [["RVA infection", "DISEASE", 111, 124], ["diarrhea", "DISEASE", 149, 157], ["NCD", "DISEASE", 298, 301], ["cow", "ORGANISM", 35, 38], ["calves", "ORGANISM", 99, 105], ["calves", "SPECIES", 99, 105], ["cow", "SPECIES", 35, 38], ["RVA", "SPECIES", 111, 114], ["a cow vaccination program", "TREATMENT", 33, 58], ["RVA infection", "PROBLEM", 111, 124], ["consequent neonatal diarrhea", "PROBLEM", 129, 157], ["The commercial vaccines", "TREATMENT", 170, 193], ["other infectious agents", "TREATMENT", 251, 274], ["calves", "ANATOMY", 99, 105], ["RVA", "OBSERVATION_MODIFIER", 111, 114], ["infection", "OBSERVATION", 115, 124], ["infectious", "OBSERVATION", 257, 267]]], ["There were 2 different RVA Brazilian vaccine formulations: i) the bivalent vaccine G10P[11] and G6P[1]; ii) and monovalent G6P[5] genotype, which is the most prevalent genotype worldwide (Papp et al., 2013) as well as in Brazil (Medeiros, 2016) .IntroductionThe aim of this study was to determine the frequency and intensity of neonatal diarrhea and the incidence of RVA and to identify the RVA G and P genotypes circulating in dairy calves born from cows that are regularly vaccinated with the RVA G6P[5] strain in a high milk yield dairy cattle herd.Herd informationThis study was conducted in a Brazilian dairy farm that is operated as a closed dairy cattle herd with 1800 Holstein cows in lactation.", [["G10P", "CHEMICAL", 83, 87], ["G6P", "CHEMICAL", 96, 99], ["G6P", "CHEMICAL", 123, 126], ["diarrhea", "DISEASE", 337, 345], ["G6P", "CHEMICAL", 499, 502], ["G6P", "CHEMICAL", 123, 126], ["G6P[1]", "SIMPLE_CHEMICAL", 96, 102], ["G6P[5]", "SIMPLE_CHEMICAL", 123, 129], ["calves", "ORGANISM", 434, 440], ["cows", "ORGANISM", 451, 455], ["G6P[5", "ORGANISM", 499, 504], ["milk", "ORGANISM_SUBSTANCE", 523, 527], ["calves", "SPECIES", 434, 440], ["cows", "SPECIES", 451, 455], ["cattle", "SPECIES", 540, 546], ["cattle", "SPECIES", 654, 660], ["cows", "SPECIES", 685, 689], ["cattle", "SPECIES", 540, 546], ["cattle", "SPECIES", 654, 660], ["2 different RVA Brazilian vaccine formulations", "TREATMENT", 11, 57], ["the bivalent vaccine G10P", "TEST", 62, 87], ["G6P", "TEST", 96, 99], ["monovalent G6P", "TEST", 112, 126], ["genotype", "TEST", 130, 138], ["this study", "TEST", 269, 279], ["neonatal diarrhea", "PROBLEM", 328, 345], ["RVA", "PROBLEM", 367, 370], ["the RVA G", "TREATMENT", 387, 396], ["This study", "TEST", 568, 578]]], ["The cows were managed using appropriate nutritional and health practices.", [["cows", "ORGANISM", 4, 8], ["cows", "SPECIES", 4, 8]]], ["This high milk yield dairy cattle herd produces an average of 37 liters/ day/cow.", [["milk", "ANATOMY", 10, 14], ["milk", "ORGANISM_SUBSTANCE", 10, 14], ["cow", "ORGANISM_SUBDIVISION", 77, 80], ["cattle", "SPECIES", 27, 33], ["cattle", "SPECIES", 27, 33], ["cow", "SPECIES", 77, 80]]], ["The calves are reared in individual pens on elevated floors.", [["calves", "ORGANISM", 4, 10], ["calves", "SPECIES", 4, 10], ["elevated floors", "TREATMENT", 44, 59], ["calves", "ANATOMY", 4, 10]]], ["The colostrum intake began shortly after birth and has taken place with adequate frequency and quantity for all newborn calves.Vaccination of cowsSixty or 45 days before calving, the cows were vaccinated against NCD.", [["colostrum", "ANATOMY", 4, 13], ["cowsSixty", "CHEMICAL", 142, 151], ["NCD", "DISEASE", 212, 215], ["colostrum", "ORGANISM", 4, 13], ["calves", "ORGANISM", 120, 126], ["cows", "ORGANISM", 183, 187], ["calves", "SPECIES", 120, 126], ["cows", "SPECIES", 183, 187], ["Vaccination of cowsSixty", "TREATMENT", 127, 151], ["colostrum intake", "OBSERVATION", 4, 20]]], ["The commercial vaccine used in this study contained inactivated rotavirus A (UK-Compton strain -G6P[5]), inactivated bovine coronavirus (Mebus strain), and E. coli (K99) adesine F5.", [["bovine coronavirus", "DISEASE", 117, 135], ["rotavirus A", "ORGANISM", 64, 75], ["UK-Compton strain -G6P[5]", "ORGANISM", 77, 102], ["bovine coronavirus", "ORGANISM", 117, 135], ["Mebus strain", "ORGANISM", 137, 149], ["E. coli", "ORGANISM", 156, 163], ["bovine", "SPECIES", 117, 123], ["coronavirus", "SPECIES", 124, 135], ["E. coli", "SPECIES", 156, 163], ["rotavirus A", "SPECIES", 64, 75], ["bovine coronavirus", "SPECIES", 117, 135], ["E. coli", "SPECIES", 156, 163], ["The commercial vaccine", "TREATMENT", 0, 22], ["this study", "TEST", 31, 41], ["inactivated bovine coronavirus (Mebus strain", "PROBLEM", 105, 149], ["E. coli", "PROBLEM", 156, 163]]], ["The vaccination was performed according to the manufacturer's instructions.Fecal samplesThe fecal samples from 122 heifer calves born from RVA-vaccinated cows were collected at 10 different time points (1, 4, 7, 10, 14, 17, 21, 24, 28 , and 30 days after birth), regardless of the presence or absence of diarrhea.", [["Fecal samples", "ANATOMY", 75, 88], ["fecal samples", "ANATOMY", 92, 105], ["diarrhea", "DISEASE", 304, 312], ["Fecal samples", "ORGANISM_SUBSTANCE", 75, 88], ["fecal samples", "ORGANISM_SUBSTANCE", 92, 105], ["calves", "ORGANISM", 122, 128], ["cows", "ORGANISM", 154, 158], ["calves", "SPECIES", 122, 128], ["cows", "SPECIES", 154, 158], ["The vaccination", "TREATMENT", 0, 15], ["Fecal samples", "TEST", 75, 88], ["The fecal samples", "TEST", 88, 105], ["RVA", "TEST", 139, 142], ["vaccinated cows", "PROBLEM", 143, 158], ["diarrhea", "PROBLEM", 304, 312], ["fecal", "ANATOMY", 92, 97], ["diarrhea", "OBSERVATION", 304, 312]]], ["The samples were collected between March and May 2017, and a total of 1220 fecal samples were stored at -20\u00b0C until analysis.", [["samples", "ANATOMY", 4, 11], ["fecal samples", "ANATOMY", 75, 88], ["fecal samples", "CANCER", 75, 88], ["The samples", "TEST", 0, 11], ["fecal samples", "TEST", 75, 88], ["analysis", "TEST", 116, 124]]], ["At the time of collection, all of the fecal samples were classified according to their consistency using the following scale: 0, normal; 1, pasty; 2, soft; 3, watery.", [["fecal samples", "ANATOMY", 38, 51], ["watery", "DISEASE", 159, 165], ["fecal samples", "CANCER", 38, 51], ["watery", "ORGANISM_SUBDIVISION", 159, 165], ["collection", "PROBLEM", 15, 25], ["the fecal samples", "TEST", 34, 51], ["watery", "PROBLEM", 159, 165], ["collection", "OBSERVATION", 15, 25], ["fecal", "ANATOMY", 38, 43]]], ["A score of 0 or 1 was considered non-diarrheic, and scores of 2 or 3 were considered diarrheic.Determination of the presence of RVAThe 10 fecal samples from the same animal that were collected at different time points were processed at the same time to avoid any bias.", [["fecal samples", "ANATOMY", 138, 151], ["diarrheic", "DISEASE", 85, 94], ["A score", "TEST", 0, 7], ["scores", "TEST", 52, 58], ["diarrheic", "PROBLEM", 85, 94], ["RVAThe", "TREATMENT", 128, 134], ["fecal samples", "TEST", 138, 151]]], ["The nucleic acid extraction was performed using a combination of the phenol/chloroform/isoamyl alcohol (25:24:1) and silica/guanidinium isothiocyanate extraction methods according to Alfieri et al. (2006) .Determination of the presence of RVAThe presence of RVA dsRNA in fecal samples was evaluated using polyacrylamide gel electrophoresis (PAGE) (Pereira et al., 1983) followed by silver staining (Herring et al., 1982) .", [["fecal samples", "ANATOMY", 271, 284], ["nucleic acid", "CHEMICAL", 4, 16], ["phenol/chloroform/isoamyl alcohol", "CHEMICAL", 69, 102], ["25:24:1", "CHEMICAL", 104, 111], ["silica", "CHEMICAL", 117, 123], ["guanidinium isothiocyanate", "CHEMICAL", 124, 150], ["silver", "CHEMICAL", 382, 388], ["phenol", "CHEMICAL", 69, 75], ["chloroform", "CHEMICAL", 76, 86], ["isoamyl alcohol", "CHEMICAL", 87, 102], ["silica", "CHEMICAL", 117, 123], ["guanidinium isothiocyanate", "CHEMICAL", 124, 150], ["polyacrylamide", "CHEMICAL", 305, 319], ["silver", "CHEMICAL", 382, 388], ["nucleic acid", "SIMPLE_CHEMICAL", 4, 16], ["phenol", "SIMPLE_CHEMICAL", 69, 75], ["chloroform", "SIMPLE_CHEMICAL", 76, 86], ["isoamyl alcohol", "SIMPLE_CHEMICAL", 87, 102], ["25:24:1", "SIMPLE_CHEMICAL", 104, 111], ["silica", "SIMPLE_CHEMICAL", 117, 123], ["guanidinium isothiocyanate", "SIMPLE_CHEMICAL", 124, 150], ["fecal samples", "ORGANISM_SUBSTANCE", 271, 284], ["RVA dsRNA", "RNA", 258, 267], ["The nucleic acid extraction", "TREATMENT", 0, 27], ["the phenol/chloroform", "TREATMENT", 65, 86], ["isoamyl alcohol", "TREATMENT", 87, 102], ["silica/guanidinium isothiocyanate extraction methods", "TREATMENT", 117, 169], ["RVA dsRNA", "PROBLEM", 258, 267], ["fecal samples", "TEST", 271, 284], ["polyacrylamide gel electrophoresis", "TREATMENT", 305, 339], ["RVA dsRNA", "OBSERVATION", 258, 267]]], ["Fecal samples with doubtful PAGE results, as bands with low intensity or in anomalous positions, extra bands or undefined electropherotype were confirmed by reverse transcription polymerase chain reaction (RT-PCR) assay.RVA genotypingThe presence of RVA in the fecal samples that were determined to be positive for RVA via PAGE was confirmed by RT-PCR using consensus primers to amplify a 1062 bp fragment from the VP7 gene (Gouvea et al., 1990 ) and a 876 bp fragment from the VP4 (VP8*) gene (Gentsch et al., 1992; Martella et al., 2006) .", [["Fecal samples", "ANATOMY", 0, 13], ["fecal samples", "ANATOMY", 261, 274], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["fecal samples", "ORGANISM_SUBSTANCE", 261, 274], ["VP7", "GENE_OR_GENE_PRODUCT", 415, 418], ["VP4", "GENE_OR_GENE_PRODUCT", 478, 481], ["consensus primers", "DNA", 358, 375], ["1062 bp fragment", "DNA", 389, 405], ["VP7 gene", "DNA", 415, 423], ["876 bp fragment", "DNA", 453, 468], ["VP4 (VP8*) gene", "DNA", 478, 493], ["Fecal samples", "TEST", 0, 13], ["bands", "PROBLEM", 45, 50], ["low intensity", "PROBLEM", 56, 69], ["extra bands", "PROBLEM", 97, 108], ["undefined electropherotype", "PROBLEM", 112, 138], ["RT-PCR", "TEST", 206, 212], ["RVA genotyping", "TEST", 220, 234], ["RVA", "PROBLEM", 250, 253], ["the fecal samples", "TEST", 257, 274], ["RVA", "PROBLEM", 315, 318], ["RT-PCR", "TEST", 345, 351], ["consensus primers", "TREATMENT", 358, 375], ["a 1062 bp fragment", "TREATMENT", 387, 405], ["a 876 bp fragment", "TEST", 451, 468], ["the VP4", "TEST", 474, 481], ["low intensity", "OBSERVATION_MODIFIER", 56, 69], ["anomalous", "OBSERVATION", 76, 85], ["RVA", "OBSERVATION", 250, 253], ["fecal", "ANATOMY", 261, 266]]], ["The RT-PCR products were analyzed using electrophoresis with 2% agarose gels stained with ethidium bromide and observed under ultraviolet (UV) light.", [["ethidium bromide", "CHEMICAL", 90, 106], ["ethidium bromide", "CHEMICAL", 90, 106], ["agarose", "SIMPLE_CHEMICAL", 64, 71], ["ethidium bromide", "SIMPLE_CHEMICAL", 90, 106], ["The RT-PCR products", "TREATMENT", 0, 19], ["electrophoresis", "TEST", 40, 55], ["2% agarose gels", "TREATMENT", 61, 76], ["ethidium bromide", "TREATMENT", 90, 106]]], ["Ten RT-PCR products of good quality from the RVA-positive fecal samples from 10 calves of 7 different ages in the range of 10 to 31 days old and 7 collections, including beginning, middle, and end of the experiment, were selected for sequence analysis.RVA genotypingThe RT-PCR products were purified using an Illustra GFX PCR DNA and Gel Band Purification Kit (GE \u00ae , Buckinghamshire, UK), quantified using a Qubit \u00ae Fluorometer (Invitrogen \u00ae Life Technologies, Eugene, OR, USA), and sequenced using an ABI3500 Genetic Analyzer sequencer with a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems \u00ae , Foster City, CA, USA).RVA genotypingThe Phred and CAP3 software packages were used for the nucleotide (nt) quality analysis and contig assembly of the RVA sequences, respectively (http://asparagin.cenargen.embrapa.br).", [["fecal samples", "ANATOMY", 58, 71], ["nucleotide", "CHEMICAL", 704, 714], ["nucleotide", "CHEMICAL", 704, 714], ["fecal samples", "MULTI-TISSUE_STRUCTURE", 58, 71], ["calves", "ORGANISM", 80, 86], ["DNA", "CELLULAR_COMPONENT", 326, 329], ["RT-PCR products", "DNA", 270, 285], ["Illustra GFX PCR DNA", "DNA", 309, 329], ["Phred and CAP3 software packages", "DNA", 653, 685], ["RVA sequences", "DNA", 764, 777], ["calves", "SPECIES", 80, 86], ["Ten RT-PCR products", "TEST", 0, 19], ["the RVA", "TEST", 41, 48], ["7 collections", "TEST", 145, 158], ["sequence analysis", "TEST", 234, 251], ["RVA genotyping", "TEST", 252, 266], ["The RT-PCR products", "TREATMENT", 266, 285], ["an Illustra GFX PCR", "TEST", 306, 325], ["Gel Band Purification", "TEST", 334, 355], ["a Qubit \u00ae Fluorometer", "TREATMENT", 407, 428], ["a BigDye Terminator", "TREATMENT", 543, 562], ["RVA genotyping", "TREATMENT", 635, 649], ["The Phred and CAP3 software packages", "TREATMENT", 649, 685], ["the nucleotide (nt) quality analysis", "TEST", 700, 736], ["the RVA sequences", "TEST", 760, 777], ["good", "OBSERVATION_MODIFIER", 23, 27], ["quality", "OBSERVATION_MODIFIER", 28, 35], ["RVA", "OBSERVATION", 45, 48], ["positive", "OBSERVATION_MODIFIER", 49, 57], ["fecal samples", "OBSERVATION", 58, 71], ["middle", "ANATOMY_MODIFIER", 181, 187]]], ["Sequence similarity searches were performed using the basic local alignment search tool (BLAST) software (http://blast.ncbi.nlm.nih.gov/), and the genotype identification was performed using the ROTAC 2.0 tool (http://rotac. regatools.be/).RVA genotypingPhylogenetic trees were obtained using the neighbor-joining method with Kimura 2-parameter model in MEGA V7 software.", [["regatools", "PROTEIN", 225, 234], ["Sequence similarity searches", "TEST", 0, 28], ["the basic local alignment search tool", "TEST", 50, 87], ["the genotype identification", "TEST", 143, 170], ["the ROTAC", "TEST", 191, 200], ["RVA genotypingPhylogenetic trees", "PROBLEM", 240, 272]]], ["The bootstrapping probabilities were calculated using 1000 replicates.", [["The bootstrapping probabilities", "TEST", 0, 31]]], ["The BioEdit software, version 7.0.8.0, was used for the construction of the nt sequence identity matrix.", [["matrix", "CELLULAR_COMPONENT", 97, 103], ["the nt sequence identity matrix", "TREATMENT", 72, 103]]], ["The gene sequences described in the present study have been deposited in the GenBank database under accession numbers: MH016179 and MH016180.Results and discussionSeventy-six (62.3%) of the 122 heifer calves were RVA-positive according to at least 1 of the 10 fecal samples evaluated, and of these, 19 (15.6%) calves were determined to have excreted RVA on more than one occasion.", [["fecal samples", "ANATOMY", 260, 273], ["MH016180", "CHEMICAL", 132, 140], ["heifer", "ORGANISM", 194, 200], ["calves", "ORGANISM", 201, 207], ["calves", "ORGANISM", 310, 316], ["calves", "SPECIES", 201, 207], ["calves", "SPECIES", 310, 316], ["The gene sequences", "TEST", 0, 18], ["the present study", "TEST", 32, 49], ["discussionSeventy", "TEST", 153, 170], ["RVA", "TEST", 213, 216], ["fecal samples", "TEST", 260, 273]]], ["Worldwide, the percentage of calves that are RVA-positive varies based on the experimental design used in each study.", [["calves", "ORGANISM", 29, 35], ["calves", "SPECIES", 29, 35], ["RVA", "TEST", 45, 48], ["positive varies", "PROBLEM", 49, 64], ["each study", "TEST", 106, 116], ["calves", "ANATOMY", 29, 35], ["positive", "OBSERVATION", 49, 57]]], ["In Scotland and northern England (Snodgrass et al., 1986) and New Zealand (Al Mawly et al., 2015) , both using commercial enzyme-linked immunosorbent assay (ELISA), rates of RVA infection of 45.9% (161/ 351) and 19.9% (246/1,226), respectively, were reported.Results and discussionIn Brazil, also using the PAGE technique, Coura et al. (2015) reported that 49.2% (33/67) of dairy heifer calves that were 0-30 days old excreted RVA during a longitudinal study, and in a transversal study only 138 of 683 (20.2%) of dairy calves 0-30 days old were found to be RVA-positive (Alfieri et al., 2006) .Results and discussionThe percentage of RVA-positive fecal samples obtained during this study was 8.1% (99/1220).", [["fecal samples", "ANATOMY", 648, 661], ["RVA infection", "DISEASE", 174, 187], ["calves", "ORGANISM", 387, 393], ["calves", "ORGANISM", 520, 526], ["calves", "SPECIES", 387, 393], ["calves", "SPECIES", 520, 526], ["commercial enzyme", "TEST", 111, 128], ["immunosorbent assay", "TEST", 136, 155], ["ELISA", "TEST", 157, 162], ["RVA infection", "PROBLEM", 174, 187], ["a longitudinal study", "TEST", 438, 458], ["a transversal study", "TEST", 467, 486], ["dairy calves", "TEST", 514, 526], ["RVA", "TEST", 558, 561], ["RVA", "TEST", 635, 638], ["this study", "TEST", 678, 688], ["positive", "OBSERVATION", 562, 570]]], ["Other longitudinal studies that have been conducted in Brazil to determine the level of RVA infection in calves born from vaccinated dairy cows had percentages of RVA-positive diarrheic fecal samples that were 5.7% (49/850) (Coura et al., 2015) and 3.9% (11/281) (Rocha et al., 2017) .Results and discussionThe distribution of the total samples and the RVA-positive fecal samples for each fecal consistency score and time point at sample collection are shown in Table 1 .", [["fecal samples", "ANATOMY", 186, 199], ["samples", "ANATOMY", 337, 344], ["fecal samples", "ANATOMY", 366, 379], ["fecal", "ANATOMY", 389, 394], ["RVA infection", "DISEASE", 88, 101], ["calves", "ORGANISM", 105, 111], ["cows", "ORGANISM", 139, 143], ["fecal samples", "MULTI-TISSUE_STRUCTURE", 366, 379], ["calves", "SPECIES", 105, 111], ["cows", "SPECIES", 139, 143], ["calves", "SPECIES", 105, 111], ["Other longitudinal studies", "TEST", 0, 26], ["RVA infection", "PROBLEM", 88, 101], ["RVA", "TEST", 163, 166], ["positive diarrheic fecal samples", "PROBLEM", 167, 199], ["the total samples", "TEST", 327, 344], ["the RVA", "TEST", 349, 356], ["positive fecal samples", "PROBLEM", 357, 379], ["each fecal consistency score", "TEST", 384, 412], ["sample collection", "TEST", 431, 448], ["RVA", "OBSERVATION_MODIFIER", 88, 91], ["infection", "OBSERVATION", 92, 101]]], ["The frequency of diarrhea in calves during the experiment, shown in the table, was not high.", [["diarrhea", "DISEASE", 17, 25], ["calves", "ORGANISM", 29, 35], ["calves", "SPECIES", 29, 35], ["diarrhea in calves", "PROBLEM", 17, 35], ["diarrhea", "OBSERVATION", 17, 25], ["high", "OBSERVATION", 87, 91]]], ["Fecal samples with scores of 0 and 1 (n = 863) represented 70.7% of the total samples, while samples with scores of 2 and 3, indicating the presence of diarrhea, comprised 17.0% (n = 208) and 12.2% (n = 149) of the total samples, respectively.", [["Fecal samples", "ANATOMY", 0, 13], ["samples", "ANATOMY", 78, 85], ["samples", "ANATOMY", 93, 100], ["samples", "ANATOMY", 221, 228], ["diarrhea", "DISEASE", 152, 160], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["samples", "CANCER", 78, 85], ["Fecal samples", "TEST", 0, 13], ["scores", "TEST", 19, 25], ["the total samples", "TEST", 68, 85], ["scores", "TEST", 106, 112], ["diarrhea", "PROBLEM", 152, 160], ["the total samples", "TEST", 211, 228], ["diarrhea", "OBSERVATION", 152, 160]]], ["In a similar study conducted in Brazil on RVAunvaccinated dairy cattle herds, the proportion of diarrheic fecal samples (36.7%; 312/850) within the total number of samples was greater than that in this study (Coura et al., 2015) .Results and discussionPrevious studies have indicated that the presence of RVA infection in feces from diarrheic calves is significantly higher than that in nondiarrheic feces (Al Mawly et al., 2015; Bartels et al., 2010; Chitambar et al., 2011) .", [["fecal samples", "ANATOMY", 106, 119], ["samples", "ANATOMY", 164, 171], ["feces", "ANATOMY", 322, 327], ["RVA infection", "DISEASE", 305, 318], ["fecal samples", "MULTI-TISSUE_STRUCTURE", 106, 119], ["feces", "ORGANISM_SUBDIVISION", 322, 327], ["calves", "ORGANISM", 343, 349], ["feces", "ORGANISM_SUBDIVISION", 400, 405], ["cattle", "SPECIES", 64, 70], ["calves", "SPECIES", 343, 349], ["cattle", "SPECIES", 64, 70], ["a similar study", "TEST", 3, 18], ["diarrheic fecal samples", "TEST", 96, 119], ["this study", "TEST", 197, 207], ["Previous studies", "TEST", 252, 268], ["RVA infection in feces", "PROBLEM", 305, 327], ["diarrheic calves", "PROBLEM", 333, 349], ["total", "OBSERVATION_MODIFIER", 148, 153], ["greater", "OBSERVATION_MODIFIER", 176, 183], ["RVA", "OBSERVATION_MODIFIER", 305, 308], ["infection", "OBSERVATION", 309, 318], ["significantly", "OBSERVATION_MODIFIER", 353, 366], ["higher", "OBSERVATION_MODIFIER", 367, 373]]], ["Forty-eight of the 357 (13.4%) diarrheic fecal samples evaluated were RVA-positive.", [["fecal samples", "ANATOMY", 41, 54], ["fecal samples", "CANCER", 41, 54], ["diarrheic fecal samples", "TEST", 31, 54], ["RVA", "TEST", 70, 73]]], ["On average, the frequency of RVA-positive samples obtained from diarrheic feces in calves worldwide ranges between 5.5 and 57.9% (Alfieri et al., 2006; Badaracco et al., 2012; Barreiros et al., 2004; Brito et al., 2000; Buzinaro et al., 2009; Caruzo et al., 2010; Chitambar et al., 2011; Falcone et al., 1999; Malik et al., 2012; Silva et al., 2012) .", [["samples", "ANATOMY", 42, 49], ["feces", "ANATOMY", 74, 79], ["diarrheic feces", "DISEASE", 64, 79], ["feces", "ORGANISM_SUBDIVISION", 74, 79], ["calves", "ORGANISM", 83, 89], ["calves", "SPECIES", 83, 89], ["RVA", "TEST", 29, 32], ["positive samples", "PROBLEM", 33, 49], ["diarrheic feces", "TEST", 64, 79]]], ["In this study, dsRNA to from the RVA was identified in 5.9% (51/863) of the fecal samples with scores of 0 or 1 and in 12.5% (26/208) and 14.8% (22/149) of the fecal samples with scores of 2 and 3, respectively.", [["fecal samples", "ANATOMY", 76, 89], ["fecal samples", "ANATOMY", 160, 173], ["fecal samples", "CANCER", 76, 89], ["this study", "TEST", 3, 13], ["dsRNA", "PROBLEM", 15, 20], ["the RVA", "TEST", 29, 36], ["the fecal samples", "TEST", 72, 89], ["scores", "TEST", 95, 101], ["the fecal samples", "TEST", 156, 173], ["scores", "TEST", 179, 185], ["fecal", "ANATOMY", 76, 81], ["fecal", "ANATOMY", 160, 165]]], ["Although RVA was more frequent in diarrheic calves, the overall frequency of RVA diagnosis was lower than that observed in unvaccinated herds (Rocha et al., 2017) .Results and discussionThe distribution of the fecal samples according to the age of the calves reveals that during the first and fourth weeks, the frequency of diagnosis of RVA was 2.2% (8/366) and 6.8% (25/366), respectively.", [["fecal samples", "ANATOMY", 210, 223], ["RVA", "DISEASE", 337, 340], ["calves", "ORGANISM", 44, 50], ["fecal samples", "MULTI-TISSUE_STRUCTURE", 210, 223], ["calves", "ORGANISM", 252, 258], ["calves", "SPECIES", 44, 50], ["calves", "SPECIES", 252, 258], ["RVA", "PROBLEM", 9, 12], ["diarrheic calves", "PROBLEM", 34, 50], ["the fecal samples", "TEST", 206, 223], ["RVA", "TEST", 337, 340], ["more", "OBSERVATION_MODIFIER", 17, 21], ["frequent", "OBSERVATION_MODIFIER", 22, 30], ["diarrheic calves", "OBSERVATION", 34, 50], ["distribution", "OBSERVATION_MODIFIER", 190, 202], ["fecal", "ANATOMY", 210, 215], ["calves", "ANATOMY", 252, 258]]], ["However, in the second and third weeks, the frequency of RVA-positive fecal samples was higher, with the rate for the second week reaching 13.5%.", [["fecal samples", "ANATOMY", 70, 83], ["RVA", "TEST", 57, 60], ["positive fecal samples", "PROBLEM", 61, 83], ["the rate", "TEST", 101, 109], ["fecal samples", "OBSERVATION", 70, 83]]], ["This finding suggests the occurrence of a decrease in passive immunity, corroborating the findings of previous studies that suggest that passive immunity protects calves during their first week and that their own natural resistance is not initiated until 4 weeks of age (Alfieri et al., 2006) ; suggesting the high susceptibility of these animals to disease during the period between the first and fourth week.", [["calves", "ORGANISM", 163, 169], ["calves", "SPECIES", 163, 169], ["a decrease in passive immunity", "PROBLEM", 40, 70], ["previous studies", "TEST", 102, 118], ["decrease", "OBSERVATION_MODIFIER", 42, 50], ["passive immunity", "OBSERVATION", 54, 70]]], ["Meganck et al. (2014) and Coura et al. (2015) reported that diarrhea caused by RVA is most frequent in 1-to 3-week-old calves, and Alfieri et al. (2006) suggested that animals from dairy cattle herds were most susceptible to RVA infection at 2 to 3 weeks of age.Results and discussionIn order to reduce the occurrence of neonatal diarrhea, the dairy farm utilizes vaccination with a commercial vaccine containing the RVA UK-Compton strain with the genotype G6P[5] .", [["diarrhea", "DISEASE", 60, 68], ["RVA", "DISEASE", 79, 82], ["RVA infection", "DISEASE", 225, 238], ["neonatal diarrhea", "DISEASE", 321, 338], ["calves", "ORGANISM", 119, 125], ["UK", "GENE_OR_GENE_PRODUCT", 421, 423], ["calves", "SPECIES", 119, 125], ["cattle", "SPECIES", 187, 193], ["cattle", "SPECIES", 187, 193], ["RVA", "SPECIES", 225, 228], ["diarrhea", "PROBLEM", 60, 68], ["RVA", "PROBLEM", 79, 82], ["dairy cattle herds", "TREATMENT", 181, 199], ["RVA infection", "PROBLEM", 225, 238], ["neonatal diarrhea", "PROBLEM", 321, 338], ["vaccination", "TREATMENT", 364, 375], ["a commercial vaccine", "TREATMENT", 381, 401], ["diarrhea", "OBSERVATION", 60, 68], ["calves", "ANATOMY", 119, 125], ["infection", "OBSERVATION", 229, 238]]], ["This vaccine is frequently used in dairy and beef cattle herds both from Brazil and other countries around the world mainly in countries of the Northern Hemisphere such as Canada, the USA, and the European Union.", [["beef", "SPECIES", 45, 49], ["cattle", "SPECIES", 50, 56], ["dairy", "SPECIES", 35, 40], ["beef", "SPECIES", 45, 49], ["cattle", "SPECIES", 50, 56], ["This vaccine", "TREATMENT", 0, 12]]], ["To determine the G and P genotypes of RVA strains present in the fecal samples collected during this study, 10 RVA-positive fecal samples were selected from 10 calves of different ages and collections for nt sequence analysis of the VP7 and VP4 amplicons.", [["fecal samples", "ANATOMY", 65, 78], ["fecal samples", "ANATOMY", 124, 137], ["fecal samples", "ORGANISM_SUBSTANCE", 65, 78], ["fecal samples", "CANCER", 124, 137], ["calves", "ORGANISM", 160, 166], ["VP7", "GENE_OR_GENE_PRODUCT", 233, 236], ["VP4", "GENE_OR_GENE_PRODUCT", 241, 244], ["VP7 and VP4 amplicons", "DNA", 233, 254], ["calves", "SPECIES", 160, 166], ["RVA strains", "PROBLEM", 38, 49], ["the fecal samples", "TEST", 61, 78], ["this study", "TEST", 96, 106], ["RVA", "TEST", 111, 114], ["positive fecal samples", "PROBLEM", 115, 137], ["nt sequence analysis", "TEST", 205, 225], ["the VP7 and VP4 amplicons", "TREATMENT", 229, 254], ["fecal", "ANATOMY", 65, 70], ["fecal", "ANATOMY", 124, 129]]], ["The analysis enabled the identification of the genotypes, which were G10P [11] in all of the wildtype RVA strains with a high (99.3 to 100%) nt similarity between them.Results and discussionViruses with the G10 and P[11] genotypes are not included in the RVA vaccine used by the dairy farm evaluated in this study.", [["The analysis", "TEST", 0, 12], ["the genotypes", "PROBLEM", 43, 56], ["the wildtype RVA strains", "PROBLEM", 89, 113], ["the G10 and P[11] genotypes", "TREATMENT", 203, 230], ["the RVA vaccine", "TREATMENT", 251, 266], ["this study", "TEST", 303, 313], ["high", "OBSERVATION_MODIFIER", 121, 125]]], ["The sequence obtained of VP7 gene of RVA had the highest (94%) nt similarity with that of the prototype B223 strain (GenBank accession number: X52650 (Xu et al., 1991) ), which belongs to G10 lineage IV (Fig. 1A) , and the VP4 gene had the highest similarity (96.1%) to that from the Turkish E16TR strain (GenBank accession number: FJ598314 (unpublished data)) of P[11] lineage III (Fig. 1B) .Results and discussionA putative vaccine breakthrough associated with heterotypic RVA infection in newborn calves was described in Turkey, where the emergence of an RVA strain with the genotype G8P[5] was reported in a cattle herd vaccinated with the G6P[5] RVA strain, which demonstrated a failure of heterologous protection (Karayel et al., 2017) .", [["RVA infection", "DISEASE", 475, 488], ["G6P", "CHEMICAL", 644, 647], ["VP7", "GENE_OR_GENE_PRODUCT", 25, 28], ["Fig. 1A", "GENE_OR_GENE_PRODUCT", 204, 211], ["VP4", "GENE_OR_GENE_PRODUCT", 223, 226], ["calves", "ORGANISM", 500, 506], ["G6P[5] RVA", "ORGANISM", 644, 654], ["VP7 gene", "DNA", 25, 33], ["G10 lineage IV", "PROTEIN", 188, 202], ["VP4 gene", "DNA", 223, 231], ["calves", "SPECIES", 500, 506], ["cattle", "SPECIES", 612, 618], ["Turkish E16TR strain", "SPECIES", 284, 304], ["RVA", "SPECIES", 475, 478], ["cattle", "SPECIES", 612, 618], ["The sequence", "TEST", 0, 12], ["RVA", "TEST", 37, 40], ["the VP4 gene", "TEST", 219, 231], ["discussionA putative vaccine breakthrough", "TREATMENT", 405, 446], ["heterotypic RVA infection in newborn calves", "PROBLEM", 463, 506], ["an RVA strain", "PROBLEM", 555, 568], ["the G6P", "TEST", 640, 647], ["RVA strain", "PROBLEM", 651, 661], ["heterologous protection", "TREATMENT", 695, 718], ["RVA", "OBSERVATION_MODIFIER", 475, 478], ["infection", "OBSERVATION", 479, 488], ["failure", "OBSERVATION", 684, 691]]], ["The occurrence of emerging heterologous RVA genotypes is a phenomenon has been previously observed in Brazilian dairy and beef cattle herds after the administration of a RV vaccine (Medeiros et al., 2015; Rocha et al., 2017) .", [["beef", "SPECIES", 122, 126], ["cattle", "SPECIES", 127, 133], ["beef", "SPECIES", 122, 126], ["cattle", "SPECIES", 127, 133], ["emerging heterologous RVA genotypes", "PROBLEM", 18, 53], ["a phenomenon", "PROBLEM", 57, 69], ["a RV vaccine", "TREATMENT", 168, 180], ["heterologous RVA", "OBSERVATION", 27, 43]]], ["Similar occurrences have also been described in humans in Brazil and other countries around the world (Banyai et al., 2012; Cowley et al., 2013; Doro et al., 2014; Khandoker et al., 2018; Santos et al., 2018) .Results and discussionHowever, depending on other factors, such as the type of cattle (beef or dairy herds), the method of cow and calf management (intensive or extensive), and the inclusion of vaccination for neonatal diarrhea in the health program, different results can be found between studies.", [["neonatal diarrhea", "DISEASE", 420, 437], ["humans", "ORGANISM", 48, 54], ["cattle", "ORGANISM", 289, 295], ["beef", "ORGANISM_SUBDIVISION", 297, 301], ["cow", "ORGANISM_SUBDIVISION", 333, 336], ["calf", "ORGANISM_SUBDIVISION", 341, 345], ["humans", "SPECIES", 48, 54], ["cattle", "SPECIES", 289, 295], ["beef", "SPECIES", 297, 301], ["cow", "SPECIES", 333, 336], ["calf", "SPECIES", 341, 345], ["humans", "SPECIES", 48, 54], ["cattle", "SPECIES", 289, 295], ["beef", "SPECIES", 297, 301], ["cow", "SPECIES", 333, 336], ["cow and calf management", "TREATMENT", 333, 356], ["vaccination", "TREATMENT", 404, 415], ["neonatal diarrhea", "PROBLEM", 420, 437], ["calf", "ANATOMY", 341, 345]]], ["In France, Kaplon et al. (2013) evaluated beef cattle herds subject to extensive management and found no differences in the frequencies of diarrhea and RVA-positive fecal samples between vaccinated and unvaccinated herds; the majority of the genotyped RVA-positive diarrheic fecal samples were found to have the same genotype (G6P[5]) as that of the vaccine strain.Results and discussionAmong the measures used to mitigate the risk of neonatal diarrhea outbreaks, the vaccination of cow herds appears to be the most important.", [["fecal samples", "ANATOMY", 165, 178], ["fecal samples", "ANATOMY", 275, 288], ["diarrhea", "DISEASE", 139, 147], ["diarrhea", "DISEASE", 444, 452], ["fecal samples", "ORGANISM_SUBSTANCE", 275, 288], ["cow", "ORGANISM", 483, 486], ["cattle", "SPECIES", 47, 53], ["cow", "SPECIES", 483, 486], ["beef", "SPECIES", 42, 46], ["cattle", "SPECIES", 47, 53], ["cow", "SPECIES", 483, 486], ["extensive management", "TREATMENT", 71, 91], ["diarrhea", "PROBLEM", 139, 147], ["RVA", "PROBLEM", 152, 155], ["positive fecal samples between vaccinated", "PROBLEM", 156, 197], ["the genotyped RVA", "TEST", 238, 255], ["positive diarrheic fecal samples", "PROBLEM", 256, 288], ["the vaccine strain", "PROBLEM", 346, 364], ["neonatal diarrhea outbreaks", "PROBLEM", 435, 462], ["the vaccination of cow herds", "TREATMENT", 464, 492]]], ["In humans, the World Health Organization recommends the inclusion of the RVA vaccination in all national immunization programs (WHO, 2009) .", [["humans", "ORGANISM", 3, 9], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["the RVA vaccination", "TREATMENT", 69, 88]]], ["Several studies have demonstrated that vaccination does not totally eliminate the risk of infection, but it certainly reduces both the frequency and severity of the episodes of neonatal diarrhea caused by RVA infection in calves (Kaplon et al., 2013; Parreno et al., 2004) .", [["infection", "DISEASE", 90, 99], ["diarrhea", "DISEASE", 186, 194], ["RVA infection", "DISEASE", 205, 218], ["calves", "ORGANISM", 222, 228], ["calves", "SPECIES", 222, 228], ["RVA", "SPECIES", 205, 208], ["Several studies", "TEST", 0, 15], ["vaccination", "TREATMENT", 39, 50], ["infection", "PROBLEM", 90, 99], ["neonatal diarrhea", "PROBLEM", 177, 194], ["RVA infection in calves", "PROBLEM", 205, 228], ["infection", "OBSERVATION", 90, 99], ["RVA", "OBSERVATION_MODIFIER", 205, 208], ["infection", "OBSERVATION", 209, 218]]], ["Considering that the immune pressure exerted by routine vaccination may have the potential to select strains containing specific G and P genotypes, it is important to monitor the genotypes present in the RVA strains that are circulating among and within vaccinated cattle herds (Cashman et al., 2010) .Results and discussionIn summary, in this longitudinal study evaluating 1220 fecal samples (122 calves), the low occurrence of RVA in diarrheic fecal samples from calves born from regularly RVA G6P[5]-vaccinated cows was determined.", [["fecal samples", "ANATOMY", 379, 392], ["fecal samples", "ANATOMY", 446, 459], ["G6P[5]", "CHEMICAL", 496, 502], ["G", "GENE_OR_GENE_PRODUCT", 129, 130], ["fecal samples", "MULTI-TISSUE_STRUCTURE", 379, 392], ["calves", "ORGANISM", 398, 404], ["fecal samples", "ORGANISM_SUBSTANCE", 446, 459], ["calves", "ORGANISM", 465, 471], ["G6P[5", "ORGANISM", 496, 501], ["cows", "ORGANISM", 514, 518], ["cattle", "SPECIES", 265, 271], ["calves", "SPECIES", 398, 404], ["calves", "SPECIES", 465, 471], ["cows", "SPECIES", 514, 518], ["cattle", "SPECIES", 265, 271], ["the immune pressure", "TEST", 17, 36], ["routine vaccination", "TREATMENT", 48, 67], ["specific G and P genotypes", "TREATMENT", 120, 146], ["the genotypes", "PROBLEM", 175, 188], ["the RVA strains", "PROBLEM", 200, 215], ["this longitudinal study", "TEST", 339, 362], ["fecal samples", "TEST", 379, 392], ["RVA", "PROBLEM", 429, 432], ["diarrheic fecal samples", "PROBLEM", 436, 459], ["vaccinated cows", "TREATMENT", 503, 518]]], ["In addition, the genotype G6P [5] , present in the RVA vaccine strain used on the farm, was not identified in any RVA field strains identified in calves in this study.", [["G6P [5", "ORGANISM", 26, 32], ["calves", "ORGANISM", 146, 152], ["calves", "SPECIES", 146, 152], ["the genotype G6P", "TEST", 13, 29], ["the RVA vaccine strain", "TREATMENT", 47, 69], ["any RVA field strains", "PROBLEM", 110, 131], ["this study", "TEST", 156, 166]]], ["Additionally, the presence of the RVA G10P[11] genotype was verified, which was different from the vaccine strain, reinforcing the vaccine protection.", [["genotype", "TEST", 47, 55], ["the vaccine strain", "TREATMENT", 95, 113], ["the vaccine protection", "TREATMENT", 127, 149]]], ["The presence of RVA in vaccinated herds may occurs due to immune pressure, individual factors, management procedures, nutrition, and environmental variations.", [["RVA", "DISEASE", 16, 19], ["RVA", "PROBLEM", 16, 19], ["vaccinated herds", "TREATMENT", 23, 39], ["immune pressure", "PROBLEM", 58, 73], ["management procedures", "TREATMENT", 95, 116], ["nutrition", "TREATMENT", 118, 127], ["RVA", "OBSERVATION", 16, 19]]], ["The constant monitoring of circulating RVA strains in neonatal diarrhea in dairy cattle herds is important to identify the emergence of new RVA strains, highlighting those with higher virulence and/or zoonotic potential.", [["neonatal diarrhea", "DISEASE", 54, 71], ["cattle", "SPECIES", 81, 87], ["cattle", "SPECIES", 81, 87], ["circulating RVA strains", "PROBLEM", 27, 50], ["neonatal diarrhea", "PROBLEM", 54, 71], ["new RVA strains", "PROBLEM", 136, 151], ["constant", "OBSERVATION_MODIFIER", 4, 12]]]], "PMC7106299": [["IntroductionData volume and the multitude of sources have experienced exponential growth, creating new technical and application challenges; data generation has been estimated at 2.5 Exabytes (1 Exabyte = 1.000.000 Terabytes) of data per day [1].", [["IntroductionData volume", "TREATMENT", 0, 23], ["exponential growth", "PROBLEM", 70, 88], ["Exabytes", "TEST", 183, 191], ["Exabyte", "TEST", 195, 202], ["new", "OBSERVATION_MODIFIER", 99, 102]]], ["These data come from everywhere: sensors used to gather climate, traffic and flight information, posts to social media sites (Twitter and Facebook are popular examples), digital pictures and videos (YouTube users upload 72 hours of new video content per minute [2]), transaction records, and cell phone GPS signals, to name a few.", [["cell", "ANATOMY", 292, 296], ["cell", "CELL", 292, 296]]], ["The classic methods, algorithms, frameworks, and tools for data management have become both inadequate for processing this amount of data and unable to offer effective solutions for managing the data growth.", [["data management", "TREATMENT", 59, 74], ["effective solutions", "TREATMENT", 158, 177]]], ["The problem of managing and extracting useful knowledge from these data sources is currently one of the most popular topics in computing research [3], [4].IntroductionIn this context, big data is a popular phenomenon that aims to provide an alternative to traditional solutions based on databases and data analysis.", [["a popular phenomenon", "PROBLEM", 196, 216], ["traditional solutions", "TREATMENT", 256, 277], ["databases and data analysis", "TEST", 287, 314]]], ["Big data is not just about storage or access to data; its solutions aim to analyse data in order to make sense of them and exploit their value.", [["analyse data", "TEST", 75, 87]]], ["Big data refers to datasets that are terabytes to petabytes (and even exabytes) in size, and the massive sizes of these datasets extend beyond the ability of average database software tools to capture, store, manage, and analyse them effectively.IntroductionThe concept of big data has been defined through the 3V model, which was defined in 2001 by Laney [5] as: \u201chigh-volume, high-velocity and high-variety information assets that demand cost-effective, innovative forms of information processing for enhanced insight and decision making\u201d.", [["big data", "TEST", 273, 281], ["size", "OBSERVATION_MODIFIER", 83, 87], ["massive", "OBSERVATION_MODIFIER", 97, 104], ["sizes", "OBSERVATION_MODIFIER", 105, 110]]], ["More recently, in 2012, Gartner [6] updated the definition as follows: \u201cBig data is high volume, high velocity, and/or high variety information assets that require new forms of processing to enable enhanced decision making, insight discovery and process optimization\u201d.", [["high volume", "PROBLEM", 84, 95], ["high velocity", "OBSERVATION_MODIFIER", 97, 110]]], ["Both definitions refer to the three basic features of big data: Volume, Variety, and Velocity.", [["Volume", "TEST", 64, 70], ["Velocity", "TEST", 85, 93], ["Variety", "OBSERVATION_MODIFIER", 72, 79], ["Velocity", "OBSERVATION_MODIFIER", 85, 93]]], ["This model can be even extended to 5Vs if the concepts of Veracity is incorporated into the big data definition.IntroductionSummarising, this set of *V-models provides a straightforward and widely accepted definition related to what is (and what is not) a big-data-based problem, application, software, or framework.", [["Veracity", "OBSERVATION", 58, 66]]], ["These concepts can be briefly described as follows [5], [7]:\u2022Volume: refers to large amounts of any kind of data from any different sources, including mobile digital data creation devices and digital devices.", [["Volume", "TEST", 61, 67], ["mobile digital data creation devices", "TREATMENT", 151, 187], ["digital devices", "TREATMENT", 192, 207]]], ["The benefit from gathering, processing, and analysing these large amounts of data generates a number of challenges in obtaining valuable knowledge for people and companies (see Value feature).\u2022Velocity: refers to the speed of data transfers.", [["people", "ORGANISM", 151, 157], ["people", "SPECIES", 151, 157], ["Velocity", "TEST", 193, 201]]], ["The data\u2019s contents are constantly changing through the absorption of complementary data collections, the introduction of previous data or legacy collections, and the different forms of streamed data from multiple sources.", [["complementary data collections", "PROBLEM", 70, 100], ["previous data", "TEST", 122, 135], ["legacy collections", "PROBLEM", 139, 157], ["streamed data", "PROBLEM", 186, 199]]], ["From this point of view, new algorithms and methods are needed to adequately process and analyse the online and streaming data.\u2022Variety: refers to different types of data collected via sensors, smartphones or social networks, such as videos, images, text, audio, data logs, and so on.", [["new algorithms", "TEST", 25, 39], ["streaming data", "TEST", 112, 126], ["images", "TEST", 242, 248]]], ["Value is the most important characteristic of any big-data-based application, because it allows to generate useful business information.\u2022Veracity: refers to the correctness and accuracy of information.", [["most important", "OBSERVATION_MODIFIER", 13, 27]]], ["Behind any information management practice lie the core doctrines of data quality, data governance, and metadata management, along with considerations of privacy and legal concerns.", [["metadata management", "TREATMENT", 104, 123]]]], "PMC7166826": [["BACKGROUNDAcute respiratory infection (ARI) is responsible for a high global disease burden, and respiratory viruses are the most common causal agents of ARIs.1, 2 Influenza virus (FLU) causes considerable mortality and morbidity worldwide, even though FLU vaccines and antiviral agents are available.", [["BACKGROUNDAcute respiratory infection", "DISEASE", 0, 37], ["ARI", "DISEASE", 39, 42], ["respiratory viruses", "DISEASE", 97, 116], ["ARIs", "DISEASE", 154, 158], ["Influenza virus", "DISEASE", 164, 179], ["FLU", "CHEMICAL", 181, 184], ["FLU", "CHEMICAL", 253, 256], ["FLU", "CHEMICAL", 253, 256], ["ARIs", "CANCER", 154, 158], ["2", "ORGANISM", 162, 163], ["Influenza virus", "ORGANISM", 164, 179], ["FLU", "CANCER", 181, 184], ["FLU", "SIMPLE_CHEMICAL", 253, 256], ["Influenza virus", "SPECIES", 164, 179], ["Influenza virus", "SPECIES", 164, 179], ["BACKGROUNDAcute respiratory infection (ARI)", "PROBLEM", 0, 43], ["a high global disease burden", "PROBLEM", 63, 91], ["respiratory viruses", "PROBLEM", 97, 116], ["ARIs", "PROBLEM", 154, 158], ["2 Influenza virus (FLU)", "PROBLEM", 162, 185], ["considerable mortality", "PROBLEM", 193, 215], ["morbidity worldwide", "PROBLEM", 220, 239], ["FLU vaccines", "TREATMENT", 253, 265], ["antiviral agents", "TREATMENT", 270, 286], ["respiratory", "ANATOMY", 16, 27], ["infection", "OBSERVATION", 28, 37], ["responsible for", "UNCERTAINTY", 47, 62], ["high", "OBSERVATION_MODIFIER", 65, 69], ["global", "OBSERVATION_MODIFIER", 70, 76], ["disease", "OBSERVATION", 77, 84], ["respiratory viruses", "OBSERVATION", 97, 116], ["Influenza virus", "OBSERVATION", 164, 179]]], ["Moreover, clinically useful antiviral agents and vaccines do not exist for most of the other respiratory viruses.", [["respiratory viruses", "DISEASE", 93, 112], ["antiviral agents", "TREATMENT", 28, 44], ["vaccines", "TREATMENT", 49, 57], ["respiratory", "ANATOMY", 93, 104], ["viruses", "OBSERVATION", 105, 112]]], ["Accordingly, understanding the epidemiology of respiratory viruses is important for promoting preparedness to tackle this public health threat.3, 4, 5, 6, 7, 8", [["respiratory viruses", "DISEASE", 47, 66], ["respiratory viruses", "PROBLEM", 47, 66], ["respiratory viruses", "OBSERVATION", 47, 66]]]], "26c6e83679b32d9574a757d4ca533ed4aa442ffa": [["The earliest known route of vaccination was respiratory, by intranasal insufflation of powdered scab material containing variola virus from smallpox patients, reportedly practiced in China as early as the 10th century AD (see Chapters 1 and 32 ).", [["respiratory", "ANATOMY", 44, 55], ["smallpox", "DISEASE", 140, 148], ["AD", "DISEASE", 218, 220], ["variola virus", "ORGANISM", 121, 134], ["patients", "ORGANISM", 149, 157], ["variola virus", "SPECIES", 121, 134], ["patients", "SPECIES", 149, 157], ["variola virus", "SPECIES", 121, 134], ["vaccination", "TREATMENT", 28, 39], ["intranasal insufflation", "TREATMENT", 60, 83], ["powdered scab material", "PROBLEM", 87, 109], ["variola virus", "PROBLEM", 121, 134], ["scab", "OBSERVATION", 96, 100], ["variola virus", "OBSERVATION", 121, 134]]], ["1 The cutaneous route for such variolation involved breaking the skin with a sharp instrument, and it was used in India perhaps as early as in China, but it was not documented until the 16th century.", [["cutaneous", "ANATOMY", 6, 15], ["skin", "ANATOMY", 65, 69], ["skin", "ORGAN", 65, 69], ["The cutaneous route", "TREATMENT", 2, 21], ["such variolation", "TREATMENT", 26, 42], ["a sharp instrument", "TREATMENT", 75, 93], ["skin", "ANATOMY", 65, 69]]], ["2 Variolation was supplanted by safer cutaneous application of material from cowpox lesions, the method of \"vaccination\" known in the 18th century and first published by Edward Jenner.", [["cutaneous", "ANATOMY", 38, 47], ["lesions", "ANATOMY", 84, 91], ["cowpox lesions", "DISEASE", 77, 91], ["cowpox", "ORGANISM", 77, 83], ["lesions", "PATHOLOGICAL_FORMATION", 84, 91], ["safer cutaneous application of material", "TREATMENT", 32, 71], ["cowpox lesions", "PROBLEM", 77, 91], ["the method of \"vaccination", "TREATMENT", 93, 119], ["cowpox lesions", "OBSERVATION", 77, 91]]]], "PMC7340251": [["IntroductionWhat began as a cluster of pneumonia cases in Wuhan, China, in December 2019 is now known as the worldwide pandemic of the novel coronavirus disease 2019, coined COVID-19.1 The first case of COVID-19 in the United States was on January 20, 2020, and as of May 4, 2020, more than 3.6 million infections have been reported globally, accounting for a death toll of more than 252,000 persons.1,2 This disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a subpopulation may present with extrapulmonary symptoms nausea, vomiting, abdominal pain and diarrhea,3 leading to a potential delay in diagnosis.IntroductionWhile currently, around 15 million people are living with cancer,4 little is known about the burden of COVID-19 in cancer patients who are at increased risk of worse outcomes.5 Here we present a case of severe COVID-19 in a patient with chronic lymphocytic leukemia (CLL) who initially evaded a timely diagnosis, but she successfully recovered after 17 days of intubation.Case PresentationA 41-year-old morbidly obese female with a diagnosis of B-cell type CLL, RAI stage 0, with 13q deletion and mutated immunoglobulin heavy chain, on active surveillance without chemotherapy, presented to an urgent care facility for four days of nausea, vomiting, and diarrhea with a low-grade fever of 100.8 \u00b0F (38.2 \u00b0C).", [["extrapulmonary", "ANATOMY", 533, 547], ["abdominal", "ANATOMY", 575, 584], ["cancer", "ANATOMY", 717, 723], ["cancer", "ANATOMY", 774, 780], ["chronic lymphocytic leukemia", "ANATOMY", 896, 924], ["CLL", "ANATOMY", 926, 929], ["B-cell type CLL", "ANATOMY", 1104, 1119], ["pneumonia", "DISEASE", 39, 48], ["coronavirus disease", "DISEASE", 141, 160], ["infections", "DISEASE", 303, 313], ["death", "DISEASE", 360, 365], ["1,2", "CHEMICAL", 400, 403], ["acute respiratory syndrome coronavirus", "DISEASE", 441, 479], ["extrapulmonary symptoms nausea", "DISEASE", 533, 563], ["vomiting", "DISEASE", 565, 573], ["abdominal pain", "DISEASE", 575, 589], ["diarrhea", "DISEASE", 594, 602], ["cancer", "DISEASE", 717, 723], ["COVID-19", "CHEMICAL", 762, 770], ["cancer", "DISEASE", 774, 780], ["chronic lymphocytic leukemia", "DISEASE", 896, 924], ["CLL", "DISEASE", 926, 929], ["B-cell type CLL", "DISEASE", 1104, 1119], ["nausea", "DISEASE", 1291, 1297], ["vomiting", "DISEASE", 1299, 1307], ["diarrhea", "DISEASE", 1313, 1321], ["fever", "DISEASE", 1339, 1344], ["COVID-19", "CHEMICAL", 869, 877], ["coronavirus", "ORGANISM", 141, 152], ["persons", "ORGANISM", 392, 399], ["SARS-CoV-2", "ORGANISM", 483, 493], ["abdominal", "ORGANISM_SUBDIVISION", 575, 584], ["people", "ORGANISM", 694, 700], ["cancer", "CANCER", 717, 723], ["cancer", "CANCER", 774, 780], ["patients", "ORGANISM", 781, 789], ["patient", "ORGANISM", 883, 890], ["chronic lymphocytic leukemia", "CANCER", 896, 924], ["CLL", "CANCER", 926, 929], ["female", "ORGANISM", 1077, 1083], ["B-cell type CLL", "CANCER", 1104, 1119], ["13q", "CELLULAR_COMPONENT", 1139, 1142], ["immunoglobulin heavy chain", "GENE_OR_GENE_PRODUCT", 1164, 1190], ["13q deletion", "DNA", 1139, 1151], ["mutated immunoglobulin heavy chain", "PROTEIN", 1156, 1190], ["coronavirus", "SPECIES", 141, 152], ["persons", "SPECIES", 392, 399], ["people", "SPECIES", 694, 700], ["patients", "SPECIES", 781, 789], ["patient", "SPECIES", 883, 890], ["severe acute respiratory syndrome coronavirus", "SPECIES", 434, 479], ["SARS-CoV-2", "SPECIES", 483, 493], ["pneumonia", "PROBLEM", 39, 48], ["the novel coronavirus disease", "PROBLEM", 131, 160], ["COVID", "TEST", 174, 179], ["COVID", "TEST", 203, 208], ["This disease", "PROBLEM", 404, 416], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 430, 479], ["SARS-CoV", "TEST", 483, 491], ["extrapulmonary symptoms", "PROBLEM", 533, 556], ["nausea", "PROBLEM", 557, 563], ["vomiting", "PROBLEM", 565, 573], ["abdominal pain", "PROBLEM", 575, 589], ["diarrhea", "PROBLEM", 594, 602], ["severe COVID", "PROBLEM", 862, 874], ["chronic lymphocytic leukemia", "PROBLEM", 896, 924], ["CLL", "PROBLEM", 926, 929], ["intubation", "TREATMENT", 1020, 1030], ["B-cell type CLL", "PROBLEM", 1104, 1119], ["RAI stage 0", "PROBLEM", 1121, 1132], ["13q deletion", "PROBLEM", 1139, 1151], ["mutated immunoglobulin heavy chain", "PROBLEM", 1156, 1190], ["chemotherapy", "TREATMENT", 1223, 1235], ["nausea", "PROBLEM", 1291, 1297], ["vomiting", "PROBLEM", 1299, 1307], ["diarrhea", "PROBLEM", 1313, 1321], ["a low-grade fever", "PROBLEM", 1327, 1344], ["pneumonia", "OBSERVATION", 39, 48], ["disease", "OBSERVATION", 409, 416], ["severe", "OBSERVATION_MODIFIER", 434, 440], ["acute", "OBSERVATION_MODIFIER", 441, 446], ["respiratory syndrome coronavirus", "OBSERVATION", 447, 479], ["may present with", "UNCERTAINTY", 516, 532], ["extrapulmonary", "ANATOMY", 533, 547], ["abdominal", "ANATOMY", 575, 584], ["pain", "OBSERVATION", 585, 589], ["diarrhea", "OBSERVATION", 594, 602], ["cancer", "OBSERVATION", 717, 723], ["chronic", "OBSERVATION_MODIFIER", 896, 903], ["lymphocytic leukemia", "OBSERVATION", 904, 924], ["B-cell type CLL", "OBSERVATION", 1104, 1119], ["heavy chain", "OBSERVATION_MODIFIER", 1179, 1190], ["nausea", "OBSERVATION", 1291, 1297], ["low-grade", "OBSERVATION_MODIFIER", 1329, 1338], ["fever", "OBSERVATION", 1339, 1344]]], ["She was treated with intravenous (IV) fluids and anti-emetics and discharged home with the presumptive diagnosis of acute gastroenteritis.", [["intravenous", "ANATOMY", 21, 32], ["gastroenteritis", "DISEASE", 122, 137], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 21, 32], ["intravenous (IV) fluids", "TREATMENT", 21, 44], ["anti-emetics", "TREATMENT", 49, 61], ["acute gastroenteritis", "PROBLEM", 116, 137], ["acute", "OBSERVATION_MODIFIER", 116, 121], ["gastroenteritis", "OBSERVATION", 122, 137]]], ["Over the following week, her gastrointestinal (GI) symptoms improved but did not resolve fully.Case PresentationTen days after symptoms onset, she presented to the Emergency Department (ED) with two days of dry cough, shortness of breath, myalgias, and persistent fevers of 102 \u00b0F (38.9\u00b0C).", [["gastrointestinal", "ANATOMY", 29, 45], ["gastrointestinal (GI) symptoms", "DISEASE", 29, 59], ["dry cough", "DISEASE", 207, 216], ["shortness of breath", "DISEASE", 218, 237], ["myalgias", "DISEASE", 239, 247], ["fevers", "DISEASE", 264, 270], ["gastrointestinal", "ORGANISM_SUBDIVISION", 29, 45], ["her gastrointestinal (GI) symptoms", "PROBLEM", 25, 59], ["symptoms", "PROBLEM", 127, 135], ["dry cough", "PROBLEM", 207, 216], ["shortness of breath", "PROBLEM", 218, 237], ["myalgias", "PROBLEM", 239, 247], ["persistent fevers of 102 \u00b0F", "PROBLEM", 253, 280], ["gastrointestinal", "ANATOMY", 29, 45], ["cough", "OBSERVATION", 211, 216], ["myalgias", "OBSERVATION", 239, 247], ["persistent", "OBSERVATION_MODIFIER", 253, 263], ["fevers", "OBSERVATION", 264, 270]]], ["The signs and symptoms are outlined in Figure 1.", [["The signs and symptoms", "PROBLEM", 0, 22]]], ["In the ED, she was hypoxic with SpO2 85% on 6 L/min nasal cannula.", [["nasal", "ANATOMY", 52, 57], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 52, 65], ["hypoxic", "PROBLEM", 19, 26], ["SpO2", "TEST", 32, 36], ["nasal cannula", "TREATMENT", 52, 65], ["hypoxic", "OBSERVATION_MODIFIER", 19, 26]]], ["She was placed on a non-rebreather mask (15 L/min of oxygen) and was later electively intubated and placed on mechanical ventilation with a lung-protective strategy.", [["lung", "ANATOMY", 140, 144], ["oxygen", "CHEMICAL", 53, 59], ["oxygen", "CHEMICAL", 53, 59], ["oxygen", "SIMPLE_CHEMICAL", 53, 59], ["lung", "ORGAN", 140, 144], ["a non-rebreather mask", "TREATMENT", 18, 39], ["oxygen", "TREATMENT", 53, 59], ["mechanical ventilation", "TREATMENT", 110, 132], ["a lung-protective strategy", "TREATMENT", 138, 164], ["lung", "ANATOMY", 140, 144]]], ["Empiric therapy with cefepime 2 g IV Q 12 hours, linezolid 600 mg IV Q 12h and doxycycline were initiated.", [["cefepime", "CHEMICAL", 21, 29], ["linezolid", "CHEMICAL", 49, 58], ["doxycycline", "CHEMICAL", 79, 90], ["cefepime", "CHEMICAL", 21, 29], ["linezolid", "CHEMICAL", 49, 58], ["doxycycline", "CHEMICAL", 79, 90], ["cefepime", "SIMPLE_CHEMICAL", 21, 29], ["linezolid", "SIMPLE_CHEMICAL", 49, 58], ["doxycycline", "SIMPLE_CHEMICAL", 79, 90], ["Empiric therapy", "TREATMENT", 0, 15], ["cefepime", "TREATMENT", 21, 29], ["linezolid", "TREATMENT", 49, 58], ["doxycycline", "TREATMENT", 79, 90]]], ["A posteroanterior chest radiograph showed bilateral diffuse lung opacities (Figure 2, panel a).Case PresentationHer laboratory studies were notable for: white blood cell count 11,700 /\u03bcl with 61% neutrophils and 35% lymphocytes, a relative lymphocytopenia in the setting of CLL.", [["chest", "ANATOMY", 18, 23], ["lung", "ANATOMY", 60, 64], ["white blood cell", "ANATOMY", 153, 169], ["neutrophils", "ANATOMY", 196, 207], ["lymphocytes", "ANATOMY", 216, 227], ["CLL", "ANATOMY", 274, 277], ["lung opacities", "DISEASE", 60, 74], ["lymphocytopenia", "DISEASE", 240, 255], ["CLL", "DISEASE", 274, 277], ["lung", "ORGAN", 60, 64], ["white blood cell", "CELL", 153, 169], ["neutrophils", "CELL", 196, 207], ["lymphocytes", "CELL", 216, 227], ["CLL", "CANCER", 274, 277], ["neutrophils", "CELL_TYPE", 196, 207], ["lymphocytes", "CELL_TYPE", 216, 227], ["A posteroanterior chest radiograph", "TEST", 0, 34], ["bilateral diffuse lung opacities", "PROBLEM", 42, 74], ["white blood cell count", "TEST", 153, 175], ["\u03bcl", "TEST", 184, 186], ["neutrophils", "TEST", 196, 207], ["lymphocytes", "TEST", 216, 227], ["a relative lymphocytopenia", "PROBLEM", 229, 255], ["CLL", "PROBLEM", 274, 277], ["posteroanterior", "ANATOMY_MODIFIER", 2, 17], ["chest", "ANATOMY", 18, 23], ["bilateral", "ANATOMY_MODIFIER", 42, 51], ["diffuse", "OBSERVATION_MODIFIER", 52, 59], ["lung", "ANATOMY", 60, 64], ["opacities", "OBSERVATION", 65, 74], ["lymphocytopenia", "OBSERVATION", 240, 255], ["CLL", "OBSERVATION", 274, 277]]], ["Troponin level <6 ng/L and total immunoglobulin G, 839 mg/dL.", [["Troponin", "GENE_OR_GENE_PRODUCT", 0, 8], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 33, 49], ["Troponin", "PROTEIN", 0, 8], ["immunoglobulin G", "PROTEIN", 33, 49], ["Troponin level", "TEST", 0, 14], ["total immunoglobulin G", "TREATMENT", 27, 49]]], ["A nasopharyngeal (NP) swab specimen was negative for common respiratory viruses.", [["nasopharyngeal", "ANATOMY", 2, 16], ["swab specimen", "ANATOMY", 22, 35], ["respiratory viruses", "DISEASE", 60, 79], ["nasopharyngeal", "CANCER", 2, 16], ["A nasopharyngeal (NP) swab specimen", "TEST", 0, 35], ["common respiratory viruses", "PROBLEM", 53, 79], ["nasopharyngeal", "ANATOMY", 2, 16], ["respiratory viruses", "OBSERVATION", 60, 79]]], ["This specimen was collected in accordance with the Centers for Disease Control and Prevention and was negative for reverse transcriptase (rRT)-polymerase-chain-reaction (PCR) for SARS-CoV-2.Case PresentationA chest computed tomography (CT) scan was performed on hospital day (HD) 2 and showed bilobar multi-segmental ground-glass opacities (GGO) located both centrally and peripherally (Figure 2, panel b).", [["specimen", "ANATOMY", 5, 13], ["GGO", "DISEASE", 341, 344], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 179, 189], ["reverse transcriptase", "PROTEIN", 115, 136], ["SARS-CoV", "SPECIES", 179, 187], ["This specimen", "TEST", 0, 13], ["Disease Control", "TREATMENT", 63, 78], ["reverse transcriptase (rRT", "TREATMENT", 115, 141], ["polymerase", "TEST", 143, 153], ["PCR", "TEST", 170, 173], ["SARS", "PROBLEM", 179, 183], ["CoV", "TEST", 184, 187], ["chest computed tomography", "TEST", 209, 234], ["CT) scan", "TEST", 236, 244], ["bilobar multi-segmental ground-glass opacities", "PROBLEM", 293, 339], ["chest", "ANATOMY", 209, 214], ["bilobar", "OBSERVATION_MODIFIER", 293, 300], ["ground-glass opacities", "OBSERVATION", 317, 339], ["peripherally", "ANATOMY_MODIFIER", 373, 385]]], ["Despite negative testing, COVID-19 pneumonia was highly suspected.", [["pneumonia", "DISEASE", 35, 44], ["COVID-19", "SPECIES", 26, 34], ["testing", "TEST", 17, 24], ["COVID", "TEST", 26, 31], ["pneumonia", "PROBLEM", 35, 44], ["pneumonia", "OBSERVATION", 35, 44]]], ["A second NP swab specimen for SARS-CoV-2 was performed and reported negative.", [["swab specimen", "ANATOMY", 12, 25], ["SARS-CoV", "SPECIES", 30, 38], ["A second NP swab specimen", "TEST", 0, 25], ["SARS-CoV-2", "TEST", 30, 40], ["negative", "OBSERVATION", 68, 76]]], ["Blood cultures, serum Aspergillus antigen, \u03b2eta-(1,3)-d-glucan, and urine legionella antigen were all negative.Case PresentationIn view of the second negative COVID testing, and the patient\u2019s risk factors for opportunistic infections, a bronchoscopy with bronchoalveolar lavage (BAL) was performed.", [["Blood cultures", "ANATOMY", 0, 14], ["serum", "ANATOMY", 16, 21], ["urine", "ANATOMY", 68, 73], ["bronchoalveolar lavage", "ANATOMY", 255, 277], ["BAL", "ANATOMY", 279, 282], ["\u03b2eta-(1,3)-d-glucan", "CHEMICAL", 43, 62], ["opportunistic infections", "DISEASE", 209, 233], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["Aspergillus antigen", "GENE_OR_GENE_PRODUCT", 22, 41], ["\u03b2eta-(1,3)-d-glucan", "SIMPLE_CHEMICAL", 43, 62], ["urine", "ORGANISM_SUBSTANCE", 68, 73], ["legionella antigen", "GENE_OR_GENE_PRODUCT", 74, 92], ["patient", "ORGANISM", 182, 189], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 255, 277], ["serum Aspergillus antigen", "PROTEIN", 16, 41], ["\u03b2eta-(1,3)-d-glucan", "PROTEIN", 43, 62], ["urine legionella antigen", "PROTEIN", 68, 92], ["patient", "SPECIES", 182, 189], ["Blood cultures", "TEST", 0, 14], ["serum Aspergillus antigen", "TEST", 16, 41], ["\u03b2eta", "TEST", 43, 47], ["d-glucan", "TEST", 54, 62], ["urine legionella antigen", "TEST", 68, 92], ["COVID testing", "TEST", 159, 172], ["opportunistic infections", "PROBLEM", 209, 233], ["a bronchoscopy", "TEST", 235, 249], ["bronchoalveolar lavage (BAL)", "TEST", 255, 283], ["bronchoalveolar lavage", "OBSERVATION", 255, 277]]], ["Precautions to avoid generating aerosolized particles were taken, such as the use of personal protective aerosolized equipment (PAPR) and paralyzing the patient during the procedure.", [["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["Precautions", "TREATMENT", 0, 11], ["generating aerosolized particles", "TREATMENT", 21, 53], ["personal protective aerosolized equipment", "TREATMENT", 85, 126], ["PAPR)", "TREATMENT", 128, 133], ["paralyzing", "TREATMENT", 138, 148], ["the procedure", "TREATMENT", 168, 181]]], ["The BAL specimen was negative for aspergillus antigen, pneumocystis jirovecii PCR, cytomegalovirus PCR, bacterial and fungal cultures.", [["BAL specimen", "ANATOMY", 4, 16], ["BAL specimen", "CANCER", 4, 16], ["aspergillus antigen", "GENE_OR_GENE_PRODUCT", 34, 53], ["pneumocystis jirovecii", "ORGANISM", 55, 77], ["cytomegalovirus", "ORGANISM", 83, 98], ["pneumocystis jirovecii", "SPECIES", 55, 77], ["pneumocystis jirovecii", "SPECIES", 55, 77], ["cytomegalovirus", "SPECIES", 83, 98], ["The BAL specimen", "TEST", 0, 16], ["aspergillus antigen", "PROBLEM", 34, 53], ["pneumocystis jirovecii PCR", "TEST", 55, 81], ["cytomegalovirus PCR", "TEST", 83, 102], ["bacterial and fungal cultures", "TEST", 104, 133], ["BAL", "ANATOMY", 4, 7], ["negative for", "UNCERTAINTY", 21, 33], ["pneumocystis jirovecii", "OBSERVATION", 55, 77]]], ["However, the BAL rRT-PCR for SARS-CoV-2 was positive on HD 4.", [["BAL", "ANATOMY", 13, 16], ["SARS-CoV-2", "ORGANISM", 29, 39], ["SARS-CoV", "SPECIES", 29, 37], ["the BAL rRT", "TEST", 9, 20], ["PCR", "TEST", 21, 24], ["SARS", "TEST", 29, 33], ["CoV", "TEST", 34, 37], ["HD", "TREATMENT", 56, 58]]], ["The treatment was transitioned to hydroxychloroquine 400 mg twice daily for two doses, then 200 mg twice daily combined with azithromycin 500 mg first dose, then 250 mg once daily for a total of 5 days.", [["hydroxychloroquine", "CHEMICAL", 34, 52], ["azithromycin", "CHEMICAL", 125, 137], ["hydroxychloroquine", "CHEMICAL", 34, 52], ["azithromycin", "CHEMICAL", 125, 137], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 34, 52], ["azithromycin", "SIMPLE_CHEMICAL", 125, 137], ["The treatment", "TREATMENT", 0, 13], ["hydroxychloroquine", "TREATMENT", 34, 52], ["azithromycin", "TREATMENT", 125, 137]]], ["Additionally, two doses of tocilizumab of 8 mg/kg every 12 hours were administered on HD 4 with one infusion of immunoglobulins (30 g).", [["tocilizumab", "CHEMICAL", 27, 38], ["tocilizumab", "SIMPLE_CHEMICAL", 27, 38], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 112, 127], ["immunoglobulins", "PROTEIN", 112, 127], ["tocilizumab", "TREATMENT", 27, 38], ["HD", "TREATMENT", 86, 88], ["immunoglobulins", "TREATMENT", 112, 127]]], ["The patient developed acute respiratory distress syndrome (ARDS), and she was dependent on mechanical ventilation thereafter.", [["respiratory", "ANATOMY", 28, 39], ["acute respiratory distress syndrome", "DISEASE", 22, 57], ["ARDS", "DISEASE", 59, 63], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["acute respiratory distress syndrome", "PROBLEM", 22, 57], ["ARDS", "PROBLEM", 59, 63], ["mechanical ventilation", "TREATMENT", 91, 113], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["respiratory distress", "OBSERVATION", 28, 48], ["syndrome", "OBSERVATION", 49, 57], ["ARDS", "OBSERVATION", 59, 63], ["dependent", "OBSERVATION_MODIFIER", 78, 87], ["mechanical ventilation", "OBSERVATION", 91, 113]]], ["On HD12, a short course of high dose intravenous methylprednisolone 1 mg/kg per day was administered and which resulted in a gradual improvement of the patient\u2019s respiratory status.", [["intravenous", "ANATOMY", 37, 48], ["respiratory", "ANATOMY", 162, 173], ["methylprednisolone", "CHEMICAL", 49, 67], ["methylprednisolone", "CHEMICAL", 49, 67], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 48], ["methylprednisolone", "SIMPLE_CHEMICAL", 49, 67], ["patient", "ORGANISM", 152, 159], ["patient", "SPECIES", 152, 159], ["high dose intravenous methylprednisolone", "TREATMENT", 27, 67], ["gradual", "OBSERVATION_MODIFIER", 125, 132], ["improvement", "OBSERVATION_MODIFIER", 133, 144]]], ["Five days after the initiation of corticosteroids (HD17), the patient was successfully extubated.", [["corticosteroids", "CHEMICAL", 34, 49], ["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["corticosteroids", "TREATMENT", 34, 49]]], ["Before discharge, a repeat SARS-CoV-2 PCR from NP specimen remained negative.", [["NP specimen", "ANATOMY", 47, 58], ["NP specimen", "CANCER", 47, 58], ["repeat SARS-CoV-2 PCR", "DNA", 20, 41], ["a repeat SARS", "TEST", 18, 31], ["CoV-2 PCR", "TEST", 32, 41], ["NP specimen", "TEST", 47, 58], ["negative", "OBSERVATION", 68, 76]]], ["She responded well to skilled occupational therapy exercises and, on HD 28, she was discharged home on room air, with stable conditions, and without sequelae.", [["skilled occupational therapy exercises", "TREATMENT", 22, 60], ["HD", "TREATMENT", 69, 71], ["sequelae", "PROBLEM", 149, 157], ["without", "UNCERTAINTY", 141, 148]]], ["After one month of discharge, serologic testing for COVID-19 (Viracor Eurofins) showed positive IgG, 56.6 Units (normal range, \u2264 9.0 Units).DiscussionTo our knowledge, this is a unique case of severe COVID-19 in a patient with CLL that illustrates several aspects of this novel infection that are not yet fully understood, and the PCR testing including specimen collection as sensitivity and specificity of the test may vary in accordance to affected organs.", [["CLL", "ANATOMY", 227, 230], ["specimen", "ANATOMY", 353, 361], ["organs", "ANATOMY", 451, 457], ["CLL", "DISEASE", 227, 230], ["infection", "DISEASE", 278, 287], ["COVID-19", "CHEMICAL", 200, 208], ["patient", "ORGANISM", 214, 221], ["CLL", "CANCER", 227, 230], ["organs", "ORGAN", 451, 457], ["positive IgG", "PROTEIN", 87, 99], ["patient", "SPECIES", 214, 221], ["serologic testing", "TEST", 30, 47], ["COVID", "TEST", 52, 57], ["IgG", "TEST", 96, 99], ["severe COVID", "PROBLEM", 193, 205], ["CLL", "PROBLEM", 227, 230], ["this novel infection", "PROBLEM", 267, 287], ["the PCR testing", "TEST", 327, 342], ["specimen collection", "TEST", 353, 372], ["sensitivity", "TEST", 376, 387], ["the test", "TEST", 407, 415], ["CLL", "OBSERVATION", 227, 230], ["infection", "OBSERVATION", 278, 287]]], ["Of note, four cases of mild COVID-19 cases in CLL patients have been reported,6 and no standardized COVID-19 treatment in patients with hematological malignancies is available.DiscussionOur patient initially reported GI symptoms in the absence of respiratory symptoms, which did not develop until a week into the illness.", [["CLL", "ANATOMY", 46, 49], ["hematological malignancies", "ANATOMY", 136, 162], ["GI", "ANATOMY", 217, 219], ["respiratory", "ANATOMY", 247, 258], ["COVID", "DISEASE", 28, 33], ["CLL", "DISEASE", 46, 49], ["COVID-19", "CHEMICAL", 100, 108], ["hematological malignancies", "DISEASE", 136, 162], ["respiratory symptoms", "DISEASE", 247, 267], ["COVID-19", "CHEMICAL", 100, 108], ["CLL", "CANCER", 46, 49], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 122, 130], ["hematological malignancies", "CANCER", 136, 162], ["patient", "ORGANISM", 190, 197], ["GI", "ORGANISM_SUBDIVISION", 217, 219], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 122, 130], ["patient", "SPECIES", 190, 197], ["mild COVID", "PROBLEM", 23, 33], ["standardized COVID", "TREATMENT", 87, 105], ["treatment", "TREATMENT", 109, 118], ["hematological malignancies", "PROBLEM", 136, 162], ["GI symptoms", "PROBLEM", 217, 228], ["respiratory symptoms", "PROBLEM", 247, 267], ["mild", "OBSERVATION_MODIFIER", 23, 27], ["CLL", "OBSERVATION", 46, 49], ["malignancies", "OBSERVATION", 150, 162], ["respiratory", "ANATOMY", 247, 258], ["symptoms", "OBSERVATION", 259, 267]]], ["The GI manifestations of COVID-19 have been described in 2 to 10% in cases series and an observational study (N=1099) reported the presence of nausea or vomiting (5.0%) and diarrhea (3.8%) in infected patients.7 However, other studies showed that up to 11% of patients had on admission at least one GI symptom, and around 50% of patients developed GI symptoms during the hospitalization.8,9 Early nonspecific symptoms of COVID-19 can lead to diagnostic difficulty in distinguishing between other common infectious diseases.DiscussionThe SARS-CoV-2 has been detected in nasopharyngeal, oropharyngeal, sputum, and BAL specimens in COVID-19.", [["GI", "ANATOMY", 4, 6], ["GI", "ANATOMY", 348, 350], ["nasopharyngeal", "ANATOMY", 569, 583], ["oropharyngeal", "ANATOMY", 585, 598], ["sputum", "ANATOMY", 600, 606], ["BAL specimens", "ANATOMY", 612, 625], ["nausea", "DISEASE", 143, 149], ["vomiting", "DISEASE", 153, 161], ["diarrhea", "DISEASE", 173, 181], ["COVID-19", "CHEMICAL", 421, 429], ["infectious diseases", "DISEASE", 503, 522], ["COVID-19", "CHEMICAL", 421, 429], ["patients", "ORGANISM", 201, 209], ["patients", "ORGANISM", 260, 268], ["patients", "ORGANISM", 329, 337], ["nasopharyngeal", "CANCER", 569, 583], ["oropharyngeal", "CANCER", 585, 598], ["BAL specimens", "CANCER", 612, 625], ["patients", "SPECIES", 201, 209], ["patients", "SPECIES", 260, 268], ["patients", "SPECIES", 329, 337], ["SARS-CoV", "SPECIES", 537, 545], ["COVID", "TEST", 25, 30], ["an observational study", "TEST", 86, 108], ["nausea", "PROBLEM", 143, 149], ["vomiting", "PROBLEM", 153, 161], ["diarrhea", "PROBLEM", 173, 181], ["other studies", "TEST", 221, 234], ["GI symptom", "PROBLEM", 299, 309], ["GI symptoms", "PROBLEM", 348, 359], ["Early nonspecific symptoms", "PROBLEM", 391, 417], ["COVID", "TEST", 421, 426], ["other common infectious diseases", "PROBLEM", 490, 522], ["The SARS", "TEST", 533, 541], ["CoV", "TEST", 542, 545], ["nasopharyngeal, oropharyngeal, sputum", "TEST", 569, 606], ["BAL specimens", "TEST", 612, 625], ["COVID", "TEST", 629, 634], ["nausea", "OBSERVATION", 143, 149], ["nonspecific", "OBSERVATION_MODIFIER", 397, 408], ["common", "OBSERVATION_MODIFIER", 496, 502], ["infectious", "OBSERVATION", 503, 513], ["nasopharyngeal", "ANATOMY", 569, 583], ["oropharyngeal", "ANATOMY", 585, 598]]], ["BAL samples are the most accurate but involve dedicated personnel and invasive procedures for the collection.10 NP swab is the recommended test for suspected COVID-19 as it is safe and well-tolerated by patients.11\u201313 However, false negatives (20\u201340% in NP swab) can occur due to viral load variability throughout stages of the disease, or due to poor technique and this could result in missed diagnosis.13\u201316 The positivity of PCR varies depending on the specimens, with higher positive rates on BAL (93%) and sputum (72%) when compared to nasopharyngeal swabs (63%).10 Despite these findings, in suspected COVID-19 cases, the use of bronchoscopy has been limited, and not recommended routinely, due to the risk it poses to medical staff.17,18 However, in immunocompromised patients, the diagnosis of COVID-19 can be obscured by other etiologies such as CMV and PJP pneumonia.", [["BAL samples", "ANATOMY", 0, 11], ["specimens", "ANATOMY", 456, 465], ["BAL", "ANATOMY", 497, 500], ["sputum", "ANATOMY", 511, 517], ["nasopharyngeal swabs", "ANATOMY", 541, 561], ["COVID", "DISEASE", 608, 613], ["COVID-19", "CHEMICAL", 802, 810], ["pneumonia", "DISEASE", 867, 876], ["COVID-19", "CHEMICAL", 158, 166], ["COVID-19", "CHEMICAL", 802, 810], ["BAL samples", "CANCER", 0, 11], ["patients", "ORGANISM", 203, 211], ["BAL", "ORGANISM_SUBSTANCE", 497, 500], ["nasopharyngeal swabs", "CANCER", 541, 561], ["patients", "ORGANISM", 775, 783], ["CMV", "ORGANISM", 855, 858], ["patients", "SPECIES", 203, 211], ["patients", "SPECIES", 775, 783], ["CMV", "SPECIES", 855, 858], ["BAL samples", "TEST", 0, 11], ["invasive procedures", "TREATMENT", 70, 89], ["the collection", "PROBLEM", 94, 108], ["COVID", "TEST", 158, 163], ["false negatives", "TEST", 227, 242], ["NP swab", "TEST", 254, 261], ["viral load variability", "PROBLEM", 280, 302], ["the disease", "PROBLEM", 324, 335], ["poor technique", "PROBLEM", 347, 361], ["The positivity of PCR", "TEST", 410, 431], ["the specimens", "TEST", 452, 465], ["higher positive rates", "PROBLEM", 472, 493], ["BAL", "TEST", 497, 500], ["sputum", "TEST", 511, 517], ["nasopharyngeal swabs", "TEST", 541, 561], ["bronchoscopy", "TREATMENT", 635, 647], ["COVID", "TEST", 802, 807], ["CMV", "PROBLEM", 855, 858], ["PJP pneumonia", "PROBLEM", 863, 876], ["viral load", "OBSERVATION", 280, 290], ["disease", "OBSERVATION", 328, 335], ["nasopharyngeal", "ANATOMY", 541, 555], ["immunocompromised", "OBSERVATION", 757, 774], ["CMV", "OBSERVATION", 855, 858], ["PJP", "OBSERVATION_MODIFIER", 863, 866], ["pneumonia", "OBSERVATION", 867, 876]]], ["In such cases, protocols within the institutions on how to perform bronchoscopies safely should be in place; some considerations might include performing BAL immediately after endotracheal intubation.", [["BAL", "ANATOMY", 154, 157], ["endotracheal", "ANATOMY", 176, 188], ["bronchoscopies", "TREATMENT", 67, 81], ["performing BAL", "TEST", 143, 157], ["endotracheal intubation", "TREATMENT", 176, 199]]], ["Moreover, as evidenced in this case, highly suspected COVID-19 cases should lead to discussions to safely pursue a diagnosis while also being able to rule out other common causes of respiratory failure in cancer patients.DiscussionA chest CT scan has a high sensitivity for COVID-19 and may be considered as a primary tool for COVID-19 detection in highly epidemic areas.19 Given the lack of clear data regarding the sensitivity of rRT-PCR NP swab in patients with GI manifestations early on in the disease, further study is needed to assess the impact of early chest CT scan on COVID-19-related outcomes.ConclusionsThis case highlights the importance of clinicians relying on indirect markers of COVID-19, such as characteristic clinical, radiographic and laboratory findings in patients seeking medical care.", [["respiratory", "ANATOMY", 182, 193], ["cancer", "ANATOMY", 205, 211], ["GI", "ANATOMY", 465, 467], ["chest", "ANATOMY", 562, 567], ["respiratory failure", "DISEASE", 182, 201], ["cancer", "DISEASE", 205, 211], ["cancer", "CANCER", 205, 211], ["patients", "ORGANISM", 212, 220], ["patients", "ORGANISM", 451, 459], ["chest", "ORGAN", 562, 567], ["patients", "ORGANISM", 780, 788], ["patients", "SPECIES", 212, 220], ["patients", "SPECIES", 451, 459], ["patients", "SPECIES", 780, 788], ["respiratory failure in cancer patients", "PROBLEM", 182, 220], ["DiscussionA chest CT scan", "TEST", 221, 246], ["COVID", "TEST", 274, 279], ["COVID", "TEST", 327, 332], ["rRT", "TREATMENT", 432, 435], ["PCR NP swab", "TREATMENT", 436, 447], ["GI manifestations", "PROBLEM", 465, 482], ["further study", "TEST", 508, 521], ["early chest CT scan", "TEST", 556, 575], ["COVID", "TEST", 579, 584], ["COVID", "TEST", 697, 702], ["respiratory", "ANATOMY", 182, 193], ["failure", "OBSERVATION", 194, 201], ["cancer", "OBSERVATION", 205, 211], ["chest", "ANATOMY", 233, 238], ["highly", "OBSERVATION_MODIFIER", 349, 355], ["epidemic", "OBSERVATION", 356, 364], ["chest", "ANATOMY", 562, 567]]], ["Improved understanding of the variety of clinical manifestation is critical for prompting appropriate specimen collection, timely diagnosis, and treatment initiation.", [["specimen", "ANATOMY", 102, 110], ["treatment initiation", "TREATMENT", 145, 165]]], ["It remains uncertain whether the combination of anti-IL-6, corticosteroids, and immunoglobulins could work synergistically in patients with chronic lymphocytic leukemia with severe COVID-19 and ARDS.", [["chronic lymphocytic leukemia", "ANATOMY", 140, 168], ["anti-IL-6, corticosteroids", "CHEMICAL", 48, 74], ["chronic lymphocytic leukemia", "DISEASE", 140, 168], ["ARDS", "DISEASE", 194, 198], ["corticosteroids", "CHEMICAL", 59, 74], ["anti-IL-6", "GENE_OR_GENE_PRODUCT", 48, 57], ["corticosteroids", "SIMPLE_CHEMICAL", 59, 74], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 80, 95], ["patients", "ORGANISM", 126, 134], ["chronic lymphocytic leukemia", "CANCER", 140, 168], ["immunoglobulins", "PROTEIN", 80, 95], ["patients", "SPECIES", 126, 134], ["anti-IL", "TREATMENT", 48, 55], ["corticosteroids", "TREATMENT", 59, 74], ["immunoglobulins", "TREATMENT", 80, 95], ["chronic lymphocytic leukemia", "PROBLEM", 140, 168], ["severe COVID", "PROBLEM", 174, 186], ["ARDS", "PROBLEM", 194, 198], ["chronic", "OBSERVATION_MODIFIER", 140, 147], ["lymphocytic leukemia", "OBSERVATION", 148, 168], ["severe", "OBSERVATION_MODIFIER", 174, 180], ["ARDS", "OBSERVATION", 194, 198]]], ["Further studies are needed to define the optimal treatment of COVID-19 in cancer patients as early treatment will likely prevent further complications and improve outcomes.", [["cancer", "ANATOMY", 74, 80], ["COVID-19", "CHEMICAL", 62, 70], ["cancer", "DISEASE", 74, 80], ["cancer", "CANCER", 74, 80], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["Further studies", "TEST", 0, 15], ["COVID", "TEST", 62, 67], ["early treatment", "TREATMENT", 93, 108], ["further complications", "PROBLEM", 129, 150]]]], "76bf125fe8e3ac70e62165c2bd829b927e5d1153": [["hydroxychloroquine and azithromycin are consistent with particularly high affinity for the intracellular lysosomal space, which has been implicated as a target site for antiviral activity.", [["intracellular lysosomal space", "ANATOMY", 91, 120], ["hydroxychloroquine", "CHEMICAL", 0, 18], ["azithromycin", "CHEMICAL", 23, 35], ["hydroxychloroquine", "CHEMICAL", 0, 18], ["azithromycin", "CHEMICAL", 23, 35], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["azithromycin", "SIMPLE_CHEMICAL", 23, 35], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 91, 104], ["lysosomal space", "CELLULAR_COMPONENT", 105, 120], ["hydroxychloroquine", "TREATMENT", 0, 18], ["azithromycin", "TREATMENT", 23, 35], ["particularly high affinity", "PROBLEM", 56, 82], ["the intracellular lysosomal space", "PROBLEM", 87, 120], ["antiviral activity", "TREATMENT", 169, 187], ["consistent with", "UNCERTAINTY", 40, 55], ["high affinity", "OBSERVATION", 69, 82], ["intracellular", "ANATOMY_MODIFIER", 91, 104], ["lysosomal space", "OBSERVATION", 105, 120], ["antiviral activity", "OBSERVATION", 169, 187]]], ["The properties of both drugs predict dramatic accumulation in lysosomes, with calculated lysosomal drug concentrations that exceed cytosolic and extracellular concentrations by more than 50 000-fold.", [["lysosomes", "ANATOMY", 62, 71], ["lysosomal", "ANATOMY", 89, 98], ["cytosolic", "ANATOMY", 131, 140], ["extracellular", "ANATOMY", 145, 158], ["lysosomes", "CELLULAR_COMPONENT", 62, 71], ["cytosolic", "ORGANISM_SUBSTANCE", 131, 140], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 145, 158], ["both drugs", "TREATMENT", 18, 28], ["dramatic accumulation in lysosomes", "PROBLEM", 37, 71], ["calculated lysosomal drug concentrations", "TREATMENT", 78, 118], ["cytosolic and extracellular concentrations", "TREATMENT", 131, 173], ["both drugs", "OBSERVATION", 18, 28], ["lysosomal drug concentrations", "OBSERVATION", 89, 118]]], ["These predictions are consistent with previously reported experimentally measured cellular and extracellular concentrations of azithromycin.", [["cellular", "ANATOMY", 82, 90], ["extracellular", "ANATOMY", 95, 108], ["azithromycin", "CHEMICAL", 127, 139], ["azithromycin", "CHEMICAL", 127, 139], ["cellular", "CELL", 82, 90], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 108], ["azithromycin", "SIMPLE_CHEMICAL", 127, 139], ["azithromycin", "TREATMENT", 127, 139], ["consistent with", "UNCERTAINTY", 22, 37]]], ["This is also reflected in the very large volumes of distribution of these drugs, which are among the highest of all drugs currently in use.", [["these drugs", "TREATMENT", 68, 79], ["all drugs", "TREATMENT", 112, 121], ["very", "OBSERVATION_MODIFIER", 30, 34], ["large", "OBSERVATION_MODIFIER", 35, 40], ["volumes", "OBSERVATION_MODIFIER", 41, 48], ["these drugs", "OBSERVATION", 68, 79]]], ["The combination of hydroxychloroquine and azithromycin produces very high local concentrations in lysosomes.", [["lysosomes", "ANATOMY", 98, 107], ["hydroxychloroquine", "CHEMICAL", 19, 37], ["azithromycin", "CHEMICAL", 42, 54], ["hydroxychloroquine", "CHEMICAL", 19, 37], ["azithromycin", "CHEMICAL", 42, 54], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 19, 37], ["azithromycin", "SIMPLE_CHEMICAL", 42, 54], ["lysosomes", "CELLULAR_COMPONENT", 98, 107], ["hydroxychloroquine", "TREATMENT", 19, 37], ["azithromycin", "TREATMENT", 42, 54], ["very high local concentrations in lysosomes", "PROBLEM", 64, 107]]], ["The clinical significance of this observation is unclear; however, the magnitude of this mechanism of drug accumulation via ion-trapping in lysosomes could be an important factor for the pharmacodynamic effects of this drug combination.", [["lysosomes", "ANATOMY", 140, 149], ["lysosomes", "CELLULAR_COMPONENT", 140, 149], ["this observation", "TEST", 29, 45], ["drug accumulation", "PROBLEM", 102, 119], ["this drug combination", "TREATMENT", 214, 235], ["drug accumulation", "OBSERVATION", 102, 119]]]]}